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Abstract 
Pituitary tumours harbour epigenetic aberrations; however, characterisation of these 
aberrations, on a genome-wide basis, is hampered by their infrequent occurrence and their 
small size. To overcome the constraint of limited tissue, whole genome amplification of 
sodium bisulphite converted DNA was employed and provided a consistent 25-fold 
amplification from individual samples. This material was used in a genome-wide analysis 
the DNA methylation of 27,578 CpG sites for each of the major adenoma subtypes. In a 
discovery cohort, on the basis of stringent criteria, pyrosequencing validated 12 of 16 
hypermethylated genes. Overall, the criteria identified 40 genes in non-functional, 21 in 
growth hormone, six in prolactin and two in corticotrophinoma. In an independent cohort, 
different frequencies of hypermethylation were apparent for each of these genes; however, 
association between methylation and reduced transcript expression was infrequent. 
For the EFEMP1 gene, following its initial identification, studies of an independent 
cohort of tumours showed frequent reduced EFEMP1 expression, irrespective of adenoma 
subtype. However, reduced expression was not invariantly associated CpG island 
methylation. Conversely, chromatin immunoprecipitation assays (ChIP) showed histone 
modifications that were consonant with expression status. The causal relationship between 
gene silencing and epigenetic change was established by observing that epidrug challenges 
induced re-expression of EFEMP1 in pituitary cells that was concomitant with histone 
modification associated with expressed genes.  
Enforced expression of EFEMP1 was without effect on cell proliferation or 
apoptotic end-points but was responsible for decreased expression of the MMP2 transcript. 
This association was not apparent in primary adenomas, however, MMP7, showed a 
positive correlation with EFEMP1 and this may reflect cell or species specific differences, 
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suggesting that the relationship between EFEMP1 and MMP7 requires more detailed 
investigation. This study is the first whole genome identification of a potential biomarker 
signature and their functional characterisation will provide insight of tumour aetiology and 
identification of new therapeutic targets.  
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Chapter 1: Introduction 
1.1. Epigenetics 
The genetic information within a genome is essentially invariant in each of the 
different cell types of an organism. However, between different cell types, despite the fact 
that they harbour the same invariant genetic information, different gene expression patterns 
are apparent prior to and following differentiation. An explanation for these findings is 
provided through an additional layer of heritable information termed “epigenetics”. The 
current accepted definition of epigenetics is ‘a process that heritably influences the 
expression of a gene without genetic change to the underlying DNA sequence itself.’ 
(Jaenisch and Bird, 2003).  In these cases, heritability is principally mediated by post-
replicative modifications that include methylation of cytosine bases in DNA and 
modification(s) of histone proteins and expression of micro RNAs (Jones and Baylin, 
2007). The combinatorial influences of these changes frequently lead to chromatin 
remodelling or effects on translation. The resultant remodelling regulates access to the 
underlying genetic information by transcription factors and can result in inappropriate 
activation or inhibition of genes. Moreover, the expression status of these epigenetically 
modified genes frequently impacts upon down-stream signalling pathways and lead to 
disease states including cancer (Egger et al., 2004; Jones and Baylin, 2002). This chapter 
will provide an overview of the principle epigenetic modification in healthy cells and those 
apparent in tumours. Furthermore, it will focus attention on the fact that epigenetic 
aberrations, unlike genetic mutations, are potentially reversible and their restoration to the 
normal state may be achieved through epigenetic therapies. Particular attention is given to 
specific reversal/restoration strategies and their impact on our understanding of tumour 
biology and on the clinical management of tumours including those of pituitary origin. 
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1.1.1. DNA methylation 
DNA methylation was first described from the tubercle bacillus (Johnson and 
Coghill, 1925) and then in calf thymus (Hotchkiss, 1948). It is the modification of 
nucleotides in which a methyl group is covalently added to the 5-carbon position of 
cytosine residue (Figure 1) in the DNA double helix to form 5-methylcytosine (5-mC) 
(Wyatt, 1951). The DNA methylation reaction is catalyzed by methyltransferase with S-
adenosyl serving as methyl donor results in S-adenosylmethionine and 5-mC. Because of 
its frequency and importance, 5-mC has been called the fifth nucleotide (Doerfler, 2006).  
 
 
Figure 1.1. Conversion of cytosine to 5-methylcyctosine 
The arrows point to the 5-carbon position before and after methylation (CH3). DNA 
methyltransferases is shown as, DNMT. 
 
In eukaryotes, the majority of DNA methylation is found at cytosine residues in the 
context of cytosine-phosphate-guanine (CpG) dinucleotides (Gorovsky et al., 1973; 
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Cummings et al., 1974; Hattman et al., 1978). Approximately 70% to 80% of CpG 
dinucleotides, throughout the genome, in human somatic cells are associated with 
methylation (Ehrlich et al., 1982) whereas  around 1% of all cytosine, that are not 
associated with a G residue, are thought to be methylated (Kriaucionis and Bird, 2003). In 
mammalian cells, the majority of 5-mC occurs within repetitive DNA sequence (Yu et al., 
2001). A large portion of these are located in transposons, such as Alu elements and L1 
sequences (Smit and Riggs, 1996). The literature suggests that more than 45% of the 
human genome is represented by transposons (Lander et al., 2001).  
I. CpG islands 
The overall  frequency of CpG dinucleotides across  the mammalian genome is 
approximately 1%, however, in some regions of the genome the observed frequency and 
ration of CpG dinucleotides  is higher at 4-6% (Kriaucionis and Bird, 2003). As previously 
discussed the majority of CpG dinucleotides in the genome are methylated whereas most 
of CpG sites in these “CpG enriched  regions” are not (Figure 1.2). These regions are 
referred to as CpG islands (CGIs) and are  DNA region which contains high frequency of 
CpG sites. In 1987, Gardiner-Garden proposed that a CGI should not be smaller than 200 
bp with CG percentage greater than 50% and CpG ratio greater than 60% (Gardiner-
Garden and Frommer, 1987). In 2002, by looking intensively at human chromosome 21 
and 22, Takai and Jones showed a different value for  CGIs where the smallest length, 
percentage of CG, and CpG ratio is 500 bp,  55%, and 65%, respectively (Takai and Jones, 
2002).  
CGIs are frequently found to be associated with the promoter regions of genes (Feil 
and Berger, 2007). In the majority of  these cases, the default setting, with the exception of 
X-chromosome inactivation, the imprinted genes, LINE-1/SINES and some tissue specific 
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genes, are that these CGIs are not methylated. The promoter regions of approximately half 
of all transcribed genes are associated with CGIs. In general, the islands are found to 
encompass  the promoter, or a proportion thereof and the first exon, however, several 
islands are also observed at a distance and/or downstream of the promoter region (Jones, 
1986). It has been suggested that the association between gene silencing is more frequent 
when the CpG island is found within promoter region and extending into the  first coding 
exon (Ushijima, 2005). 
 
Figure 1.2. DNA methylation profile in normal cells in mammals. 
CGIs are not, in general, methylated and non-CGI CpGs are frequently methylated. 
 
II. Heritability of DNA methylation 
DNA methylation reactions are catalysed by a conserved group of eukaryote 
proteins named DNA (cytosine-5) methyltranferases (DNMTs). DNMT methylate cytosine 
at  carbon 5 (also see figure 1.1) resulted in 5-methylcytosine (Klimasauskas et al., 1994). 
DNA methylation is a post synthetic modification where 5-mC is established after DNA 
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replication. Once formed, the modification is stable and can be transferred to the next 
generation during cell division (Reik and Dean, 2001). For example, the silenced Lmyc 
gene was found to be heritable not because of nucleotide sequence change but due instead 
to inherited DNA methylation patterns (Cubas et al., 1999).  
There are two principle mechanisms that are thought to be responsible for DNA 
methylation (Riggs, 1975; Holliday and Pugh, 1975). The first is de novo methylation, that 
creates a DNA methylation profile during the early stage of development. The second is 
maintenance methylation, and as its name implies is responsible for the inheritance of 
previously formed DNA methylation patterns during cell division and to the daughter 
cell(s) (Figure 1.3). 
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Figure 1.3. Establishment and maintenance of DNA methylation in mammalian cells. 
Newly formed methylation patterns are catalysed by DNMT3A/B. Un-methylated, but 
complimentary, single, daughter DNA strand, the result of DNA replication becomes methylated 
by the maintenance methylase, DNMT1. 
 
The first DNA methyltranferases enzyme, reported in 1988 was DNMT1 (Bestor et 
al., 1988). This enzyme is considered  responsible for maintaining  DNA methylation in 
mammalian cells since it catalyses the reaction in which hemi-methylated DNA became 
methylated at 5-to-30 fold the rate than that seen for unmethylated DNA (Yoder et al., 
1997). DNMT1 was shown to maintain the methylation profile created by DNMT3a and 3b 
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(Pradhan et al., 1999). During the G1-G2 phase of the cell cycle the enzyme, DNMT1, is 
found to be  diffuse throughout the cell, however, in S phase of the cell cycle it is 
associated with the replication fork. This observation suggests that DNMT1 plays a role in 
maintaining DNA methylation pattern through the process of semi-conservative replication 
and in this way ensures that the hemi-methylated daughter chromosomes are fully 
methylated (Liu et al., 1998; Leonhardt et al., 1992).    
Following the identification and characterisation  of DNMT1 the DNA methylases, 
DNMT3a and DNMT3b were identified  as the enzymes principally responsible for de 
novo methylation (Okano et al., 1999). In mouse embryonic stem cells, knock down of 
these two enzymes led to the blocking of DNA methylation patterns, however, the DNA 
methylation profiles of the imprinted genes are maintained in these  cells (Okano et al., 
1999). This data suggests that DNMT3a and DNMT3b are not directly involved in the 
maintenance of DNA methylation, however, studies suggest that, these two enzyme have 
overlapping functions in de novo and maintenance of DNA methylation during 
development (Okano et al., 1999). 
III. DNA demethylation 
Many of the aberrant epigenetic alterations are frequently harmful, however, these 
changes are reversible. In contrast to the enzyme responsible for methylation those leading 
to demethylation and, therefore, the removal of the methyl group from  5-mC has not thus 
fare been identified. Indeed, although several DNA methyltransferases have been identified 
there are still no conclusive reports of bone fide DNA demethylating enzyme. Where DNA 
demethylation does occur it is through a process that leads to dilution through successive 
cell generations and during the DNA replication process. In these cases,   an unmethylated 
single DNA strand is synthesised and this can  result, following a further round of 
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replication,  in both strands of the double helix becoming methylation free (Lim and van 
Oudenaarden, 2007). However, for this to occur the maintenance DNA methylase 
(DNMT1) must be inhibited and available evidence suggests that DNMT1 recognises 
hemi-methylated DNA. Recently, putative mechanism of DNA demethylation by oxidation 
of 5-mC to 5-hydroxymethylcytosine (5-hmC) has been proposed and briefly reviewed in 
section 1.1.2.  
IV. Abnormal regulation of DNA methylation in cancer 
Numerous studies that have focused on the relationship between abnormal 
epigenetic modifications and cancer have revealed two major phenomena. Global genome 
wide hypomethylation is a  common feature of most cancer types, for review see, (Sharma 
et al., 2010). Concomitant with this change is the observation of hypermethylation of the 
normally unmethylated CGIs associated with promoter regions (Figure 1.4). These 
changes, in promoter associated CGI are common and  observed in numerous  growth 
regulating genes and those involved in receptor mediated pathways and apoptosis (Sharma 
et al., 2010; Portela and Esteller, 2010). 
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Figure 1.4. Abnormal DNA methylation in cancer. 
In contrast to the epigenetic changes (in DNA methylation) apparent in normal cells the DNA 
methylation profiles in cancer cells are reversed. In these cases, CGIs are methylated but non-CGI 
CpGs are hypomethylated. 
 
IV.1. Global hypomethylation 
Multiple reports have described a link between global, genome-wide 
hypomethylation of DNA, and a broad spectrum of  tumour  types. In these cases, most of 
the genome-wide hypomethylation is found within DNA repeat elements that comprise 
45% of the genome (Ehrlich, 2002; Hoffmann and Schulz, 2005). As described previously, 
this phenomenon is linked to genomic instability and is also associated with  reactivation 
of repetitive DNA elements and oncogenes (Ehrlich, 2002). In cancer cells, data has 
suggested the link between global hypomethylation, chromatin restructuring and nuclear 
disorganization precede and are perhaps causal for changes in the activity and expression 
of the histone-modifying enzymes and chromatin regulators (Hoffmann and Schulz, 2005). 
Interestingly, although global hypomethylation is  a common feature across multiple  
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tumour types  it frequency shows differences  between tumour type, tumour stage, and the 
specific sequences harbouring these changes (Hoffmann and Schulz, 2005). Genome-wide 
hypomethylation has also been shown, in some, but infrequent, cases, to lead to 
inappropriate  activation of  growth-promoting genes such as S1000A4 in colon cancer 
(Nakamura and Takenaga, 1998), carbonic anhydrase in renal-cell cancer (Uemura et al., 
2000), H-RAS, C-MYS, SERPINB5, CCND2 in gastric cancer (Fang et al., 1996; Akiyama 
et al., 2003; Oshimo et al., 2003), and PAX2 in endometrial cancer (Wu et al., 2005). 
Moreover, in testicular cancer, hypomethylation has been shown to activate some 
cancer/testis specific genes (Jang et al., 2001) and the micro-RNA gene let-7a-3 
(Brueckner et al., 2007). 
IV.2. Gene specific CpG island hyper- and hypo-methylation 
In addition to global hypomethylation, there is an association between gene 
silencing and gene specific promoter CGIs methylation. Although this association has been 
reported in a larger number of publications, it is still not entirely clear  whether CGIs 
methylation is a cause or the consequence of gene inactivation (Costello and Plass, 2001). 
For example, the genes on one of the two X chromosome in females are inactivated, 
however, the inactivation occurs prior to the associated CGI methylation. Thus, while 
some studies  suggest a causal association between methylation and gene silencing other 
studies suggest that silencing precedes methylation and that methylation is necessary to 
maintaining the gene silencing (Gartler et al., 1992).   
Similar to global hypomethylation, gene specific CGI methylation is also 
frequently observed in many cancer types. This phenomenon was first detected in 
retinoblastoma (Greger et al., 1989; Sakai et al., 1991) as  associated with the inactivation 
of RB1 that is regarded as a key tumour suppressor genes (TSG) (Ohtani-Fujita et al., 
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1993). Subsequent to these early studies numerous other TSGs have been identified, where 
loss of expression is associated with promoter methylation rather than genetic mutation. As 
example only, these include  CDKN2B (Herman et al., 1996), the Von Hippel-Lindau gene 
(VHL) (Herman et al., 1994), CASP8 (Teitz et al., 2000), and GADD45 (Zerbini and 
Libermann, 2005) in numerous different tumour types. Epigenetic silencing by methylation 
of promoter regions are also observed in some genes responsible for DNA repair 
mechanisms such as hMLH1, MGMT, and BRCA1 in sporadic cancers (Esteller, 2000).  
Gene silencing, in association with  CGI methylation frequently  occurs in the early 
stages  of tumour development (Feinberg et al., 2006). Indeed a broad range of genes, 
including CDKN2A, SFRP1, GATA4, and GATA5 show increased promoter methylation  in 
tumour associated and histologically normal tissue and in the pre-invasive stages of many 
cancers whereas genetic mutations are rarely detected at this stage (Issa, 2004).    
The majority of gene specific CGIs changes are methylation of previously 
unmethylated CGI and leads to gene inactivation. However,   relatively few publications 
reported the inverse phenomenon, that is, hypomethylation associated with increased 
expression of genes with oncogenic properties. As example, the melanoma associated 
antigen (MAGE) family were found to be overexpression by promoter hypomethylation in 
testis cancer (De Smet et al., 1996), and MAGE-A3 in pituitary tumour (Zhu et al., 2008a). 
Another example is the S100A4 gene encoding a calcium binding protein which is also 
reactivated in brain tumours by CGI hypomethylation (Singh et al., 2003).  
The involvement of hypo- and hyper-methylation mechanisms is summarized in 
figure 1.5. 
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Figure 1.5. Similarities and differences in cancer-associated hypo- and hyper-methylation of 
DNA. 
(Ehrlich, 2009). 
 
IV.3. Aberrant methylation of CpG island shores 
It is apparent that DNA methylation of CGIs is frequently associated with promoter 
regions and this change frequently  leads to or reinforces transcriptional silencing (Deaton 
and Bird, 2011). However and more recently the potential involvement of CpG sites 
outside, or on the borders of bone fide CpG islands has been subject to detailed 
investigation and has revealed important new understanding. In these studies, the 
importance of low density CpG dinucleotides,  that lie approximately 2 kb up- and/or 
down-stream of CGIs has been uncovered. In these cases, these regions are named and 
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referred to as CpG island shores (Irizarry et al., 2009). Similar to CGI, methylation of CpG 
island shores also leads to  gene inactivation and may indeed  correlate more closely with 
these events (Portela and Esteller, 2010). It is perhaps surprising, that the majority of the 
tissue- and cancer-specific DNA methylation is not specific for  the gene associated CpG 
islands, but rather at CpG island shores (Doi et al., 2009; Irizarry et al., 2009). CpG island 
shores methylation is conserved between human and mouse and can serve as an epigenetic 
hallmark to distinguish tissue specificity. Furthermore, the importance of these regions is 
further reinforced by the findings that, 70% of the differentially methylated regions, 
implicated in cell type reprogramming, are associated with CpG island shores (Ji et al., 
2010; Doi et al., 2009). In addition, for genes with non-CGI associated promoters, these 
too can be directly silenced by DNA methylation in these shores (Han et al., 2011). These 
observations suggest that CGI shore methylation may be involved in tissue differentiation, 
epigenetic reprogramming and cancer. Indeed, and as example, a genome-wide analysis of 
CpG methylation has shown that CpG island shore, but not CGI methylation , regulates 
caveolin-1 expression in breast cancer (Rao et al., 2012). 
IV.4. Abnormal imprinting  
It has been proposed that inappropriate  inactivation of the previously active allele 
at imprinted gene loci can lead to loss of gene expression (Knudson, 1970). In addition to 
these changes in imprinting status, X-chromosome inactivation, loss of heterozygosity, and 
DNA mutation of the normally expressed allele can all lead to gene silencing. Thus, and in 
accord with the “two hit” hypothesis proposed by Knudson, the possibility of inactivation 
of an imprinted gene is higher than for non-imprinted genes (Garinis et al., 2002). Data has 
suggested that abnormal DNA methylation of imprinted genes might play a role in the 
development of cancer. A number of imprinted genes are silenced  in cancer cells, such as 
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PEG1 in breast cancer, DLK/GLT2 in pheochromocytoma, neuroblastoma, and Wilms’ 
tumours (Astuti et al., 2005).  
Silencing of the normally expressed allele of imprinted genes (referred to as loss of 
imprinting) is often related to the development of various types of cancer (Falls et al., 
1999). Moreover, if the imprinted gene is a TSG, loss of imprinting of this gene usually 
leads to tumourigenesis. For example, 40% of breast and ovarian cancer case found 
associated with the defects of the non-imprinted allele of a TSG ARH1 (Yu et al., 1999).   
Loss of imprinting in most cases, leads to re-expression of the normally silenced 
and imprinted allele (referred to as relaxation of imprinting). However, and somewhat 
counter-intuitively the term loss if imprinting can lead to gene silencing. In this case the 
normally expressed allele becomes methylated. In those cases where relaxation of 
imprinting is apparent and for  the growth promoting genes and/or oncogenes this change 
can lead to or promote tumour growth. An example is the autocrine growth factor gene 
IGF2 in Wilms’ tumours. In normal cells only the paternally derived allele is  expressed, 
however, in tumour cells the paternal and maternal  alleles are expressed and this  leads to 
increased  IGF2 expression (Ogawa et al., 1993). In pituitary derived growth-hormone-
secreting tumours, relaxation of imprinting of the oncogene GNAS is associated with 
activation of the normally silenced allele (Hayward et al., 2001).  
1.1.2. DNA hydroxymethylation 
Recently, a further modification of DNA methylation has been described as 5-
hydroxymethylcytosine (5-hmC) (Kriaucionis and Heintz, 2009; Tahiliani et al., 2009). 
Formation of 5-hmC is derived from 5-mC by the activity of chromosome ten-eleven 
translocation (TET) protein family (Kohli and Zhang, 2013). Oxidization of 5-mC to 5-
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hmC is catalysed by TET1 (Tahiliani et al., 2009), TET2 (Ko et al., 2010) and TET3 (Ito et 
al., 2010). Moreover, TET enzymes can further convert 5-hmC to 5‑formylcytosine (5-fC) 
(Ito et al., 2011) and 5‑carboxylcytosine (5-caC) (He et al., 2011; Ito et al., 2011).   
Because 5-hmC is found at high frequency in several types of mammalian cells, 
this epigenetic modification may play important roles in cell functions. For example, in 
cerebellar Purkinje cell DNA, approximately 20% of all cytosine in CpG dinucleotides are 
present as 5-hmC (Kriaucionis and Heintz, 2009). Strong evidences are available to 
support that formation of 5-hmC plays a role as a mechanism of DNA demethylation in 
vivo. Overexpression of TET1 in cultured cells leads to decrease in 5-mC levels together 
with increase in the unmodified cytosine levels (Tahiliani et al., 2009). The converse 
phenomenon was observed in mouse embryonic stem cells where knock-down of TET1 
leads to the increase in levels of 5-mC (Xu et al., 2011). Furthermore, a two-steps 
mechanism of replication-independent demethylation has been proposed. The first step is 
the deamination of 5-mC into thymine by cytosine deaminases of the activation-induced 
cytidine deaminase (AID)/apolipoprotein B mRNA editing enzyme, catalytic polypeptide 
(APOBEC) family (Zhu, 2009). Alternatively, there is another route in which 5-mC is 
oxidized to 5-hmC by TET proteins followed by the conversion of 5-hmC to 5-
hydroxyuracil (5-hmU). The second step is the excision of the previously formed 
thymine/5-hmU by DNA glycosylases (thymine DNA glycosylase (TDG), methyl-CpG-
binding domain protein 4 (MBD4), and single-strand-selective monofunctional uracil-
DNA glycosylase 1 (SMUG1)) followed by base excision repair (BER) which results in 
unmodified cytosine (Cortellino et al., 2011; Guo et al., 2011).  
Data suggested that 5-hmC epigenetic marks may be involved in the development 
of the human brain, and the abnormal  5-hmC mark may play a role in the molecular 
 17 
 
pathogenesis of neurodevelopmental disorders (Wang et al., 2012). In cancer, several 
pioneer studies have shown that 5-hmC is an epigenetic mechanism. For example, loss of 
5-hmC has been shown to be an epigenetic hallmark of melanoma (Lian et al., 2012).  
1.1.3. Histone modification 
DNA methylation, once established, is a stable modification that silences gene 
transcription and is inherited through successive cell divisions. However, histone 
modifications are labile and can be reversed by cellular processes and enzymatic pathways 
(Sharma et al., 2010). In contrast to DNA methylation, histone modifications can lead to 
either activation or repression of gene transcription (Hebbes et al., 1988; Kouzarides, 
2007). In particular, the N-terminal tails of histones can undergo several different and often 
concomitant modifications, including methylation, acetylation, ubiquitylation, sumoylation 
and phosphorylation of key residues (Kouzarides, 2007).  
Most descriptions of histone modifications and their influence on gene expression 
have focused on the changes in acetylation and methylation patterns of lysine residues in 
histone N-terminal tails (Bilodeau et al., 2006; Ezzat et al., 2006; Al-Azzawi et al., 2011; 
Jenuwein and Allis, 2001; Hebbes et al., 1988; Kouzarides, 2007). The principal 
modifications associated with either active or silent genes can be summarised as follows: 
histone tail acetylation is associated with active genes, as is tri-methylation of lysine 4 in 
the N-terminal of histone 3 (H3K4me3); (Liang et al., 2004; Hebbes et al., 1988) however, 
tri-methylation of lysine  9 and/or lysine  27 in the N-terminal of histone 3 (H3K9me3 
and/or H3K27me3, respectively) or lysine 20 in the N-terminal of histone 4 (H4K20me3) 
are associated with transcriptional repression (Kondo et al., 2008; Berdasco and Esteller, 
2010; Fraga and Esteller, 2005) (Figure 1.6). These changes have been termed “the histone 
code” (Jenuwein and Allis, 2001). Thus, the combinations of changes to the histone tails, 
 18 
 
acting either alone or in concert with CpG island methylation, determine gene expression 
profiles in normal cells. Moreover, the expression status of these epigenetically modified 
genes frequently affects down-stream signalling pathways and can lead to diseases such as 
cancer (Egger et al., 2004; Jones and Baylin, 2002). Epigenetic changes, together with 
genetic alterations, have important roles in tumour initiation, progression and responses to 
therapeutic interventions (Jones and Baylin, 2002). 
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Figure 1.6. Epigenetic modifications associated with transcriptionally active and 
transcriptionally silent genes. 
(a) A transcriptionally active gene with an open, relaxed, chromatin structure. DNA (black line) 
with non-methylated CpG islands (grey circles) in the promoter regions. The DNA is coiled around 
the nucleosomes (blue and yellow cylinders). Histone 3 tails (blue lines) are acetylated (red 
triangles) at lysine 9 (H3K9Ac) or trimethylated (blue stars) at lysine 4 (H3K4me3). The relaxed 
chromatin configuration allows access by transcription factors and associated transcriptional 
machinery, including RNA polymerase II.  
(b) A silent gene with a closed chromatin structure. The promoter CpG islands are methylated (red 
circles), and the histone 3 tails are trimethylated (red stars) at lysine 9 (H3K9me3) or lysine 27 
(H3K27me3). Accompanying these changes in methylation, the histone tails are hypoacetylated 
(green triangles) and these patterns are associated with closed chromatin.  
Abbreviations: HAT, histone acetyl transferase; HDAC, histone deacetylase; Pol II, RNA 
polymerase II; TF, transcription factor. (Yacqub-Usman et al., 2012b) 
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Multiple members of the  histone methyl transferases (HMTs) family have been 
described and one of these, EZH2, is overexpressed in breast and prostate tumours and 
leads to aberrant H3K27me3 (Valk-Lingbeek et al., 2004).  Acting in concert with, and 
opposing the actions of the HMTs, is a family of lysine specific demethylases that, together 
with the HMTs, maintain global histone methylation patterns. Inappropriate expression of 
lysine specific demethylases has been reported for some tumours (Metzger et al., 2005; Shi 
et al., 2004; Cloos et al., 2008). In one such example, LSD1, a lysine demethylases 
efficiently removes both activating, histone 3 lysine 4 methylation (H3K4me) and 
repressive, histone 3 lysine 9 methylation marks (H3K9me), depending on its specific 
binding partner (Metzger et al., 2005; Shi et al., 2004). In this case, therefore, the binding 
partner dictates the role of LSD1 as either a co-repressor or co-activator of gene 
expression. 
1.1.4. Mechanistic interdependence between DNA methylation and histone 
modifications 
The histone changes associated with condensed chromatin and gene silencing are 
frequently accompanied by, or associated with, DNA methylation (although not 
invariably). The mechanism by which DNA methylation might directly regulate gene 
expression is not entirely clear. Indeed, chromatin remodelling, as described above, is 
principally mediated through repressive histone modifications (Figure 1.6). However, the 
observation that transcriptional silencing is frequently associated with gene promoter 
methylation might reflect the interdependence of these two processes (Figure 1.7). 
Examples of how these processes are integrated are apparent from multiple studies 
showing that methylated DNA sequences preferentially bind a family of methyl-binding 
domain proteins that recruit HDACs to these sites (Figure 1.7) (Wade, 2001). Similarly, 
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DNMT1, which maintains DNA methylation patterns, also binds to HDACs (Fuks et al., 
2000; Rountree et al., 2000; Robertson et al., 2000). Conversely, at nonmethylated DNA 
sequences, the associated histones are acetylated by histone acetylases (HATs) that 
contribute to an open chromatin structure conducive to gene transcription (Belinsky et al., 
2003; Jones and Baylin, 2002). 
 
Figure 1.7. Interdependence of DNA methylation and histone modifications. 
(a) Interaction between DNA methylation and histone deacetylation. DNA CpG island methylation 
(red circles) by DNMTs precedes binding of MBDs, which recruit HDACs to induce transcriptional 
repression by mediating deacetylation (green triangles) of histone tails and chromatin remodelling.  
(b) Interaction between histone 3 lysine methylation and DNA methylation. Nonmethylated CpG 
islands in promoters (grey circles) are accompanied by histone 3 trimethylation at lysine 4 and 
lysine 27 (H3K4me3 and H3K27me3; blue stars) mediated by the HMTs precedes de novo DNA 
methylated (red circles) by DNMTs.  
Abbreviations: DNMT, DNA methyltransferase; HDAC, histone deacetylase; HMT, histone 
methyltransferase; MBD, methyl-CpG binding domain protein. (Yacqub-Usman et al., 2012b).  
 
Although the interdependence of DNA methylation and histone modification has 
not been directly investigated in pituitary cells and tumours, the siRNA-mediated 
knockdown of DNMT3B transcription in pituitary cells provides some insight into this 
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relationship (Zhu et al., 2008b).  DNMT3B is thought to be a de novo DNA methylase, but 
its knock-down in pituitary cells is associated with increased histone acetylation and 
decreased histone methylation (Zhu et al., 2008b). No reports indicate any direct effect of 
this enzyme on histone acetylation or methylation, which suggests that changes in DNA 
methylation status in this experimental model indirectly affect histone modifications. 
Studies of the promoter CpG islands associated with D2DR and BMP-4, and of histone 
modifications in these regions  also suggest that these changes are indeed integrated (Al-
Azzawi et al., 2011; Yacqub-Usman et al., 2012a).  
The opposing actions of HATs and HDACs on covalent histone modifications 
contribute to the reversible nature of acetylation and deacetylation patterns and to their 
subsequent effects on gene expression (Figure 1.7). However, other histone tail 
modifications, such as methylation, also show widespread changes in both normal cells and 
tumour cells (Sharma et al., 2010). Methylation of histone tails is mediated by histone 
methyl transferases (HMTs). Although the principal function of these enzymes is histone 
modification, they are also able to recruit the DNA-methylating enzyme DNMT1 to these 
regions (Figure 1.7). In this way, and in contrast to DNA-directed histone modifications, 
histone methylation can drive CpG island methylation.  
1.1.5. Pharmacological reversal of epigenetically silence gene 
The epigenetic aberrations that distinguish tumour cells from their “normal” 
counterparts are, in essence, reversible (Yang et al., 2010; Kelly et al., 2010).  Indeed, a 
broad range of drugs, the “epidrugs” that target the epigenome and effectively reverse 
DNA methylation and histone modifications have been described (Karagiannis and El-
Osta, 2006a; Gore et al., 2006; Cortez and Jones, 2008). Many of these drugs have as their 
target the enzymes responsible for these aberrations, that is the DNMT’s and HDACs 
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(Sharma et al., 2010).   Their principle mode of action is to either lead to the “trapping” of 
enzymes (DNMTs) on to the DNA, leading to their relative depletion within cells or, for 
the HDACs, to directly inhibit enzyme activity. For some of these drugs US Food Drug 
Administration (FDA) approval has resulted in their use for the treatment of, as example, 
myelodyplastic syndrome (Plimack et al., 2007; Sharma et al., 2010).  
I. DNMT inhibitors 
The two approved drugs that target the DNMTs are nucleoside analogues, and 
marketed as Azacidine and Decitabine, while still others are in various stages of clinical 
trials.  For these analogues there are some concerns regarding toxicity, particularly as high 
doses (Egger et al., 2004).  However, since these drugs should target mainly dividing 
tumour cells they are thought to exert minimal effect on other slowly dividing cells (Yang 
et al., 2003). The most significant issues and concerns associated with the use of these 
particular drugs is that they are they are chemically unstable in aqueous solutions. 
Secondarily, they have also been shown to suppress the proliferation of blood cells from 
the myeloid lineage and thereby lead to toxicity problems (Kantarjian et al., 2003). 
However, other nucleoside analogues, including zebularine (see below) are much more 
stable in aqueous solution and this drug is also reported to  preferentially target tumour 
cells rather than their non-malignant counterpart (Cheng et al., 2004b; Cheng et al., 2003).  
Other drugs in development that reverse DNA methylation achieve their inhibitory effects 
by directly blocking enzyme activity (Mai and Altucci, 2009).   
II. HDAC inhibitors 
Similar to the spectrum of drugs that target methylation, a range of useful and 
promising drugs have been described that target and inhibit the HDACs. Most of these 
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drugs exert their effect by blocking the enzymes catalytic domain and thereby blocking 
substrate recognition and binding. It is beyond the scope of this review to discuss the 
various HDAC inhibitors and the reader is directed toward an excellent review of this area 
by Kristensen and colleagues (Kristensen et al., 2009).  However, and of note, one of these 
inhibitors, trichostatin A (TSA), that displays considerable efficacy as an inhibitor of de-
acetylation (Yoshida et al., 1990), has not progressed to clinical trial because of its severe 
side effects. Although several other HDAC inhibitors are at various phases of clinical trial 
(Mai and Altucci, 2009) the only inhibitor with US FDA approval is, vorinostat, also 
known as SAHA, for the treatment of cutaneous T-cell lymphoma. A frequent concern is 
that the HDAC inhibitors might exert global effects on gene expression; however, this does 
not appear to be the case since several microarray studies have shown them to affect only a 
small fraction of the transcriptome (Chiba et al., 2004; Dannenberg and Edenberg, 2006). 
III. Combinations of DNMT and HDAC inhibitors 
The histone changes associated with condensed chromatin and gene silencing are 
frequently, but not invariantly, accompanied by, or associated with, DNA methylation. 
Indeed, as previously discussed, the latter can direct the former and vice versa (Figure 1.7). 
This frequent mutual interdependence has led to exploration of combinatorial drug 
treatments. Cameron and co-workers first showed a synergistic effect through combined 
and sequential challenge with a DNMT and HDAC inhibitor (Cameron et al., 1999). 
Subsequent studies by other groups have confirmed and extended these findings (Klisovic 
et al., 2003; Belinsky et al., 2003). In fact our own studies that are discussed in a 
subsequent section also used combined drug challenges. In this case, in a pituitary context 
the demethylating agent zebularine and a HDAC inhibitor, TSA, to induce expression of 
epigenetically silenced genes (Al-Azzawi et al., 2011; Yacqub-Usman et al., 2012a).    
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IV. Combinations with conventional therapies 
Several studies, principally of haematological malignancies treated with DNA 
methylation inhibitors, report significant improvement of overall survival compared with 
more conventional treatment regiments. The efficacy of epigenetic therapies as part of a 
combined therapeutic approach with chemotherapeutic agents has recently been reviewed 
(Gore and Hermes-DeSantis, 2008; Fenaux et al., 2009).   An extension to these types of 
studies is suggested by Kim and colleagues where approaches using DNMT inhibitors 
and/or HDAC inhibitors before chemotherapy are reported to be a promising therapeutic 
option (Kim et al., 2003). In addition, other combined strategies, in this case where 
epigenetic therapy preceding radiotherapy are also reported and have been shown to 
increasing the radiosensitivity of tumour cells (Karagiannis and El-Osta, 2006a; 
Karagiannis and El-Osta, 2006b).  To date there are relatively few reports that describe the 
effects of epigenetic therapy in combination strategies with chemo-  or radio- therapy in 
solid tumours.      
V. Genome-wide and gene-specific reactivation of silenced genes  
V.1. Genome wide studies 
Several groups have exploited epidrugs to reverse epigenetic modifications for 
identification of genes subject to epigenetic regulation. In general, epidrug challenges, 
either alone or in combination lead to expression of previously silenced genes. In these 
types of investigation, genome-wide expression is commonly characterised by cDNA 
microarray interrogation and has/is used to identify hitherto unknown, and in some cases, 
tumour-specific genes. Interestingly, and perhaps surprisingly, there appears to be little 
overlap of genes when different de-methylation and or re-acetylation agents are compared 
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(Gius et al., 2004; Flotho et al., 2009). In addition, some genes that are re-expressed 
following drug challenges are not methylated prior to challenge and still others show 
reduced expression (Gius et al., 2004; Flotho et al., 2009). These findings may reflect 
epigenetic silencing of an upstream regulator that may in turn stimulate or repress its 
downstream and “array-identified” targets (Zhu et al., 2001; Soengas et al., 2001; 
Komashko and Farnham, 2010). Our laboratories  investigations  in this arena initially 
employed AtT20 cells challenged with the demethylating agent,  5-aza-2'-deoxyctidine (5-
Aza-2-Dc), with the intention of interrogating gene expression by cDNA microarray. 
However, we found that cell cytoxicity, at least in AtT20 cells, represented a significant 
problem and experiments were discontinued (unpublished data). Instead, we initially used 
a siRNA knock-down approach targeting the maintenance methylase, DNMT1, to “reveal” 
silenced genes (Revill et al., 2009; Dudley et al., 2008). These types of approaches, either 
drug or genetic based respectively hold significant promise for identification of novel 
genes and potential drug targets in multiple tumour types including those of pituitary 
origin.      
V.2.Pharmacologic unmasking for gene specific investigations  
Given that epimutations in most tumour types including pituitary adenomas can be 
functionally equivalent to genetic loss or inactivating mutation, our laboratory has 
investigated this phenomenon as a potential mechanism for silencing of the dopamine 
receptor (D2R) and of the cytokine bone morphogenic protein, BMP-4 (Yacqub-Usman et 
al., 2012a). Our rationale for studying these genes was that some pituitary tumours show 
reduced expression of these genes and their protein products (An et al., 2003; Giacomini et 
al., 2006). Indeed, in other tumour types, as example, breast and prostate cancer, loss or 
reduced expression of the alpha and beta isoforms of the estrogen receptor, ERα/ ERβ  
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respectively is associated with CpG island methylation (Li et al., 2000; Lapidus et al., 
1996). In these cases, treatment of tumour cells with inhibitors of DNA methylation,  
azacitidine, and/or in combination with TSA resulted in re-expression of estrogen receptor,  
restoration of receptor activity and re-sensitization to antiestrogen therapy (Yang et al., 
2000; Yang et al., 2001; Walton et al., 2008).   
As a first line of investigation and as proof of principle in a pituitary context and 
we used the rodent pituitary cell line, GH3, that does not expressed the endogenous D2R. 
However, given our previous experience with 5-Aza-2-Dc and cytoxicity (see above) we 
employed zebularine, reported by others to be a less toxic demethylating agent (Cheng et 
al., 2003; Cheng et al., 2004b).  Our lab’s studies showed that zebularine in combined 
challenges with TSA is synergistic in the induction of D2R in GH3 cells. Drug challenges 
were associated with or were responsible for partial demethylation of the D2Rs CpG island 
and led to  histone modification associated with active genes (Al-Azzawi et al., 2011).  
Studies by other groups have also shown that partial, zebularine induced, demethylation is 
sufficient to induce gene re-expression (Cheng et al., 2003; Cheng et al., 2004a; Scott et 
al., 2007). Similar studies of the BMP-4 promoter also showed that loss of BMP-4 
expression in pituitary cell lines and in primary tumours was also associated with 
epigenetic changes (CGI methylation and histone modifications) (Yacqub-Usman et al., 
2012a). As in our laboratories studies of the D2R promoter we found that combined 
“epidrug” challenges restored gene expression and led to relaxation of chromatin as 
determined by change in histone modification profiles  (Al-Azzawi et al., 2011; Yacqub-
Usman et al., 2012a). 
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1.2. The pituitary gland 
In the vertebrate brain, the pituitary, or master gland, is an endocrine organ located 
at the base of the hypothalamus. The pituitary gland and the hypothalamus are connected 
to each other by the median eminence through the pituitary stalk. The pituitary gland is 
about the same size as a pea and weighs approximately 0.5 g. There are two lobes, the 
anterior and posterior lobe. Both of the lobes are regulated by the hypothalamus. The 
anterior lobe comprises at least five hormone secreting cell types including somatotrophs, 
gonadotrophs, lactotrophs, thyrotrophs, and corticotrophs (Dworakowska and Grossman, 
2009). Hormones secreted by the pituitary gland play important roles in the regulation of 
many physiological processes such as metabolism, growth, sexual development, and 
response to stress (Dworakowska and Grossman, 2009).  
1.2.1. Pituitary adenomas 
Pituitary adenomas account for approximately 10–25% of all intracranial 
neoplasms and are the third most common intracranial tumours in surgical practice 
(Scheithauer et al., 2006). Pituitary adenomas have been observed approximately at the 
ratio 1/1000 in the human population (Daly et al., 2007). There are no difference of the 
tumour incidence between sexes, and similar to most other tumour types it increases with 
age. Most pituitary adenomas are benign although approximately one third will show 
invasive growth characteristics. Pituitary carcinomas represent only 0.2% of these  
adenomas (Scheithauer et al., 2006). 
The different types of pituitary adenomas are shown in table 1.1. The most frequent 
type of pituitary adenomas are prolactinomas (PRL-omas) which  represent approximately 
50% of cases. Non-functioning pituitary adenomas (NFPAs) – accounts for about 30%, 
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somatotroph adenomas (GH-omas) 15–20%  and corticotroph adenomas (ACTH-omas) 
account for 5–10% and thyrotroph adenomas (TSH-omas) less than 1% (Lindholm et al., 
2001; Levy, 2008). Gonadotrophic adenomas are rare.  
Once developed, pituitary adenomas can invade upwards into brain and/or 
downwards into the cavernous sinuses resulted in the compressive effect. Symptoms 
associated with this invasion including headaches, visual defects, and cranial nerve 
dysfunction. Invasion of pituitary adenomas into the brain usually leads to death. While 
invasion causes similar effects among pituitary adenomas patients, symptoms associated 
with cell subtype-specific effects are caused by or associated with over-secretion of a 
particular hormone (Table 1.1) and  are varied.   
 
Type of adenoma Secretion Pathology 
Lactotrophic adenomas  Prolactin 
Galactorrhea, Hypogonadism, Amen
orrhea, Infertility, and Impotence 
Non-functioning adenomas None 
Mainly mass effects and can result in 
hypopituitarism 
Somatotrophic adenomas Growth hormone (GH) Acromegaly 
Corticotrophic adenomas  
Adrenocorticotropic 
hormone (ACTH) and Pro-
opiomelanocortin (POMC) 
Cushing's disease 
Thyrotrophic adenomas  
Thyroid-stimulating 
hormone (TSH) 
Hyperthyroidism 
Gonadotrophic adenomas  
Luteinizing hormone (LH) 
and Follicle-stimulating 
hormone (FSH)  
None 
Table 1.1. Types of pituitary adenomas. 
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1.2.2. Epigenetic changes in pituitary tumour cells 
Tumours of pituitary origin display a diverse array of epimutations that affect the 
transcription of hormone and growth factor receptors, members of the signal transduction 
pathway, transcription factors and cell-cycle regulators. These epigenetic changes usually 
(but not invariably) include changes in the DNA methylation status of promoter-associated 
CpG islands and/or modifications to the underlying histones. 
Several key genes are aberrantly expressed in sporadic pituitary adenomas, and the 
epimutations responsible for their aberrant expression have been identified. Table 1.2 
details the major genes subject to epigenetic change in this tumour types. In the majority of 
cases the genes described, with limited exceptions, have been identified by candidate gene 
approaches. In these cases investigations have focused on genes previously shown, in other 
tumour types, to impact upon tumourigenesis. In addition, early studies of the pituitary 
tumour epigenome and indeed in other tumour types,  focused primarily on gene silencing 
associated with DNA methylation (Simpson et al., 2002; Simpson et al., 2000; Simpson et 
al., 1999; Woloschak et al., 1997; Farrell, 2006). However, subsequent studies have 
included characterisations of histone modifications (Al-Azzawi et al., 2011; Yacqub-
Usman et al., 2012a; Zhu et al., 2007a). These changes are frequently interdependent, and 
rarely affect gene expression as independent modifications.  
I. Cell-cycle regulators 
As summarised in Table 1.2,  key tumour suppressors,  including CDKN2A gene, 
which encodes the  p16 protein, is silenced in the majority of pituitary-derived adenomas, 
and  silencing  is associated with CGI methylation (Simpson et al., 1999; Woloschak et al., 
1997). Furthermore, enforced expression of p16 in pituitary cells reveals that this protein 
 31 
 
as a bona fide tumour suppressor (Frost et al., 1999). Furthermore,  a proportion of growth-
hormone-secreting pituitary adenomas, which show reduced expression of retinoblastoma 
protein have shown this to be associated with  CGI methylation or discrete sequence 
deletions within the protein-binding pocket (Simpson et al., 2000). Other genes with 
reduced or complete loss of expression, and associated with  increase CGI methylation, 
include MEG3 (Zhao et al., 2005), GADD45γ (Zhang et al., 2002), and NNAT (Dudley et 
al., 2008; Revill et al., 2009). Enforced or induced expression of these genes in pituitary 
and other tumour cell lines inhibits cell proliferation. Moreover, additional roles for some 
of these genes have been described; for example, the MEG3 transcript that is not translated 
induces p53 expression (Zhou et al., 2007). Interestingly, MEG3 and NNAT are 
genomically imprinted in normal pituitary cells and most other tissues. 
II. Signal transduction pathways 
In pituitary tumours, abnormal expression of genes related to signal transduction 
pathways have been reported. As example, the guanine nucleotide-binding protein Gsα 
subunit is a component of numerous signal transduction pathways and is encoded by the 
GNAS gene (also known as GSP).  In this case, inappropriate  expression is confined  to 
growth-hormone-secreting adenomas. Activation is associated with genetic mutation at one 
of two discrete sites in this gene. However, subsequent to the description of activation,  
through genetic mutation, inappropriate expression of Gsα has also been shown to be 
associated with relaxation of imprinting at the GNAS locus (Hayward et al., 2001). 
Moreover,  relaxation of imprinting  is only observed in tumours that do not harbour the 
activating mutation, suggesting that these aberrations are mutually exclusive. Pro-apoptotic 
factors, including the so named, pituitary tumour apoptosis gene (PTAG), is silenced by 
CGI methylation at high frequency across the majority of pituitary adenoma subtypes 
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(Bahar et al., 2004b). Enforced expression studies in  pituitary tumour cells  augments 
bromocriptine mediated apoptosis. The DAPK1 gene is also silenced through CpG 
methylation in pituitary tumours, although this epimutation seems to be confined to the 
invasive adenoma subtype (Simpson et al., 2002).  
III. Hormone and growth factor receptors 
Table 1.2 also describes hormone and growth factor receptors where inappropriate 
expression is associated with epimutation. These include the fibroblast growth factor 
receptor 2 (FGFR2) gene transcript that  is subject to alternative splicing and  reduced 
expression of this isoform (FGFR2-IIIb) is a result of DNA and histone methylation  
(Abbass et al., 1997).  Re-expression of FGFR2 can be induced in pituitary cells following 
exposure to a DNA demethylating agent and a histone deacetylase inhibitor (Zhu et al., 
2007b).  Of note, in tumour cells of both pituitary and thyroid origin, a reciprocal 
expression pattern exists with the normally silenced MAGEA3 gene, which encodes 
melanoma-associated antigen A3 (MAGE-A3) (Zhu et al., 2008a; Kondo et al., 2007).  
Interestingly, inappropriate expression of MAGEA3 is associated with DNA 
hypomethylation, and both FGFR2-IIIb and MAGE-A3 rely on DNA hypo-methylation 
and histone modification to inter-regulate each other’s expression (Asa and Ezzat, 2002; 
Zhu et al., 2008a).    
Inappropriate increases in expression of the de novo DNA methylase enzyme 
DNMT3B have also been reported in pituitary tumours. Interestingly, increased expression 
is associated with changes in histone modifications rather than DNA methylation status 
(Zhu et al., 2008b). Knockdown of DNMT3B  (Zhu et al., 2008a) decreases cell 
proliferation and induces expression of  other cell cycle regulators including p21, p27 RB1  
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These findings suggest that DNMT3B might exert broad epigenetic control on the 
transcriptome. 
IV. Transcriptional regulators 
A dominant-negative isoform of the transcription factor Ikaros, Ik6  is expressed in a 
proportion  of pituitary adenomas (Ezzat et al., 2006).  This protein increases both 
acetylation of histone H3 and expression of the anti-apoptotic gene BCL-XL 
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Gene* 
Mode of activation or 
inactivation 
Effect on 
expression 
Product Function 
GNAS  
Mutation or relaxation of 
imprinting 
Increase 
Guanine nucleotide-binding protein Gsα 
subunit (short isoform) 
Signalling pathways, oncogene 
MAGEA3 
Hypomethylation or relaxation 
of imprinting 
Increase Melanoma-associated antigen 3 Cell cycle regulation, oncogene 
DNMT3B Histone modification Increase DNA (cytosine-5)-methyltransferase 3B De novo methylase 
CDKN2A CpG island methylation 
Silencing or 
reduction 
Cyclin-dependent kinase inhibitor 2A, 
isoforms 1/2/3 (p16INK4a) 
Cell cycle regulation, tumour 
suppressor 
RB1 
CpG island methylation or 
deletion 
Silencing or 
reduction 
Retinoblastoma protein 
Cell cycle regulation, tumour 
suppressor 
DAPK1 
CpG island methylation or 
deletion 
Silencing or 
reduction 
Death-associated protein kinase 1 Apoptosis 
MEG3 
Promoter or enhancer 
methylation 
Silencing or 
reduction 
Very putative protein from MEG3locus 
‡ 
Cell cycle regulation, tumour 
suppressor 
GADD45G 
CpG island methylation or 
deletion 
Silencing or 
reduction 
Growth arrest and DNA damage-
inducible protein GADD45γ 
Cell cycle regulation, tumour 
suppressor 
RHBDD3 (also 
known as 
PTAG) 
CpG island methylation or 
deletion 
Silencing or 
reduction 
Rhomboid domain-containing protein 3 
(also known as pituitary tumour 
apoptosis gene) 
Apoptosis 
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NNAT 
CpG island methylation or 
deletion 
Silencing or 
reduction 
Neuronatin 
Cell cycle regulation, tumour 
suppressor 
FGFR2 DNA and histone methylation 
Silencing or 
reduction 
Fibroblast growth factor receptor 2 (IIIb 
isoform) 
Cell surface receptor; inhibits 
proliferation and induces apoptosis 
 
D2R 
CpG island methylation and 
histone modification 
Silencing or 
reduction 
Dopamine D2 receptor 
Cell surface receptor; induces 
apoptosis 
BMP4 
CpG island methylation and 
histone modification 
Silencing or 
reduction 
Bone morphogenetic protein 4 
Bifunctional, cell-type-specific 
stimulates/inhibits proliferation  
Table 1.2. Epigenetic changes associated with pituitary tumours. 
(adapted from Yacqub-Usman et al., 2012b) 
*This list is not exhaustive, and does not include genes with inappropriate expression for which the associated mechanism is not known.  
‡No protein has been found. This gene probably only encodes an RNA.
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1.3. Identification of novel genes involved in pituitary tumourigenesis 
As described in previous sections, epimutations play key roles in the development 
of most tumour types including those of  pituitary origin. It is, therefore,  important to 
develop efficient high-throughput techniques to explore epimutations in tumour cells. To 
date, numerous studies in this and other tumour type, that have  focused on epigenetic 
change have been published, however, earlier studies  were confined or restricted to 
identification on a gene-by-gene (single gene approach) that examined perhaps  one or a 
limited number of candidate genes. Therefore, genome-wide epigenome profiling 
techniques were a natural successor for these types of study.  
1.3.1. Limitation and advances in studies of epigenetic changes associated with  
pituitary adenomas 
I. Candidate gene approach 
For epimutations that characterise pituitary adenomas, their identification, in early 
studies has been through use of candidate gene approaches (Dudley et al., 2009). Less 
frequently, for identification of novel genes, investigators have used differential display 
techniques. These approaches have employed either tumour-derived cDNA (Zhang et al., 
2003) or DNA that has been subject to prior methylation-sensitive digestion (Bahar et al., 
2004b). Although these techniques have identified novel genes, a limitation is that 
identification is frequently confined to a single transcript or gene, that is, on a gene-by-
gene basis. With the exception of several repetitive elements such as LINE-1, a further  
limitation of single gene approaches is that they are unable to provide a picture of genome-
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wide epigenetic changes such as region specific  hypomethylation and subtype-specific 
methylation patterns. 
II. Subtype specific 
In common with specific genetic aberrations which frequently show subtype 
specificity, epimutations also show a degree of specificity (Simpson et al., 2000; Zhang et 
al., 2002; Zhao et al., 2005). As an example, subtype-specific genetic changes are apparent 
for the gsp oncogene and are also apparent for inappropriate expression of HMGA2 in 
somatotroph- and lactotroph-derived adenomas, respectively (Farrell and Clayton, 2000; 
Hayward et al., 2001; Fedele et al., 2006).  
Genome-wide studies employed differential display technique (Zhang et al., 2002; 
Zhang et al., 2003) have identified novel genes involved in pituitary tumourigenesis. 
Although this technique was not focused on epigenetic change, the mechanism of 
GADD45γ silencing was subsequently shown to be through DNA methylation (Bahar et 
al., 2004a). A further limitation of this technique is that it can only compare the cDNA 
library of a subtype specific adenoma (monoclonal cell population) with the cDNA of 
normal pituitaries (polyclonal cell populations). As described in section 1.1.2, of the total 
cells of a normal pituitary, the number of subtype-specific cells is limited. Therefore, the 
novel genes identified by comparing the two unequal cDNA libraries may not accurately 
reflect or represent their expression levels. If this is the case, then epigenetic modifications 
might not impact on expression. To overcome this problem our lab has conducted a siRNA 
knock-down study of DNMT1 in the pituitary cell line AtT20 cell line (Dudley et al., 2008) 
and compared findings to these cells treated with a non-target siRNA. In this cases, while 
comparing cell that were like-for-like they were restricted to the corticotroph cell types. 
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III. Species boundaries 
Of the few genome-wide studies in pituitary tumourigenesis using siRNA knock-
down or pharmacological unmasking strategies (Al-Azzawi et al., 2011; Dudley et al., 
2008), a limitation of these techniques is that they are reliant upon actively dividing cells 
for the effective reversal and/or erasure of epimutations. Moreover, primary pituitary 
adenomas show limited proliferative potential in vitro and investigations are, therefore, 
reliant upon pituitary adenoma cell lines of mouse or rat origin. While these approaches 
have uncovered novel genes, they are constrained by the issue of extrapolation across 
species boundaries, and their promoter methylation status had to be assessed by further 
experiments (Dudley et al., 2008).  
IV. Limitation of clinical sample 
As described in the section 1.1, the limitation and constrain of tumour size, where 
most tumours  measure no more than 5mm in diameter is formidable and particularly for 
genome wide investigations. Since epigenetic studies frequently require significant 
amounts of samples for characterisation of multiple changes (modifications) and include: 
histone modifications, DNA methylations, and expression gene transcripts and protein 
expression techniques for whole genome amplification are necessary. A subsequent section 
of this thesis will describe the optimisation and validation of this technique in this tumour 
types. 
 39 
 
1.3.2. DNA methylation profiling strategies 
Considering the factors and limitations described above, genome-wide DNA 
methylation profiling provides significant advantage for identification of novel genes 
involved in pituitary tumourigenesis. The rapid evolution of genome-wide techniques in 
recent years has provided researchers with the ability to perform genome-wide DNA 
methylation profiling that can identify multiple novel genes involved in tumourigenesis. . 
Second, the limitation of monoclonal versus multi-clonal cell populations which affect 
mRNA differential display technique can be overcome. In this case, and by default, CGI in 
normal pituitary is in general not methylated while in tumours, assuming it is associated 
with gene silencing, will be methylated, however, this association is not invariant. Thus, 
comparing CGI methylation levels between a particular tumour subtype (monoclonal cell 
population) with the normal pituitary (multi-clonal cell population) will reflect the actual 
epigenetic changes that are implicated in or casual in the evolution or progression of a  
tumour. Moreover, by looking directly at DNA methylation, this reduces the number of 
other experimental manipulations required to identify mechanism of gene silencing. Third, 
the challenges imposed by extrapolating across  species boundaries is also surmounted and 
that beset pharmacological unmasking strategy. Finally the limitation imposed by restricted 
amounts of clinic specimens can be partly overcome by employing whole genome 
amplification technique. 
At the start of my thesis work, and as already eluded to a number of genome-wide 
DNA methylation profiling techniques were available.   To select the appropriate approach, 
it was first necessary to review the principles of each of the techniques and to determine 
their relative advantages and disadvantages. The major techniques in the context of my 
studies are described and discussed below. 
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I. Underlying methodologies for detection of DNA methylation  
I.1. Sodium bisulphite conversion  
 Classic dideoxy DNA sequencing is not able to detect  DNA methylation either 
directly and particularly since this information is  erased by PCR. Therefore, as a  first step 
of DNA sequencing based on, or able to interpret DNA methylation  methods for 
converting DNA or more specifically, DNA bases that are not methylated whilst leaving 
those that are methylated resistant to conversion. In this case the technique termed sodium 
bisulphite sequencing achieves this outcome through converting unmethylated cytosine to 
uracil which will subsequently become thymine after PCR amplification (Clark et al., 
1994). In contrast, the methylated cytosine is not converted. Therefore, in the final 
sequencing reaction the unmethylated and methylated cytosines are distinguishable as T 
and C, respectively.  Since the initial report in 1992 (Frommer et al., 1992), bisulphite 
conversion has become the strategy for analysis of DNA methylation.  
A remarkable advantage of bisulphite conversion is that it then allows use of 
several technique, including direct dideoxy sequencing and array based analysis, for the 
detection  at the single base level. However, a concern of bisulphite-conversion-based 
methods is the incomplete conversion rate which may have critical effects in the accuracy 
and reliability of the results (Grunau et al., 2001; Genereux et al., 2008). However, most 
techniques now result in success rates of between 99.5% to 99.7% (Grunau et al., 2001).   
I.2. Methylation sensitive restriction enzymes  
The majority of the methylation-sensitive endonucleases are inhibited by 
methylation of their recognition sites. For example, HpaII recognise the sequence CCGG, 
and its endonuclease activity is blocked by methylation of either cytosine (Korch and 
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Hagblom, 1986). However, there are also a very limited number of enzymes for example 
McrBC, that specifically digest methylated sequence (Sutherland et al., 1992). Therefore, 
digestion of DNA with a methylation-sensitive restriction enzyme is another underlying 
methodology to detect DNA methylation. This methodology enables the possibilities of 
either discriminating and/or enriching for particular methylated or unmethylated fractions 
of DNA throughout the genome (Khulan et al., 2006; Lippman et al., 2005). Because the 
recognition sequence of each specific enzyme is known, an advantage of this technique is 
resolution at a single base level. However, compared to sodium bisulphite which allows 
detection of methylation at any CpG, detection possibility of methylation-sensitive 
enzymes is limited to CpG lying within their specific recognition sequences. In addition, 
and similar to sodium bisulphite methodology, digestion reaction by endonucleases can 
also face the problem of incomplete digestion that lead to biased methylation result. This 
issue is especially important in those cases where a PCR step is involved in the 
downstream methylation profiling procedure. Furthermore, and of particular importance in 
the area  of pituitary research, methods based on methylation-sensitive endonuclease 
digestion usually require high quality, quantity, and integrity of input DNA (Laird, 2010). 
I.3. Methylated DNA immunoprecipitation  
The third underlying methodology for DNA methylation analysis is the affinity 
purification of methylated or unmethylated DNA fragments using antibodies that recognise 
specific modifications. Commercially available antibodies that recognise methylated 
cytosines can be used to enrich methylated DNA sequences (Weber et al., 2005; Gebhard 
et al., 2006). An alternative to antibody enrichment is by using recombinant protein 
containing methylated DNA binding domains (MBD) (Rauch et al., 2006; Gebhard et al., 
2006). Methylated DNA fragments can also be purified by an indirect approach that 
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employs chromatin immunoprecipitation technique using antibodies against MBDs 
(Ballestar et al., 2003). The major limitation of affinity-based methods is relatively low 
resolution since they can only look at methylation status of a DNA region instead of single 
CpG site resolution.   
II. Genome-wide DNA methylation profiling strategies 
Following use of one or several of the pre-treatment methods  described  above 
various types  of genome-wide DNA methylation analysis strategies can be used. A 
summary of the major DNA methylation profiling strategies are shown in table 1.3. 
Furthermore, an appraisal of sample throughput versus genome coverage of of each of the 
major  techniques has been subjected to recent  review (Laird, 2010) and is shown in  
figure 1.8. In general, the evolution of global DNA methylation profiling can be classified 
into three stages (Laird, 2010). The first stage employed classical methods, including gel 
electroforesis and Sanger dideoxy sequencing, to read out DNA methylation information. 
The second stage uses array techniques. The third stage takes the advantages of the Next 
Generation Sequencing (NGS) technologies. It is noteworthy that the classification is not 
always applicable since combinations of the methods are also used in some cases.
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Pretreatment 
method 
Resolution Advantages Disadvantages 
Bisulphite 
conversion 
High  Applicable to any 
samples 
 Require complete 
conversion 
 Degradation of DNA 
Methylation-
sensitive 
restriction enzyme 
Moderate  Highly sensitive 
 Simple 
 Analysis limited to 
methylation at restriction 
sites 
 Complete digestion 
required 
 Require high quality, 
quantity, and integrity of 
input DNA 
Affinity 
purification 
Moderate  Good for studies focus 
on CGIs and repetitive 
sequences 
 High 5mC density 
required 
 Only suitable for rapid, 
large scale, low resolution 
DNA methylation studies 
Table 1.3.1. Genome-wide DNA methylation analysis: sample pretreatments 
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Readout 
method 
Theoretical 
genome 
coverage 
Sample 
throughput 
Advantages Disadvantages 
Oligo-
nucleotide 
Arrays 
Genome-
Wide 
Low to 
moderate 
 Provides a  “snap shot” 
of methylation within 
specific Tiled regions, 
such as promoters 
 Custom Arrays options 
available 
 Bioinformatic and 
analytical 
requirements are less 
challenging relative  to 
NGS 
 Require a priori 
knowledge of the 
regions to be probed 
 Cross-hybridisation 
between similar 
sequences 
BeadArray 
(Illumina) 
~450,000 
CpG sites 
Moderate  Compatible with low 
levels of input DNA 
 No PCR bias 
 Good snap shot of 
methylation at key 
promoter- associated 
CpG site and other 
regions 
 Reproducible results 
 Bioinformatic and 
analytical 
requirements are less 
challenging relative to 
NGS 
 Requires a prior 
knowledge of the 
regions to be probed 
Dideoxy  
sequencing  
following 
sodium 
bisulphite 
conversion  
Genome-
Wide 
Low  Technically simple  
 Single base resolution 
 
 Large number of 
“hands-on” 
experiments 
 Usually requires T:A 
cloning and multiple 
sequencing runs 
 Time consuming 
 High cost and labour 
intensive for 
genome-wide study 
Next 
generation 
sequencing 
(NGS) 
Genome-
Wide 
Low  Fast 
 Genome-wide single 
base resolution 
 High cost 
 Bioinformatics 
technically 
demanding 
Table 1.3.2. Genome-wide DNA methylation analysis: readout methods  
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Figure 1.8. Sample throughput versus genome coverage. 
(Laird, 2010) 
A plot of sample throughput against genome coverage for various DNA methylation techniques. 
Throughput is determined by the number of samples that can be analysed per experiment, based on 
large eukaryotic genomes. Coverage is determined by the number of CpGs in the genome that can 
be analysed per experiment. BC–seq, bisulphite conversion followed by capture and sequencing; 
BS, bisulphite sequencing; BSPP, bisulphite padlock probes; –chip, followed by microarray; 
COBRA, combined bisulphite restriction analysis; MeDIP, methylated DNA immunoprecipitation; 
MSP, methylation-specific PCR; RRBS, reduced representation bisulphite sequencing; –seq, 
followed by sequencing; WGSBS, whole-genome shotgun bisulphite sequencing 
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II.1. Classical strategies 
Gel-based strategies 
The first genome-wide DNA methylation profiling study was reported in 1991 
which developed a gel-based strategy named restriction landmark genomic scanning 
(RLGS) (Hatada et al., 1991). Briefly, genomic DNA was treated with methylation-
sensitive restriction enzymes which preferably digest certain regions such as CGIs, 
followed by two dimensional gel electrophoresis. Differences in methylation are reflected 
by different patterns of restriction fragments visualized on the gel. To date, RLGS has been 
used in ~100 studies according to Pubmed search for “DNA methylation restriction 
landmark genome scanning”. The major disadvantage of this strategy is labour intensive 
and requires further steps to identify differently methylated fragments. In addition, sample 
requirement of RLGS is ~2 µg of high-purity, high-molecular-weight genomic DNA. 
Compare to most other techniques, this sample size  requirement is  higher than most other 
technique or technologies (reviewed by Laird, 2010). For example, Illumina Infinium 27K 
assay requires less than 1 µg genomic DNA to profile >27,000 CpG sites, while Illumina 
GoldenGate is reported to be compatible with degraded DNA extracted from formalin-
fixed, paraffin-embedded samples (Killian et al., 2009). To date, the maximum number of 
CpG islands interrogated in a single RLGS experiment is reported at ~1000 (Costello et al., 
2000) which is relatively small compare to modern array- or NGS-based strategies. 
Another gel-based strategy is Methylation-sensitive Arbitrary Primed PCR (MsAP-
PCR) (Liang et al., 2002). Similar to RLGS, this technique also employs methylation-
sensitive enzyme to digest genomic DNA. Digested fragments were amplified by arbitrary 
primers following by visualization by gel electrophoresis to compare the differences 
between the samples. Our lab used this technique coupled with differential display to 
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compare the pool of normal pituitaries with tumours subtypes. As result, we found a novel 
gene, PTAG, aberrantly methylated in non-functioning tumours but not in normal 
pituitaries. Subsequent functional studies reported its involvement in pituitary 
tumourigenesis PTAG (Bahar et al., 2004b). Although this technique allows isolation of 
novel aberrantly methylated/unmethylated DNA fragments, the following cloning and 
sequencing steps to identify these fragments is gene-by-gene basis. 
Bisulphite sequencing based strategies 
In the absence of high throughput NGS techniques, classical approaches using 
Sanger dideoxy sequencing of  bisulphite converted DNA to profile methylation status of 
target regions. The major problems of the Sanger sequencing technique for analysis of 
methylation status is that it requires a cloning step, usually a T:A vector, and  each sample 
requires 10 to 20 clones to be subject to individual sequencing, thus significantly 
increasing experimental manipulations  and  costs. This issue is highly critical in genome-
wide study. To overcome these issues, an integrated pipeline which allows direct high-
throughput bisulphite sequencing of PCR products (Rakyan et al., 2004) has been 
developed that allows for the elimination of the cloning steps. In addition to this approach, 
a bioinformatics algorithm has been applied to calculate methylation values of the directly 
sequence PCR fragments, and also to adjust for incomplete conversion signals (Lewin et 
al., 2004). This method was employed to interrogate human chromosomes number 6, 20, 
and 23 in 12 different tissues (Eckhardt et al., 2006). The most comprehensive database of 
methylation generated by pre-NGS bisulphite sequencing strategies is the Human 
Epigenome Project. To date, methylation values of ~2 million CpG sites have been 
published online at www.epigenome.org. Despite  these developments, genome-wide 
studies using classical Sanger bisulphite sequencing technique still require significant 
“hands-on” experimental time and high cost consumable budgets. 
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Considering the size of human genome, another issue of whole-genome bisulphite 
sequencing is that a large proportion of sequenced regions do not contain CpG dyad. 
Therefore, a method that allows genome-wide analysis to focus on CpG rich regions is 
desirable (Suzuki and Bird, 2008). Reduced-Representative Bisulphite Sequencing 
(RRBS), a restriction-enzyme-based method, has been developed for this purpose 
(Meissner et al., 2005). Briefly, genome DNA is first digested by a restriction enzyme 
which recognizes a CpG-containing sequence. This ensures that every clone to be 
sequenced contain at least one CpG site. The following steps include size-selection and 
isolation of digested fragments by gel electrophoresis, ligation to a linker, sodium 
bisulphite conversion, PCR amplification, and cloning to generate a reduced representative 
library of the genome. This library is then subsequently  sequenced. Early studies have 
necessitated  thousands of sequencing reactions (Meissner et al., 2005) which are not 
always applicable to smaller laboratories or where cost or labour are a limiting factor.  
II.2. Array hybridization based strategies 
Technological evolution apparent through the advent and use of microarray based 
techniques has enabled the interrogation of a larger number of CpG sites in a single 
experiment. Basically, there are two major kinds of arrays based on their probe types 
including region specific array and tiling array. Region specific array provide direct 
answers with respect to the methylation status of specific regions, however,  these 
techniques are not suitable to interrogation of DNA methylation at a genome-wide level. In 
contrast, tiling arrays can in principal interrogate methylation across the genome (in a 
region or tile specific manner), but require multiple arrays to cover large genome such as 
that found in homo sapiens. For these reasons and for  the technical constraints and 
limitation  NGS techniques provide significant advantage(s). Indeed, from a tiling array 
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perspective these also require multiple further steps to identify aberrantly methylated 
regions. To date, several types of array assays are commercially available. In considering 
the number of probes offered by these commercial arrays, as example >450.000 CpG sites 
on the Illumina Infinium Methylation Assay 450K, these region specific arrays are 
preferred. However, it is important to emphasise that although these would be regarded as 
region specific this specificity relates primarily to the absolute number of CpGs analysed 
across the genome. 
The first array-based genome-wide DNA methylation study was conducted in 1999 
(Huang et al., 1999). Differential methylation hybridization (DMH) method had in this 
case had been developed to profile methylation of CpG islands in breast cancer. Briefly, 
CpG island probes are fixed on the glass slide. Genomic DNA of normal and cancer 
samples are firstly treated with MseI which cut the genome frequently but rarely in CGI, 
and secondly with the methylation-sensitive endonuclease BstU1. Digested fragments are 
ligated with linkers and subsequently amplified by PCR using primers targeted to the 
linker sequences. As a result, different methylation patterns between samples are now 
reflected as different amplified amplicons. These amplicons are labelled and then applied 
onto the array chip to read out the differences of methylation. This technique was 
employed to profile the pool of 28 primary breast tumours paired with corresponding 
normal tissues. Number of probes reported in this study is 1104 (Yan et al., 2000). Several 
modifications/developments based on principle of DMH have been reported. Instead of 
methylation-sensitive enzyme, the methylation-dependent enzyme McrBC has been used 
for efficient profiling of densely methylated regions (Pietrobono et al., 2002).  
It is noteworthy that DMH can only answer “yes – no” question but is not 
quantitative. This issue can be addressed by array-based methods utilize affinity enriched 
samples. In the technique named Methylated DNA Immunoprecipitation (MeDIP) (Weber 
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et al., 2005), genomic DNA is randomly sheared to fragments, denatured, and enriched by 
a monoclonal antibody against 5-mC. As a result, only methylated DNA fragments are 
enriched. The non-enriched (input) and enriched samples are differently fluorescence 
labelled and subsequently applied on to the chip for competitive hybridization with probes. 
Fluorescence density between input and enriched sample are calculated and methylation 
levels of each specific target sequence can be quantitatively read out. To enhance the 
signal strength and/or deal with limited source of DNA sample, enriched and input 
fragments can be subjected to a whole genome amplification (WGA) step prior to labelling 
(Ren et al., 2000). There are several alternatives of MeDIP such as methylcytosine 
immunoprecipitation (mDIP or mCIP) and methylated CpG island recovery assay (MIRA).  
Illumina Infinium Methylation assay  
At the time when my studies began a high throughput, quantitative approach for 
genome-wide profiling of DNA methylation had become available for researchers as the so 
named Illumina Infinium Methylation assay. The initial array based technology marketed 
by this company interrogate 1536 CpG sites per sample and 96 samples per run was known 
as the GoldenGate (Bibikova et al., 2006). Subsequently, the so named, 27K array were 
made available that interrogated 27,578 CpG sites across 14,495 protein-coding gene 
promoters and 110 microRNA gene promoters and allow for the simultaneous 
interrogation across 12 samples on a single “chip” (Bibikova et al., 2009). This array 
includes almost 13,000 genes in the NCBI Consensus CDS Database (Genome Build 36). 
Most of the important loci of nearly 1,000 cancer-related genes reported in literature have 
been covered. Highest attention, by increasing the number of CpG per gene, was paid to 
144 established cancer genes which showed abnormal DNA methylation status. Within 
each of the CGI, optimal CpG sites were chosen by i) holistically analysing the anticipated 
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assay performance, ii) location in CGI, and distance to the transcriptional start site. Data 
has proven that in one CGI the methylation status of one specific CpG site often correctly 
reflects the methylation status of other closely surrounding CpG sites (Eckhardt et al., 
2006). Therefore, it seems sufficient to evaluate the methylation status of  a CGI by 
accessing it’s two representative CpGs. It was this array that has been used in my study. 
However, more recently a 450K array has become available but this was not commercially 
available until 2011.   
The technique itself comprises two speciﬁc “bead” types: The first bead type 
(labelled U) comprise probes designed to match, that is base pair, with unmethylated site; 
the second bead type (labelled M) containing probe designed to match with a methylated 
site (Figure 1.9). To distinguish between these two possibilities, that is a methylated or 
unmethylated DNA, the genomic DNA is first subjected to sodium bisulphite conversion. 
In this case, and after conversion  C residues (not in the context of a guanine, that is not as 
a CpG) are then converted to T. This conversion ensures that the “probe” is specific for 
converted DNA. However, for C residues in the context of a CpG their conversion is 
dependent upon their methylation status. As described earlier, cytosine that are not 
methylated will be converted whereas, cytosine that are methylated will be resistant to 
conversion and remain as C residues (Figure 1.10). Each of the bead-associated probes is 
then subject to single base pair extension. As shown in figure 1.10, it is this extension with 
a differentially fluorescently labelled single base that generates the signal. The relative 
values are then computationally calculated and converted to Beta value to indicate the 
methylation state of desired locus (Bibikova et al., 2009).  
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Figure 1.9. Principle of Illumina Infinium Methylation assay. 
(Bibikova et al., 2009). 
 
 Since the technology does not require a PCR amplification step it avoids selective 
bias towards short fragments. It looks at an average of 2 CpG sites, each in discrete sites 
within a CGI to provide genome-wide coverage of methylation patterns. Interestingly, the 
data generated by Infinium can be integrated with other platforms such as gene expression 
and microRNA profiling. Moreover, and of high importance to pituitary research, sample 
requirement of 27K Beadarray is ~1 µg of genomic DNA is smaller than most of other 
genome-wide DNA methylation profiling techniques (Laird, 2010). 
II.3 NGS-based strategies 
There are ~55 million CpG dyads in each human diploid cell (Martin-Subero and 
Esteller, 2011). Therefore, although array-based platforms have significantly been 
revolutionized the ability to profile genome-wide DNA methylation they are not applicable 
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or suitable to generate information at single CpG resolution. The largest array-based 
platform, Illumina 450K, interrogates ~450.000 CpGs which represents  less than 0.1% of  
CpGs across the genome. However, the development of NGS platforms now enables us to 
interrogate CpGs at the single base level across the genome. To date, there are several 
commercially available high-throughput genome wide sequencing platforms. These 
platforms  include the Roche Genome Sequencer FLX, Illumina Genome Analyzer, ABI 
Sequencing by Oligonucleotide Ligation and Detection. Pre sequence sample treatments 
and methodologies are broadly similar as to those  for arrays, and with the incorporation of  
minor modifications can then  be used for NGS platforms. To distinguish array-based and 
sequencing-based strategies derived from the similar sample treatment process, the suffix –
seq is added. For example, MeDIP-seq is the NGS approach of MeDIP. 
As described in section 1.3.2.II.1, the major issues associated with  classical Sanger 
sequencing for analysis of  DNA methylation  is that cloning and sequencing of multiple 
clones are required. This limitation  has largely been  circumvented  by the pyrosequencing 
technique that  was initially developed by Mostafa Ronaghi (Ronaghi et al., 1996; Ronaghi 
et al., 1998). The application of this technology and its application to epigenetic studies is 
usually termed  bisulphite pyrosequencing (Colella et al., 2003). This technique is ideal for 
DNA methylation analysis at not only the single-gene level  but  also applicable to 
genome-wide investigations (coupled with genome-wide platforms). Pyrosequencing 
significantly reduces man power and cost compared to classical Sanger sequencing and the 
core methodology of pyrosequencing is based on a sequencing-by-synthesis technology in 
which nucleotide incorporation is measured using a luminescence signal generated by 
pyrophosphate release. Bisulphite-converted DNA is first amplified by PCR where  one of 
the two primers is biotinylated. The subsequent PCR products is then “captured” and 
immobilized on streptavidin beads, then  denatured to ssDNA and sequenced. A significant  
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limitation of pyrosequencing is read lengths where, and at best,  sequence reads are 
restricted to  300-500 nucleotides which is at least half the length  of Sanger dideoxy 
sequencing. This issue is exacerbated in  bisulphite pyrosequencing where read lengths are 
restricted to 25–30 bases. This limitation has been partially  improved by modifications of 
the protocol to allow sequence reads of up to 75 bp (Dupont et al., 2004). Based on a 
similar principle to that of bisulphite pyrosequencing, the Roche GS FLX has been 
developed (Margulies et al., 2005). Each single DNA molecule is amplified by emulsion 
PCR, following by attached to beads and then placed in a microtitre plate for subsequent 
pyrosequencing. The fluorescence released in the reactions is calculated and converted to 
methylation values. To date, it is able to process 400,000 reactions of approximate 250 bp 
and incorporate data from 100 Mb of sequence information per run. Roche GS FLX is 
currently one of the strongest platforms for profiling cytosine methylation by shotgun 
sequencing of bisulphite-treated DNA.  
The major challenge of genome-wide DNA methylation profiling by NGS 
techniques is the reduced sequence complexity after bisulphite treatment. In this case, the 
genetic code that comprised four bases is reduced in complexity to three bases since most 
of cytosines, except for methylated ones, are converted to thymidines. This challenge has 
been partly overcome by employing RRBS and/or different capture methods of specific 
DNA sequence before or after bisulphite conversion (Ball et al., 2009; Hodges et al., 2009; 
Li et al., 2009). Also, current NGS methods have not yet been able to interrogate the 
recently discovered 5-hmC modifications. A protocol has been developed to profile 5-hmC 
(Song et al., 2012), and undoubtedly this will attract interest to be adapted to NGS 
platforms.   
The current state of the art with respect to genome-wide DNA methylation profiling 
is by whole-genome shotgun bisulphite sequencing (WGSBS) for Arabidopsis thaliana 
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(Cokus et al., 2008) and Homo sapiens (Lister et al., 2009; Laurent et al., 2010). However, 
the high cost and limited number of sample per run of NGS (Figure 1.8) should be 
considered for each study purpose. Different aspects of available genome-wide DNA 
methylation strategies are overviewed in table 1.3. In addition, because of the huge amount 
of raw data which is measured in gigabyte or even terabyte unit, processing of this data 
usually needs considerable computational infrastructure and professional bioinformatics 
and/or statistics human power.  
1.3.3. DNA hydroxymethylation profiling strategies 
It is challenging to detect and quantify 5-hmC because the majority of methods 
used for studying 5-mC do not distinguish this modification from 5-hmC. In the bisulphite 
reaction 5-hmC is not converted to uracil but to cytosine 5-methylenesulfonate (CMS). 
Therefore, 5-hmC is undetectable by bisulphite sequencing because it is remained as 
cytosine in the final sequencing read (Huang et al., 2010). However, the combination of 
bisulphite conversion and immunoprecipitation of CMS allows detection of this 
modification form (Pastor et al., 2011). Moreover, DNA fragments with high density of 
CMS shows low efficiency in PCR amplification because of the stalling of taq DNA 
polymerase (Huang et al., 2010). In some circumstances, this leads to underestimation of 
5-hmC level with bisulphite-based strategies. Difficulty was also observed with methods 
based on methylation sensitive restriction enzymes where the activity of most of enzymes 
is inhibited by both 5-mC and 5-hmC presented in their recognition sites (Tahiliani et al., 
2009). In case of affinity-based methods, the constrain is that the affinity is specific to 5-
mC but not to 5-hmC (Jin et al., 2010). 
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I. Glucosylation methods  
Although there are constrains in detecting 5-hmC, several strategies of detecting 
and quantifying 5-hmC have been developed. The first strategy uses  bacteriophage T4 
beta-glucosyltransferase (BGT) to glucosylate 5-hmC. This method, in combination with 
MspI restriction enzyme which digest C
m
CGG and C
hm
CGG, but not C
gluc
CGG  
recognition sites, has enabled locus-specific 5-hmC quantification by quantitative PCR 
(Ficz et al., 2011). Moreover, BGT-based strategy also allows genome-wide quantification 
of 5-hmC by adding a radiolabeled substrate in the glycosylation reaction and measuring 
the amount of this indicator relative to standards (Szwagierczak et al., 2010). Another 
affinity-based method named GLIB is the combination of glucosylation, periodate 
oxidation, and biotinylation to add biotin to 5-hmC. Subsequently, this complex is purified  
by streptavidin and sequenced by either Helicos or Illumina (Pastor et al., 2011; Song et 
al., 2011a). Sensitivity of GLIB was reported at 90% of enriched DNA fragments 
containing at least one 5-hmC (Pastor et al., 2011).  
II. Affinity enrichment methods  
Affinity enrichment methods are divided into two groups according to the 
corresponding antibodies which can detect either 5-hmC or CMS. The efficiency of 5-hmC 
antibodies is dependent to the density of 5-hmC. This property causes inefficiency of the 
method in some tissues where the level of 5-hmC is low (Pastor et al., 2011). Based on the 
principle of MeDIP-seq, hMeDIP-seq has been developed (Ficz et al., 2011; Xu et al., 
2011). Compared to anti-5-hmC methods, the anti-CMS antibodies are less density 
dependent and more sensitive, therefore CMS enrichment results in lower background 
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noise. CMS enrichment couples with Illumina NGS platform has been reported (Pastor et 
al., 2011).    
  
 58 
 
1.4. Aims of this study 
Although there are specific and important exceptions, genetic aberration associated 
with or perhaps responsible for the outgrowth of primary sporadic human pituitary 
adenomas are an infrequent finding. However, in marked contrast to the paucity of genetic 
aberration, and at the outset of my research, it is apparent that a propensity toward 
epigenetic changes is a feature and inherent property of this tumour types. At the 
instigation of this project several studies had shown that these changes are manifest as 
inappropriate methylation of CpG islands (Dudley et al., 2009; Yacqub-Usman et al., 
2012b).  However, more recently, in this and indeed other tumour types, epigenetic change 
apparent as histone modification, either alone or in combination with CpG island 
methylation has been reported (Al-Azzawi et al., 2011; Yacqub-Usman et al., 2012a; 
Yacqub-Usman et al., 2012b). 
For the majority of genes identified, as showing epigenetic change in this tumour 
types, a candidate gene approach had been adopted. This approach, and other less frequent 
approaches designed to identify novel genes are subject to extensive review in the 
Introduction to this thesis.  Therefore, in this thesis the principle questions I wished to 
address related to characterisation of genome-wide changes in methylation. However and 
in this case, although essentially genome-wide, it had as its focus CpG islands and in 
particular those associated with gene associated promoter regions. Furthermore an aim was 
to perform this analysis in each of major pituitary adenoma subtypes and determine the 
effect or consequences of these changes on gene expression. The longer term aims were to 
identify specific epigenetic signature that characterised each of the adenoma subtype and 
perhaps identify common genes responsible for tumour outgrowth or those particular to a 
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subtype. Finally a further aim, assuming novel genes were identified, was to determine 
their functions through use of cell line model systems.   
To perform these studies it was necessary to use what was at that time a relatively 
new technology, namely Illumina Infinium 27K Array in combination with sodium 
bisulphite converted DNA from each adenoma subtype. However, it was first necessary to 
overcome the technical limitation imposed by limited tumour material for the analyses. To 
circumvent this issue it was necessary to use whole genome amplification (WGA). 
However, since this technique was relatively untried it was first necessary to determine not 
only the relative fold amplification but also the correlation between analysis prior to and 
following WGA. In a similar manner it was also necessary to validate data derived through 
BeadArray analysis and conventions bisulphite sequencing. To address these aims receptor 
pathways associated with dopaminergic regulation (D2 receptor [D2R]) and the cytokine 
(bone morphogenic protein 4 [BMP-4]) pathway were investigated in pituitary cell lines 
and primary tumours. The epigenetic aberrations examined included CpG island 
methylation and chromatin remodelling, in this case manifest as histone tail modifications.
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Chapter 2: Material and methods 
2.1. Primary Tissue material 
2.1.1. Normal Pituitary Tissue 
Pathological normal mouse pituitaries (CD-1) and rat pituitaries (Sprague Dawley) 
were obtained from a commercial source, Charles River Research laboratories (Kent, UK). 
As control four normal human pituitaries were used. These were post-mortem 
normal pituitaries (NP) acquired within 12 hours of death with no evidence of endocrine 
disease. The normal pituitaries were pulverised under liquid nitrogen using a Biopulveriser 
stainless steel mortar and pestle device (Biospec, California, USA). The resulting granular 
admix was then stored as 30-50 mg aliquots in sterile tubes at -80°C until required for 
downstream analysis. 
2.1.2. Pituitary Tumours 
Primary sporadic pituitary tumours were also investigated within this study. They 
comprised each of the major subtypes and were graded according to a modified Hardy 
classification (Bates et al., 1997). The subtypes were as follows: growth hormone (GH)-
secreting adenomas, corticotroph adenomas (CT), prolactinomas (PRL), and non-
functioning adenomas (NF). Tumours were collected from patients during 
hypophysectomy. Adenoma subtype classification was on the basis of staining for mature 
hormone (GH, ACTH, FSH, LH and PRL but not for the α-subunit). The non-functional 
adenomas did not stain for mature hormones. All GH secreting adenomas were classified 
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as pure somatotrophinomas because they did not stain for any mature hormones other than 
GH.  
Only those adenomas, in which tumour cells comprised at least 80% of the 
specimen, as determined at surgery and confirmed by neuropathological assessment, were 
used in the study. All tumours were freeze fractured using a biopulveriser as described for 
the normal pituitaries. Tumour tissues were obtained with informed consent and all studies 
performed with Regional Ethics Committee (South Birmingham Committee: REC 
reference number: 10/H1207/406) and institutional approval.  
The primary sporadic human pituitary tumours used in this study comprised a 
discovery and an independent cohort (See Appendix 1). The discovery cohort comprised 
three each of the major adenoma subtypes. The investigation cohort comprised seven GH-
secreting tumours all of which were grade 2 macroadenomas; seven corticotrophinomas 
(CT), four of which were grade 1 microadenomas and three were grade 2 macroadenomas; 
seven prolactinomas (PRL) five of which were grade 1 microadenomas and two were 
grade 2 macroadenomas and 13 non-functioning (NF) adenomas seven of which were 
grade 2 and six were grade 3 macroadenomas.  
2.2. Cell culture methods 
2.2.1. Pituitary Cell Lines: 
I. AtT20 Cells 
The AtT20/D16v-F2 (AtT20) murine pituitary adenoma cell line in the corticotroph 
lineage was purchased from the European collection of Cell Cultures (ECACC, Porton 
Down, Salisbury, UK). Cells were passage 13 upon purchase but were designated passage 
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0 for the purpose of these studies. Cells were not passaged more than 10 times for the 
studies described in this thesis. 
II. GH3 Cells  
The rodent pituitary adenoma cell line (GH3, ATCC code: CCL-82.1.) in the 
somato-lactotroph cell lineage were purchased from the American Type Culture Collection 
(Manassas, Virginia) Cells were passage 1 upon arrival and were designated passage 0 for 
the purpose of these studies. Cells were not passaged more than 10 times for the studies 
described in this thesis.  
2.2.2. Growth Conditions 
The GH3 and AtT20 cell lines were grown  in Dulbecco’s modified Eagle’s 
Medium (DMEM) with 4500 mg/L of glucose, 0.584 g/L of L-Glutamine and 0.11 g/L of 
sodium pyruvate (Biosera, Ringmer, UK), and supplemented with 10% heat-inactivated 
fetal bovine serum (FBS, Biosera). Cells were incubated in a Thermo Scientific HEPA 
filtered single chamber water jacketed incubator, at 37⁰C in a humidified 5% CO2 
atmosphere. 
2.2.3. Antibiotic Supplementation 
To minimise the risk of bacterial infection the cell culture medium was 
supplemented with 4 µg/mL of aminoglycoside antibiotic Gentamycin (Sigma-Aldrich, 
Dorset, UK) and 2 µg/mL of antibiotic ampicillin (Sigma). 
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2.2.4. Detachment of adherent cells 
Prior to experimental manipulation or routine passage of cell lines it was first 
necessary to detach and dissociate adherent cells from each other and from the base of 
culture flask. This was achieved using a solution of 1.7 M EDTA. Cell dissociation was 
facilitated by mechanical pipetting to further aid the release of the cells into solution before 
use.  Cells were incubated for 5 minutes at room temperature and then following vigorous 
pipetting. Cells were neutralised by addition of 1 volume of DMEM containing 10% FBS. 
Resuspended cells were transferred to a sterile 15 mL polypropylene tube (Sarstedt, 
Leicestershire, UK) and centrifuged at 150 x g for 5 minutes at room temperature in MSE 
Mistral 2000 centrifuge (UK). The cell pellet was re-suspended in fresh medium by careful 
pipette mixing. 
2.2.5. Culture Vessels 
The type of vessels in which the cells were cultured depended on the experimental 
procedure being undertaken. For general sub-culturing purposes T25 filtered tissue culture 
flasks (Sarstedt, Leicester, UK) were used, whereas T75 filtered tissue culture flasks were 
used for the purpose of growing cells to sufficient density for cryogenic storage. A variety 
of tissue culture plates (96-well, 24-well, 12-well, 6-well; Sarstedt) were used for 
transfection and drug treatment studies. 
2.2.6. Sub-culture  
Sub-confluent (70-80%) cells were routinely sub-cultured in sterile conditions 
every three to four days. Cultured medium was removed and cells were washed with PBS, 
and then PBS-EDTA was added to cells and further diluted with media post detachment as 
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described above. Diluted cells were then transferred to a 15mL tube and centrifuged. Cells 
were then resuspended prior to counting with a haemocytometer. Cells were then diluted to 
1 X105 per mL and transferred to the appropriate culture vessel and incubated at 37°C. For 
routine culture cells were not grown beyond 10 passages and at this point, earlier passage 
and cryopreserved cells were revived from liquid nitrogen storage. 
2.2.7. Cryopreservation of cells 
For long term storage cells were cooled to sub-zero temperatures in a solution 
containing the cryopreservant dimethyl sulphoxide (DMSO). Cells were first grown to 
approximately 75% confluence in a T75 tissue culture flask and were then released from 
the adherent surface as described above and transferred to a 15mL polypropylene tube, and 
centrifuged at 150 x g for 5 minutes. Cell pellets were re-suspended in 900 µL of FBS 
(90%) and 10% DMSO (Sigma), and transferred to a 2 mL cyrovial (BD labs). Vials were 
placed into a “Mr Frosty” freezing container (Nalgene, Neerijse, Belgium) filled to the 
appropriate level with isopropanol (Sigma) and frozen overnight at -80°C. Frozen vials 
were then transferred to liquid nitrogen. 
2.2.8. Reviving cryopreserved cells 
Cells were revived from liquid nitrogen storage by rapid thawing to 37°C. Thawed 
cell were transferred to a 50 mL polypropylene tube and 20 mL of DMEM without FBS 
supplemented was added in a drop wise motion with constant swirling. Cells were then 
centrifuged 150 x g for 7 minutes and re-suspended in 6 mL of DMEM containing 10% 
FBS. Cells were then transferred to a T25 tissue culture flask and incubated overnight at 
37°C. The following day medium was replaced in order to remove dead cells, whilst 
healthy cells were grown to sufficient density for sub-culturing purposes. 
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2.2.9. Cell Counting 
Disposable haemocytometer chamber (Glasstic® Slide 10 with grids, Hycor 
Biomedical Inc, California, USA) were used to count cells. Cells were first stained with 
trypan blue to distinguish dead from live cells and suitable dilutions, such that between 20-
50 cells, in each of the squares were enumerated to determine live-cell counts.  The 
average number of cells per millilitre (cell/mL) was determined using the equation below. 
Total number of cells per mL = average count per mm2 X 10
4
 X Dilution factor.   
2.2.10. Incubation of cell lines with pharmacological agents 
The epi-drugs in this study were 1-(β-D-ribofuranosyl)-1,2-dihydropyrimidin-2-one 
also known as Zebularine and Trichostatin A (Sigma, UK). Zebularine is a cytidine 
deaminase inhibitor and a DNA demethylating agent. TSA (Trichostatin A) is a histone 
deaceytlase inhibitor (Cheng et al., 2003; Cameron et al., 1999).  
Zebularine was prepared in DMSO and TSA was prepared in ethanol. Both drugs 
were stored at -20°C.Typically, drugs were stored as stock solutions: Zebularine (1µM) 
and TSA (10 ng/mL) and diluted prior to use. 
24 hours prior to drug treatment, 2.5 mL of cells, at a concentration of 1 x 10
5
/mL 
were seeded into 6 well plates. Cells were then treated with the appropriate concentration 
of drug(s) (see figures and figure legends) every 24 hours for 48 hours. Post Zebularine 
and/or TSA challenges cells were harvested prior to extracting protein, nucleic acids and 
chromatin.  
In some experiments, bromocriptine (BC) [2-Bromo-α-ergocryptine 
methanesulfonate salt] was used. This was obtained from Sigma. Stock solutions were 
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prepared in DMSO and PBS respectively and stored according to manufacturer’s 
instructions.  
2.3. Molecular biology methods 
2.3.1. Isolation of genomic DNA from cell line and primary pituitary tissue 
The extraction and purification of genomic DNA from cell lines and primary tissue 
(normal pituitaries and primary pituitary tumours) was performed using a standard lysis 
and phenol/chloroform procedure.  
Lysis of tissue specimens: 3 mL of lysis buffer was added to 10-30 mg of tissue and 
incubated overnight at 56°C.  
Lysis of cell line samples: Monolayers of cells (1-3 x 10
5
 cells) were washed once 
with sterile PBS and harvested into a PBS-EDTA solution. Cells were collected by 
centrifugation at 150 x g for 5 minutes and the pellets were resuspended in lysis buffer (see 
Appendix 2). Cell samples were incubated overnight at 37°C. 
Extraction and precipitation of DNA: After overnight incubations samples were 
vortexed vigorously and an equal volume of phenol was added to lysates and mixed on a 
rotary shaker for 10 minutes. The samples were then centrifuged at 914 x g for 10 minutes. 
The upper aqueous phase was then transferred to a fresh tube, and an equal volume of 
chloroform added and mixed on a rotary shaker for 10 minutes, and then centrifuged 914 x 
g for 10 minutes at 4°C. The upper aqueous layer was transferred into a fresh tube and 
sodium acetate was added to achieve a final concentration of 0.3M. 100% ethanol was 
added and allowed to precipitate overnight at -20°C. This was then centrifuged at 150 x g 
for 25 minutes at 4°C. The supernatant was discarded and the pellet washed twice with 
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70% ethanol. After removal of the supernatant the pellet was left at room temperature to 
dry and resuspended in 50-150 µL of double distilled RNase and DNase free water prior to 
quantification and storage at -20°C. 
2.3.2. RNA extraction from cell lines and primary pituitary tissue 
Total RNA was extracted using the guanidinium iso-thiocyanate-phenol-
chloroform method previously described (Chomczynski and Sacchi, 1987). This is a 
chaotropic compound that denatures proteins including ribonucleases, whilst maintaining 
the integrity of RNA.  
Isolation from cell lines: 1-3 x 10
6
 cells were pelleted by centrifugation at 150 x g 
in a 15 mL polypropylene tube then washed in PBS, and re-suspended in 1mL of 
Guanidinium thiocyanate solution (see Appendix 2 for composition, concentration and 
storage of stock solution). 
Isolation from tissue:  1mL of Guanidinium isothiocyanate lysis buffer was added 
to 10-30 mg of tissue and homogenised in a dounce homogeniser to a slurry like 
consistency. Lysates were then transferred to a 15 mL poly propylene tube. 
200 µL of 2M sodium acetate (pH 4.5) was added and mixed by vortexing. RNA 
was extracted from the solution by addition of equal volume of phenol and 800µL of 24:1 
chloroform isoamyl-alcohol solution. Vigorous shaking ensured that the organic and 
aqueous phases were adequately mixed, and samples were incubated on ice for 30 minutes. 
The samples were centrifuged at 914 x g for 20 minutes at 4°C to separate the two phases; 
the upper aqueous phase was transferred to a fresh sterile tube. A double extraction was 
carried out by adding a further 800µL of chloroform isoamyl alcohol and shaking 
vigorously. Samples were incubated on ice for a further 30 minutes. Centrifugation was 
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carried out using the above settings and the upper aqueous phase was transferred to a fresh 
tube. RNA was precipitated by addition of equal volumes of 99% isopropanol and 
incubated overnight at -20°C. Precipitated RNA was pelleted by centrifugation at 914 x g 
for 30 minutes at 4°C. The supernatant was removed and the pellet was washed with 70% 
ethanol. Following re-centrifugation and removal of the supernatant the pellets were air 
dried to remove residual ethanol, and dissolved in 10-50 µL of sterile RNase and DNase 
free water (Sigma) depending on the size of the individual pellets. RNA samples were 
aliquoted out and stored at -80°C. 
2.3.3. Purification of nucleic acid 
During some experiments it was important to further purify the nucleic acid 
product. This was achieved using The GenElute
Tm
 PCR Clean-up Kit which is designed to 
rapidly purify single and double stranded PCR amplification products (100-10 kb) whilst 
removing excess primers, nucleotides, DNA polymerase, oils and salts. 
DNA is initially bound to a silica impregnated membrane within the spin column 
by the addition of a binding buffer. The bound DNA is washed with a wash buffer and the 
DNA is released from the membrane in elution buffer by centrifugation. Purified DNA is 
the suitable for several downstream applications including enzymatic digestions, 
conventional or automated sequencing, ligation, cloning and microarray analysis in this 
case prior to and following sodium bisulphite conversion.  
2.3.4. Quantification of nucleic acid and assessment of purity 
The quality of the nucleic acid isolated in any given RNA or DNA sample was 
estimated by spectrophotometric analysis using the NanoDrop 2000 (ND2000) (Thermo 
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Scientific, Nelson, UK). The NanoDrop is a spectrophotometer that measures micro 
volumes with a patent sample retention technology. It allows samples as small as 0.5µL to 
be measured without the need of cuvettes or capillaries. 
The absorbance measurement made on the spectrophotometer will be of all 
molecules in the sample that absorb at the wavelength of interest. Since RNA, ssDNA and 
dsDNA all absorb at 260nm, they will contribute to the total absorbance of the sample so 
some samples will therefore require purification prior to measurement. 
The ratio of the absorbance at 260nm and 280nm (260:280) is used to assess the 
purity of the DNA and RNA. A ratio of ~1.8 is typical for DNA while a ratio of ~ 2.0 is 
typical for high quality/purity of RNA. Lower ratios suggest the presence of proteins, 
phenol or other contaminants that absorb strongly at a wavelength of approximately 
280nm. 
2.3.5. Agarose gel electrophoresis 
Electrophoresis refers to the separation of charged molecules in an electrical field. 
Molecules in a mixture are separated from each other on the basis of size, shape or charge. 
In this study a variety of electrophoresis methods were used to separate and visualise DNA 
and RNA molecules. To enable visualisation of the products from sqPCR agarose gel 
electrophoresis was employed.  Low percentage (1-2%) agarose gels were used to separate 
DNA and RNA fragments. A typical 1% Agarose gel solution was prepared by melting 1 g 
of Agarose (Bioline, London UK ) in 100 mL of 1X TAE buffer (diluted from 50X stock; 
see Appendix 2) using a microwave oven at high power for 2 minutes. The solution was 
then allowed to cool before addition of ethidium bromide (Sigma) to achieve a 
concentration of 0.5 µg/mL. The gel was then poured into a pre-assembled Bio-Rad gel 
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casting tray that had been sealed at each end using autoclave tape. A comb with the 
appropriately sized wells was immersed into the gel, which was then left to cool at room 
temperature for approximately 30 minutes in order for the gel to polymerise. The comb and 
autoclave tape were then removed, and the gel was immersed into a Bio-Rad resolving 
tank containing sufficient 1 X TAE buffer to cover the gel by 2-3 mm. 1 µL of 6 X loading 
dye (see Appendix 2) was added to 5 µL of nucleic acid samples, which were transferred to 
individual wells of the gel. Samples were electrophoresed from the negatively charged 
cathode to the positively charged anode for 45 minutes at 100V, alongside a GeneRuler 
100 base pair DNA ladder (Fermentas, Yorkshire, UK), and nucleic acid fragments were 
detected and photographed by UV Transillumination using a Syngene gel documentation 
system (Cambridge, UK). 
2.4. Whole genome amplification of bisulphite converted DNA 
2.4.1. Sodium bisulphite modification of genomic DNA 
Sodium bisulphite conversation of DNA was performed using a commercial kit. 
The kit used was EZ DNA Methylation-Gold
TM
 Kit (ZYMO Research, Cambridge, UK). 
In this protocol 500 ng of genomic DNA is first treated with sodium bisulphite, essentially 
as first described in (Clark et al., 1994). For efficient conversion genomic DNA was first 
denatured by incubating with conversion reagent and heated to 98°C for 10 minutes and 
then 64°C for a further 3 hours.  
The converted DNA and M-binding buffer was added to a column (provided in the 
kit) that had been inserted into a 2 mL eppendorf tube (provided in the kit) and inverted 
several times. This was then centrifuged at full speed (914 x g) for 30 seconds. The flow-
through was discarded and M wash-buffer was then added to the column. This was 
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centrifuged as described above. The flow-through was again discarded. The columns were 
centrifuged again at full speed to remove any residual wash buffer. The M-desulphonation 
buffer was then added to the column to desulphonate the DNA and left to incubate at room 
temperature for 20 minutes.  The column was then centrifuged at full speed and all flow-
through discarded. The desulphonated column-bound DNA was then washed twice by 
addition of M-wash buffer and centrifuged at full speed removing all flow-through. Finally 
the DNA was eluted into 21 µL of elution buffer and then quantified on the Nanodrop 
ND2000 under the option of single stranded DNA. Samples were stored in -80°C after 
conversion. 
2.4.2. Whole genome amplification  
Whole genome amplification (WGA) was performed following a slightly modified 
version of the Zhang’s primer extension preamplification (PEP) protocol (Zhang et al., 
1992).  1 μL bisulphite-treated DNA, corresponding to 20 ng of the BSC DNA, was used 
as template for whole genome amplification reaction. The reaction volume was increased 
to 25 μL. To each of the WGA reactions  200 pmol of a 15-mer random primers (5′-
NNNNNNNNNNNNNNN-3′[ where N is any of the four bases]) and 0.4 mM dNTPs were 
added. Amplification was performed for a total of fifty cycles. Each cycle including a 
denaturing step at 95°C for 1 minute, an annealing step at 37°C for 2 minutes, and an 
incubation step at 55°C for 4 minute. Ramping rate was set at 10 s/°C. The WGA products 
were stored at 20°C. 
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2.5. DNA methylation analysis  
2.5.1. Genome-wide DNA methylation analysis by Illumina BeadArray assay 
I. Sample preparation and processing 
For the discovery cohort, DNA was extracted from three of each of the major 
pituitary adenoma subtypes (NF, GH, PRL and CT) and from three NP. Total DNA (500 
ng) from each of the samples was sodium bisulphite converted as described (see above). 
After conversion, DNA was eluted in 12 µL elution buffer and 4 µL converted DNA was 
used as template on the Infinium Methylation 27K Arrays (Illumina, San Diego, CA, USA) 
and was processed according to the manufacturer’s recommendations. In these cases, 
Array hybridizations were performed under a collaborative agreement with Dr Charles 
Mein (Queen Mary’s and London University Hospital (formerly Bart’s), London, UK). 
This array examines the methylation status of 27578 CpG sites across 14496 genes. Data 
were collected using the Illumina BeadArray (Illumina) reader and analysed with 
GenomeStudio V2009.1 methylation module 1.1.1 (Illumina). This assigns a ‘β value’ that 
is a quantitative measure of methylation for each CpG site and ranges from 0 (no 
methylation) to 1.0 (100% methylation of both alleles).  
II. Data analysis 
The analysis of the initial, array generated data-set, was performed as part of 
collaboration with Dr Richard Emes (Reader and Associate Professor in Bioinformatics, 
University of Nottingham, UK). Subsequent to this analysis I was able to generate a data-
set on the basis of the criteria described below. Initially, of the 27,578 sites on the array, 
we removed all probes targeted on X and Y chromosomes (n = 1092) and this reduced  the 
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probe number to 26,486. Following discussions with my supervisor and with our 
collaborator (Dr Richard Emes) and to to reduce the number of non-variable sites from 
subsequent analyses, probes where β values in all samples were ≥0.8 or ≤0.2 were 
excluded (n = 13,945) from the analysis and this reduced the probe count to 12,541. From 
this dataset, I also eliminated all sites where one or more of the samples demonstrated i) 
detection P values of >0.05 (internal quality control) or ii) null (missing) β values. I  took, 
after discussion,  the decision to remove probes that failed in any one of the samples rather 
than excluding probe values for individual tumour samples as this was deemed  a more 
robust way to identify probes that varied between tumours in a limited number of samples. 
This resulted in a final dataset of 10,667 probes for further analysis.  
For the further analysis, that defined criteria for inclusion or exclusion of specific 
genes it was necessary for me to derive this data-set empirically. In these cases, these 
criteria are described in the results section of this thesis.    
2.5.2. Bisulphite sequencing 
I. Primer design for sodium bisulphite converted DNA 
Primers, that were specific for sodium bisulphite treated  DNA were designed for 
the amplification of  bisulphite converted DNA. DNA sequences of genes of interest were 
obtained from Ensembl database (www.ensembl.org). The sequences were in silico 
bisulphite converted using the PyroMark Assay Design 2.0 software where the non-
methylated cytosine would have been converted to uracil. The primer is only able to 
recognise this conversion if a thymidine (T) is incorporated into the design. Since 
methylated Cs are usually found  in the context of a CpG they are not converted  in a 
sequencing reaction  and are read as C. Typically, for specificity and efficient 
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amplification primers  were in the size rage, 24-32 bases. Optimal amplicon sizes were 
between 150-300 bp. See Appendix 3 for Primer sequence for sodium bisulphite converted 
DNA. 
II. PCR amplification  
The polymerase chain reaction (PCR) is an in vitro method of DNA synthesis that 
allows particular regions of DNA (or cDNA in the case of RT-PCR) to be copied and 
amplified. The DNA template is first denatured by incubation at high temperature: then the 
temperature is lowered and two oligonucleotide primers that flank the DNA fragment to be 
amplified are annealed to their complementary sequences on opposite ends of the target 
sequence. The primers are then extended by Taq polymerase and the sequence between the 
primers is synthesised. Multiple rounds of denaturation, annealing and extension allow for 
specific amplification of the sequence of interest. 
A touchdown PCR was performed using sodium bisulphite converted DNA or 
whole genome amplified DNA as template. It was necessary in some cases to perform 
nested PCR whereby the initial primary PCR product was subjected to a second round of 
PCR amplification. 
III. Purification of DNA from agarose gels 
Prior to T:A cloning of PCR amplicons it was necessary to first resolve them by 
agarose gel electrophoresis. This step ensured that the fragment corresponded to the right 
size and that it was separated from primer sequences.  Fragments were, therefore, 
electrophoresed through a 2% agarose gel (as described in a previous section) and isolated 
and purified using a QIAquick Gel Extraction Kit (QIAGEN, West Sussex). The region of 
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agarose containing the DNA fragment was first visualised with a UV transilluminator and 
excised from the gel using a sterile scalpel blade. The gel fragment was then transferred to 
a 1.5 mL microcentrifuge tube and the volume of agarose estimated by measuring the mass 
of the excised fragment.  3 volumes (relative to the volume of the gel fragment) of Buffer 
QG was added and the agarose was melted by incubation at 50°C on a heat block for 10 
minutes. A further 1 gel volume of isopropanol was added and the sample vortexed prior to 
addition of the DNA containing sample to a column provided within the kit. The sample 
was the subject centrifugation and the flow through discarded. This step was repeated. 
After further wash steps using Buffer PE the column was put into in a 2 mL collection tube 
and elution buffer EB used to release bound DNA as described in the manufacturer’s 
protocol.  
IV. Ligation 
The ability of Taq DNA polymerase to extend PCR amplicons by the template 
independent addition of a single adenine (A) to the 3’–end, enables the rapid and efficient 
ligation of PCR products into a T:A cloning vector, the pGEM T-Easy vector (Promega, 
Southampton, UK, see Appendix 4). The vector is a pre-linearized with a single 3’ –
terminal thymidine at either ends. The overhang at the insertion site greatly increases 
efficiency of ligation of PCR products. PCR reactions were first performed in duplicate 
and then combined in a single tube. 6uL of this reaction mix was resolved on a 1% gel to 
confirm amplicon size. The remaining reaction was then cleaned on a Gene Elute PCR 
cleaning column (Sigma-see above). The quantity of the purified PCR product was 
determined on the Nano-drop (OD 260nm). An appropriate quantity (see calculation 
below) was then used for ligation into the pGEM vector at a 6:1 insert:vector molar ratio. 
This was calculated according to the following equation. 
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ng of vector X kb size of insert 
X insert:vector molar ratio = ng of insert 
kb size of vector 
 
50ng of the 3000bp size pGEM vector was typically used in a ligation reaction; 
therefore at a 6:1 insert:vector molar ratio, approximately 5 ng per 100 bases of insert was 
used. To this reaction 400 U of T4 DNA ligase (Promega) and 4.5 uL of 10X T4 DNA 
ligase buffer was added. Ligation reactions were incubated at 4°C for 16 hours. 
Ligation reaction: 
Ligation Reagents 1 reaction (µL) 
10 X T4 Ligase buffer 4.5 
T4 Easy Vector 0.7 
PCR product 1-4 
T4 DNA Ligase 4 
H2O (10 µL Total) (~10) 
Table 2.1. Ligation Reaction. Ligation reagents for one reaction. 
V. Transformation  
8 µL of the total 10 µL reaction was added to a 50 µL volume of competent cells 
(See appendix III on growing chemically competent cells) in a sterile 0.5 mL 
microcentrifuge tube, and incubated on ice for 20minutes. The microcentrifuge tube was 
gently flicked to mix the DNA and cells. The cells were then heat shocked for 2 minutes at 
42°C in a thermal cycler, followed by a further incubation on ice for 2 minutes. The 
transformation mixture was then transferred to a sterile 15 mL polypropylene tube 
followed by the addition of 1mL sterile LB medium. Samples were incubated at 37°C for 
2.5 hours in an orbital shaker with vigorous shaking. 
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VI. Spread plating 
350µL of the bacterial culture was spread onto a LB-agar plate containing 60µg/mL 
of ampicillin using a sterilised spreader. In addition, 0.1M IPTG (isopropyl β-D-1-
thiogalactopyranoside) and 50 µL/mL Xgal (5-bromo-4-chloro-3-indolyl β-D-
galactopyranonide) were added to agar plates if TA cloning was being carried out, as this 
allowed for blue-white colony selection. Plates were incubated inverted at 37°C for 16 
hours.  
VII. Screening 
All vectors used during this investigation contain the ampicillin resistance gene, 
AMPr, which meant that inclusion of ampicillin in the LB agar enabled positive selection 
of transformed colonies. In addition, successfully ligated PCR inserts into the T-Easy 
vector were screened by a simple colour selection procedure due to the presence of IPTG 
and Xgal in the LB agar. This substrate is catalysed by the enzyme β-galactosidase 
(product of the lacZ gene), yielding colonies that appear a distinctive blue colour. As the 
incorporation of a PCR product into the pGEM vector destroys the lacZ gene, β-
galactosidase is not produced by successfully transformed cells, which therefore produces 
white colonies. 
To confirm that successfully transformed cells contained an insert, it was necessary 
to carry out sequencing analysis. Colonies were picked off the agar plate using a sterile 
pipette tip and lysed in 50 µL of ddH2O. This was done by heating at 96°C and then 
centrifuging at 914 x g for 10 minutes. 5 µL of the lysate was subjected to sqPCR 
amplification using primers that flank the cloning site SP6 reverse and T7 forward. PCR 
products were purified using the Gene Elute PCR Purification kit (Sigma) and sent to be 
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commercially sequenced (gene service, Cambridge UK) using the T7 forward primer. 
Typically, 4-5 molecules that were isolated from individual bacterial colonies were 
sequenced from each of the sample.  
2.5.3. Pyrosequencing 
Pyrosequencing, of sodium bisulphite converted DNA, is a sequence based analysis 
and can be used to accurately quantify the level of methylation at CpG sites. In this way it 
provides data on the individual level of methylation in the context of the underlying DNA 
sequence (Colella et al., 2003).  Pyrosequencing uses a single-stranded DNA templates for 
synthesis of a complementary strands and this is achieved  through the sequential addition 
of the four nucleotides (A, T, G, and C), where every successful nucleotide incorporation 
releasing pyrophosphate (PPi). PPi is converted to ATP by the enzyme sulfurylase and 
subsequently emits a light signal catalysed by the enzyme luciferase which is proportional 
to the number of incorporations. A pyrogram is generated with peak heights representing 
the intensity of light emitted from successful nucleotide incorporations informing on the 
sequence content in the analysed fraction. The degree of methylation is calculated from the 
pick heights of C and T as demonstrated in figure 2.1. 
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(A) 
 
 
(B) 
Figure 2.1. Representative pyrosequencing pyrogram. 
A sample read out of the program generated by the Pyro Q-CpG program of the EFEMP1 gene in a 
human post mortem pituitary (A) and a non-functioning pituitary tumour (B). The top left of each 
pyrogram shows the sequence analysed, where each of the individual CpG dyads are shown as YG. 
The sequence shown on the x axis is the nucleotide dispensation order, where the ratio between the 
T and C peak heights (wide grey vertical highlight) defines the percentage methylation (shown on 
the y axis). As internal control the efficiency of bisulphite conversion was determine from a 
cytosine (C) that was not in the context of a CpG dyad. The internal C is highlighted as a narrow 
grey vertical highlight. 
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I. Assay design 
For each gene, the methylation status of its promoter region-associated CpG island 
in normal pituitaries, cell lines, and primary human pituitary tumours was determined 
using primers that encompassed CpG dinucleotides within bona fide CpG islands. In these 
cases the islands were upstream of the transcription start site and frequently  extended into 
the first exon of the gene.  The primers used to examine the CpG island in each of the 
species, the number of CpG interrogated by pyrosequencing, and the sequence to analyse 
of each assay are shown in Appendix 3. These primers were designed to recognize sodium 
bisulphite converted DNA. For each gene, DNA sequences were downloaded from the 
Ensembl genome browser (http://ensembl.org). CpG islands were identified using online 
tool (http://cpgislands.com) and imported into PyroMark Assay Design 2.0 software for 
primer design of sodium bisulphite-converted DNA (Qiagen, Crawley, UK). In some cases 
the sequence analysed in human pituitary and adenomas encompassed and interrogated 1 
or 2 CpG sites which had also been interrogated in BeadArray analysis.  
II. PCR amplification 
2 µL sodium bisulphite-converted and whole genome amplified DNA were used as 
template in the first round of a nested PCR reactions. The product of the first round was 
diluted 100-fold in dH2O and 2 µL used as template in a second round nested PCR 
reaction. In the second round of each PCR reaction, 2 µL of template DNA, 1 unit of Taq 
DNA polymerase, 100 µM of dNTPs, and 10 pmol of each primer (see Appendix 3) in 
total volume of 25 µL. The same cycling condition were used for each  round of 
amplification. After initial denaturation at 98
o
C for 10 min,  touch-down cycling was 
employed for 14 further cycles, where,  in each successive cycle the temperature was 
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touched down by 0.5
o
C. The subsequent 35 amplification cycles include denaturing at 
98
o
C for 30 s, annealing at 55
o
C for 30 s and elongation at 72
o
C for 30 s. Additional 
elongation was set at 72
o
C for 10 min. Size and quantity of PCR products derived from the 
second round of amplification were determined on a semi-quantitative basis by 
visualization on agarose gel electrophoresis.  
III. Pyrosequencing  
20 µL of PCR products were mixed with 50 µL of streptavidin beads in binding 
buffer (Biotage, Upsala, Sweden) (10 mM Tris, 2 M NaCl, 1mM EDTA, 0.1% Tween 20, 
pH 7.6) at room temperature on a rotary shaker for at least 10 minutes. The biotinylated 
strand formed a complex with the streptavidin beads  due to the high affinity of biotin for 
avidin. During this binding reaction, a master mix of the annealing buffer, comprising each 
of the sequencing oligonucleotide (see Appendix 3) was prepared (0.5 µL of 100 pmol 
sequencing primer and 39.5 µL of annealing buffer) and 40 µL was pipetted into each well 
of a  96 well pyrosequencing plate. Once the plate was prepared the Biotage pyrosequencer 
(PSQ 96MA) (Biotage, Upsala, Sweden) was programed with the sequence for analysis 
and the dispensation order for the run. The PCR product/bead mixture was transferred  
from the shaker and the capture of the single-stranded and biotin-labelled DNA achieved 
using a Pyromark Q96 ‘Vacuum Prep’ Workstation (Biotage, Upsala, Sweden). The 
workstation aspirated the binding mixture which filtered the streptavidin-biotinylated 
single strand from the non-biotinylated single strand and removed all remnants of the PCR 
reaction by washing first with 70% ethanol, strand separation with 0.2 M NaOH and 
neutralisation with washing buffer (10 mM Tris pH7.6, adjusted with acetic acid). The 
washed biotinylated strands were then released into the prepared pyrosequencing plate. 
The plate was placed on a heating block at 80
0
C for 2 minutes to allow sequencing primers 
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to anneal to the target and then loaded into the pyrosequencer. The pyrosequencer cartridge 
contained the Pyro Gold sequence analysis reagent, provides each nucleotide, substrate, 
and the enzyme mix.  
Pyrosequencing was performed using a PSQ96A Pyrosequencer using Pyro Q CpG 
Software (version 1.0.9; Qiagen). For each set of independent bisulphite modification 
reactions, a control DNA sample was run to ensure efficient sodium bisulphite-mediated 
conversion. In addition, another bisulphite converted control was generated by adding of 
an additional C/T incorporation at non-CpG site in the sequence subject to-analysis (see 
Figure 2.1). The dispensation order (see Appendix 3) instructs the pyrosequencer to 
dispense each nucleotide based on the sequence order dictated for the  analysis and this can 
be modified to dispense more than one nucleotide at a particular site in order to determine 
which of the nucleotide is incorporated. In this instance the dispensation order was 
modified to dispense a C after a T nucleotide at each CpG site to provide information on 
the level of incorporation of either of these nucleotides. This gives an accurate measure of 
methylation which is directly related to successful C incorporations (see Figure 2.1). The 
results were analysed using the Q-CpG (Biotage) program and displayed as a pyrogram 
with each CpG site assigned percentage cytosine content and the mean of methylation level 
across all CpG sites interrogated in each assay. 
2.6. Gene expression analysis  
2.6.1. cDNA synthesis 
First strand cDNA synthesis was carried out from 1 µg of good quality total RNA 
prepared as described above. For the synthesis, 250 ng of random primers (Promega, 
Southampton, UK ) was added and incubated at 70°C for 5 minutes to melt and denature 
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any secondary structure. Samples were snap frozen before addition of 2.5 µL of 5 µM 
dNTP mixture and 200 units of M-MLV RT (Promega) and a reverse transcriptase buffer  
added to yield a final reaction volume of 25 µL. Samples were then incubated at 37°C for 1 
hour and stored at -80°C until required for RT-PCR. 
2.6.2. Primer design 
Primer 3 online software (http://frodo.wi.mit.edu/cgi-bin/primer3/primer3_www.cgi) 
was used to design all PCR primers used throughout this project, other than those used for 
PCR amplification of sodium bisulphite converted DNA and described in the preceding 
section. Genomic and cDNA sequences were obtained from the Ensemble genome browser 
(www.ensembl.org). Primer sequences with minimum self-complementarity, especially 3’ 
self-complementarity were chosen to avoid and mitigate against primer dimer 
amplification. In addition, primers yielding amplicons within a size range 100-300 bp were 
preferred, as these are known to produce more reliable results in quantitative analytical 
procedures.  
See Appendix 3 for a list of all primer sequence and amplicon sizes used 
throughout the study. All primers used throughout the study were purchased from Biomers 
and Invitrogen.  
2.6.3. qRT-PCR 
Real time quantitative qPCR allows quantification of PCR products in “real time” 
during each successive PCR cycle in the course of the reaction. Such reactions are carried 
out in a thermocycler that permits measurement of the fluorescent detector molecule such 
as the intercalating dye SYBR green, which fluoresces upon incorporation into double 
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stranded DNA. Increased fluorescence occurs as more dye is incorporated into the DNA as 
each cycle of the PCR reaction. Detection of fluorescence at each successive cycle allows 
an amplification plot to be generated. As well as decreasing post-processing steps this 
methodology minimises experimental error since SYBR Green is not sequence dependant 
and (unlike other qPCR probes for example TaqMan), it can be used for any reaction. 
Quantitative PCR amplification was performed using a Stratagene Mx3005P 
thermal cycler (Agilent, Cheshire, UK). Reactions were prepared containing 1X Brilliant 
III SYBR Green QPCR mastermix (Agilent), 0.5 µL 20 pmol of forward and reverse 
primer and ddH2O. 11.5uL of the reaction mixture was added to individual wells of 96 
well plate or to individual wells of 8 strip tubes (Agilent) and 1 uL of either cDNA 
template or no template control was added to each well. All samples were analysed in 
triplicate to account for technical variation. The following reaction conditions were carried 
out, which comprised activation of hot start Taq  (96°C for 3 minutes) followed by 40 
cycles (96°C 30 seconds followed by an annealing and elongation step for 30 seconds). A 
dissociation curve was included at the end of each reaction to ensure that specific 
amplification has been achieved.  
This method is relative, as it requires normalisation to an endogenous control gene. 
In the studies described in this report the endogenous controls were Glyceraldehyde 3-
phosphate dehydrogenase (GAPDH) or Porphobilinogen deaminase (PBGD) (see appendix 
2 for primer sequences). There are two methods by which qRT-PCR can be performed: the 
relative standard curve and the 2-ΔΔCT method. The relative standard curve method uses 
serial dilutions of cDNA samples, of known concentrations, from which unknown samples 
are quantified. This is achieved by amplification of the standards alongside the unknowns. 
It is possible to derive a standard curve for both the target gene and the endogenous 
control, thereby permitting relative levels of expression to be determined. In these types of 
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experiments it is important to include a standard curve on every plate analysed to 
counteract potential variability between PCR runs. This method requires minimal 
validation because the PCR efficiencies of the target and endogenous control do not have 
to be equivalent as different efficiencies are accounted for by the standard curve.  
For samples analysed by the 2-ΔΔCT method the comparative differences between 
the gene of interest and the endogenous control are calculated by a mathematical formula, 
and as such a standard curve is not required. First, the difference in the cycle threshold 
(CT) of the gene of interest and endogenous control is calculated (the ΔCT). Next, 
subtraction of the control ΔCT from the treated ΔCT yields the ΔΔCT. The negative value 
of subtraction, the –ΔΔCT, is used as the exponent of 2 in the equation and represents the 
difference in “corrected” number of cycles to threshold. For all genes analysed using this 
method it is necessary to ensure the template amplification for the target gene occurs at the 
same efficiency as for the endogenous control. Therefore, during optimisation experiments, 
the standard curve analyses are carried out as described above, however, the difference in 
CT between endogenous control and gene of interest are plotted against log (base 10) input 
across the dilution range. Regression slopes <0.1 are considered to be acceptable for 2-
ΔΔCT analyses.  
2.7. Histone modification analysis  
Chromatin immunoprecipitation assay (ChIP) is a powerful technique allowing 
analysis of protein modifications within specific genomic regions. ChIP is used to 
determine changes to epigenetic signatures, chromatin remodelling and transcription 
regulators that are recruited to specific genomic sites. Although ChIP is a versatile and 
powerful tool it is technically demanding and for the studies described in this thesis the 
Active Motifs ChIP-IT Express Enzymatic Kit (Rixensart, Belgium) was employed. There 
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are five main stages to the procedure. In brief intact cells are fixed using formaldehyde, 
which crosslinks and preserves protein and DNA interactions. The DNA is then sheared 
using an enzymatic digestion cocktail containing micrococcal nuclease, into small uniform 
fragments. Specific protein and DNA complexes are immunoprecipitated using antibodies 
directed against the DNA-binding protein of interest (see below for more detail). Once 
antibodies have bound the enriched fractions are pulled down with the aid of magnetic 
beads coated in protein G which has a high binding affinity for the antibody. Following 
immunoprecipitation cross linking is reversed, the proteins are removed by treatment with 
proteinase K and DNA is recovered. The DNA is then analysed to determine which DNA 
fragments were bound to the protein modification of interest. In this study this was 
achieved through qRT-PCR. The steps of ChIP protocol are illustrated in figure 2.2. 
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Figure 2.2. Schematic of chromatin Immunoprecipitation using ChIP-IT
TM
 Express. 
Adapted from ActiveMotif Epigenetic Products and Services 2013 Brochure  
 
2.7.1. Cell collection and DNA-protein crosslinking 
Cells were first grown to 70-80% confluency (approximately 1-1.5 million cells) in 
a T75 flask. Cells were then detached from the surface of the flask using PBS-EDTA and 
transferred to a siliconised 50 mL tube and centrifuged at 150 x g for 5 minutes. The 
supernatant was discarded and the pellet washed with ice cold PBS. This was again 
centrifuged. A solution of DMEM media containing a final concentration of 1% 
formaldehyde was added to cells and the cell pellets were disassociated by pipetting and 
incubated on a rotary shaker for 5 minutes. For tissue samples, the 1% formaldehyde-
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DMEM solution was added to the tissue and homogenised in a dounce homogeniser. 500 
µL of the glycine solution, supplied with the kit, was added at room temperature and 
rotated on the rotary shaker for 5 minutes to stop excessive crosslinking and  centrifuged as 
described above. 
2.7.2. Cell lysis and enzymatic chromatin shearing 
After the fixation step described above, the cells were first lysed in the lysis buffer 
supplemented with PIC (Protease Inhibitor Cocktail) and PMSF (Phenylmethanesulfony 
fluoride) for 30 minutes on ice. During this incubation the enzymatic shearing cocktail was 
prepared by diluting the supplied enzymatic shearing cocktail (2 x 104 U/ml) to 1:100 with 
a 50% glycerol solution. For the chromatin shearing step, and to generate fragments in the 
size range 150-1500 bp, it was necessary to perform enzymatic shearing in the presence of 
micrococcal nuclease. For these fragment sizes it was first necessary to optimise shearing 
in time course experiments. Therefore, the lysis solution together with the cells were 
transferred to an ice cold dounce homogeniser and then gently homogenised for 10 strokes 
on ice to aid nucleic acid release.  After transfer to a siliconised microcentrifuge tube and 
centrifugation (914 x g for 10 minutes at 4°C) the supernatant was discarded and the pellet 
resuspended in warm digestion buffer supplemented with PIC and PMSF and incubated at 
37°C for 5 minutes. 17 µL of the enzymatic shearing cocktail was added to the pre-warmed 
nuclei and subjected to gentle vortexing and incubated for 12 minutes at 37°C with 
intermittent vortexing. The enzyme activity was stopped by addition of 7 µL of ice cold 
EDTA and incubated on ice for 10 minutes. All samples were then centrifuged at 914 x g 
for 10 minutes at 4°C and the sheared chromatin supernatant collected. This could be 
stored at -20°C for later use. In this study, optimal enzymatic chromatin shearing generated 
bands and smearing between 150-1500 bp as shown in figure 2.3 
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Figure 2.3. Gel analysis of optimal enzymatic shearing. 
L: 100 bp ladder; GH3 and AtT20: sheared chromatin derived from GH3 and AtT20 cells, 
respectively 
2.7.3. Immunoprecipitation 
The antibodies used for the described studies were purchased from Abcam 
(Cambridge, UK). The antibody used to detect active genes recognises the H3K9Ac 
(histone 3 lysine 9 acetylation) modification (Jenuwein and Allis, 2001). The antibody 
used to detected silenced genes recognises the H3K27Me3 (histone 3, lysine 27 tri-
methylation)  modification (Cao et al., 2002a).  
After thawing the samples generated in step 2 (see above), 10 µL of the chromatin 
was set aside and represented input DNA. For the samples subject to immunoprecipitation,  
60 µL of sheared chromatin was added to  siliconised tubes together with the following 
reagents; 25 µL protein G beads, 10 µL Chip Buffer, 1 µL PIC water and  modification 
specific antibody and transferred to a rotary shaker for 4 hours at 4°C. The protein G beads 
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were magnetic beads coated with protein G. The protein G has a binding affinity for the 
antibody heavy chains and was, therefore, able to pull down the antibody in a complex 
with the specific histone modification. The DNA-histone complexes were 
immunoprecipitated and washed. Immunoprecipitation was achieved by placing the tubes 
on a magnetic stand to pellet the beads and the supernatant was removed without 
disturbing the beads. The beads containing the complex were washed with ChIP buffers 1 
and then 2 several times and pelleted using the magnetic stand. 
2.7.4. Reversal of Crosslinking and DNA isolation. 
Following the wash steps, the chromatin was eluted from the antibody that was in 
turn bound to the protein G beads. This was achieved by addition of 50 µL elution buffer 
and incubating for 15 minutes with intermittent pipette mixing at room temperature. The 
reverse cross linking buffer was added (50 µL) and tubes immediately transferred to the 
magnetic stand to allow the beads to pellet. The supernatant (100 µL at this point), which 
contained the chromatin was transferred to a fresh tube. 
The immunoprecipitated chromatin and the input chromatin (see step 1) were 
treated separately. 88 µL of ChIP buffer was added to the 10 µL of input sample.  2 µL 
sodium chloride solution was added to both input and immunoprecipitated samples and 
heated to 95°C for 15 minutes in a thermal cycler. Proteinase K (2 µL) was then added to 
both immunoprecipitated chromatin and Input chromatin and incubated at 37°C for 1 hour. 
This step effectively digests proteins including the histones that were in complex with the 
DNA. After the incubation period proteinase K stop solution (2 µL) was added to the 
reaction. The DNA within this solution was then concentrated by binding onto PCR 
GeneElute columns (as described in a previous section).   
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2.7.5. Quantitative PCR and data analysis. 
Primers were designed to amplify a region within 300 bp of the known or presumed 
transcription start site (TSS) (Roh et al., 2006). In cases of human and mouse, TSSs of 
EFEMP1/Efemp1 genes were obtained from The Eukaryotic Promoter Database (EPD) 
available online at http://epd.vital-it.ch/. This database was considered at the highest priority 
for selecting TSS because it provides experimentally validated promoters (Dreos et al., 
2013). However, EPD does not include rat genome. Therefore, the TSS of rat Efemp1 was 
obtained from University of California, Santa Cruz (UCSC) Genome Browser available at 
http://genome.ucsc.edu. After determining TSS, the sequence of -150 to +150 relative to 
TSS was retrieved and served as template for primer design using Primer 3 online tool 
http://bioinfo.ut.ee/primer3-0.4.0/.  
The input DNA was further diluted 1:10 using ddH2O. A qRT-PCR was set up 
using the DNA isolated by immunoprecipitation of the sheared chromatin and also the 
Input DNA as a control sample for 50 cycles. The method used to normalise the ChIP-
qPCR data is the percentage input method. It is important to normalise against the input as 
the input sample represents the total chromatin pre-enrichment. There are several dilution 
steps subject to immunoprecipitation it is therefore necessary to use a dilution correction 
factor for the input. This allows you to calculate equal concentrations of the 
immunoprecipitated sample and the input. It allows comparison of “like with like” 
samples. The input sample represented 1/60 of the sample used for immunoprecipitation 
and therefore necessary to adjust this to 60%. The correction factor of this is to subtract 5.9 
Ct values (The starting material is 1/60, a dilution factor of 60 needed to be taken into 
consideration, this is 5.9 cycles and was found by log2 of 60. This was then subtracted 
from the Ct values of the input as demonstrated in figure 2.4). 
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The following equation was used to calculate the percentage enrichment relative to 
the input 100 X 2
(adjusted input - CT IP)
 see figure 2.4 below for a breakdown of this calculation. 
 
Figure 2.4. ChIP calculations. 
A detailed example of the ChIP calculations used within this study. IP is the immunoprecipitated 
sample. 
(*) 5.9 cycles was found by log2 of 60 fold dilution 
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2.8. Functional analysis 
2.8.1. Subcloning of target gene into pTUNE vector 
The complete coding sequence of human EFEMP1 (GenBank accession no. 
NM_004105) was purchased as a cDNA clone (OriGene). The entry vector containing 
EFEMP1 and the empty pTUNE vector (see Appendix 4) were transformed into E. coli 
strain DH5α by heat shock as described previously in this thesis and spread onto LB-agar 
plate containing 60 µg/mL kanamycin and 60 µg/mL ampicillin, respectively. Individual 
colonies were grown at 37
o
C overnight in LB media supplemented with appropriate 
selective antibiotics. E. coli cells were pelleted by centrifugation at 4000 RPM and 
plasmids were extracted by QIAprep Spin Miniprep Kit (Qiagen) following manufacturer’s 
protocol.  
1 µg of EFEMP1 entry vector and empty pTUNE vector were digested by KpnI and 
XhoI restriction enzymes in 1X Tango buffer (Thermo Scientific) at 37
o
C for 90 minutes. 
Digested products were purified, ligated, and transformed as described in 2.5.2 section. 
Transformed E. coli cells were plated on the surface of LB plate supplemented with 
60µg/mL ampicillin. Individual colonies were screened by PCR using human EFEMP1 
qRT-PCR primers (Appendix 3). Positive clones were confirmed by digestion with KpnI 
and XhoI restriction enzymes where bands correspond to EFEMP1 and linearized pTUNE 
vector (1482 bp and 12.1 kb, respectively) were visualized. One single clone of pTUNE-
EFEMP1 (clone number 2) was selected for the subsequent experiments. 
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2.8.2. Stable transfection of rat pituitary cell line GH3 
Lipofection, was the technique of choice and was used to introduce genetic material 
into cells via liposome mediated endocytosis. Liposomes are artificially prepared vesicles 
that are composed of a phospholipid bilayer, a property that allows them to easily fuse with 
the mammalian cell membrane. This technique is efficient and is capable of transfecting 
most types of nucleic acids into a wide range of cell types. This technique is a simple, 
reproducible and in general shows minimal toxicity. For the studies described in this thesis 
this technique was used exclusively for the introduction of inducible expression vector 
pTUNE into GH3 cells. 
The day before transfection cells were seeded at a density of 2 X 10
5
 cells per well 
in a 6 well plate such that the cells would be at approximately 50% confluence at the time 
of transfection. For each transfection two separate solutions were prepared in sterile 1.5 ml 
tubes. The first solution contained of 15 µL of Lipofectin and 85 µL of serum free DMEM 
culture medium  and was left at RT for 45 minutes. The second solution contained 10 µL 
of DNA (at 1 µg/µL) and 90 µL of serum free DMEM culture medium. The two solutions 
were combined, mixed by inverting and incubated at RT for 15 minutes. During the course 
of this incubation the media was removed from the cells and cells washed twice with 2 mL 
of serum free media. Following incubation 800 µL of serum free media was added to the 
combined solution and the 1 mL DNA/lipofectin/media mixture was dispensed onto the 
cells in drop wise manner. Cells were then incubated in cell culture incubator at 37
0
C for 6 
hours. The transfection solution was then replaced by 2 mL of complete media and the 
cells allowed to proliferate for 48 hours. Cells were then detached and diluted 1 in 5 into 
separate chambers of a 6 well plate. Selective agent, geneticin, was added to the cells at 
600 µg/mL and cells grown for 14 days with washing and feeding every two days. Cells 
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harbouring the inducible vector, on the basis of their antibiotic resistance were harvested 
and used for subsequent analysis.  
2.8.3. Characterization of stable transfected cells 
Inducible expression of EFEMP1 was determined by treating cells with a range of 
IPTG concentrations and measuring expression of EFEMP1 at transcript level by qRT-
PCR. Cells were seeded at density of 1 X 10
5
 cells/mL into 25 cm
2
 culture flasks in total 
volume of 5 mL of media and induced with 2.5 µM, 5 µM, 25 µM, 100 µM, and 500 µM 
of IPTG for 24 hours. Cells were then harvested and used for total RNA  extraction 
following by cDNA synthesis. qRT-PCR was performed using transcript specific primer 
for the  EFEMP1 and rat Pbgd genes (see Appendix 3).  
2.8.4. Cell proliferation analysis by growth curve 
The effect of induced EFEMP1 expression was first assessed in stable transfected 
clones (GH3-EFEMP1) relative to cells harbouring an empty vector control (GH3-Cont). 
GH3 cells were seeded into six-well plates (Corning) at a density of 2.5 X 105 per well 
supplemented with 600 µg/ml of Geneticin and induced with 100 µM IPTG or vehicle 
control. Media were replenished at 2 day intervals. Triplicate individual flasks were 
sacrificed at each time point (2 day) and cells were counted and their viability determined 
by trypan blue exclusion. The experiment was repeated three times. 
2.8.5. Apoptosis analysis by caspase 3/7 assay 
Activated caspases were detected using Caspase-Glo
TM
 KIT (Promega) that 
specifically detects either  of the initiator caspases (Caspase-8 or Caspase-9) or the 
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terminal caspases (Caspase 3 and 7). Caspase-Glo assay is a luminescent assay that utilizes 
the proluminescent caspase substrate and a thermostable luciferase in a single reagent 
optimized for caspase activity, luciferase activity, and cell lysis. Addition of Caspase-Glo 
reagent to the cells results in cell lysis, followed by caspase cleavage of the substrate to 
generate aminoluciferin. The liberated aminoluciferin is consumed by the luciferase 
enzyme generating a “glow-type” luminescent signal. The signal is proportional to the 
specific caspase activity. This assay system enables detection of caspase activity in a 
multiwell plate format using cells (treated or untreated) in culture. 
Cells were seeded into 96 well plates at a density of 1X10
5
 cells/ml and incubated 
overnight in growth media. For various duration of time, semi-confluent cultures were 
challenged with bromocriptine, shown previously to induce apoptosis in the cells (Rowther 
et al., 2010), but in this case  in the absence of presence of inducer IPTG. Duplicate sets of 
the cells treatments were carried out such that one set was used for caspase activity while 
the second one was used for the cell number correction (see 2.8.6). 
The assay reagents which include caspase-glo substrate, caspase-glo buffer, and 
MG-132 (proteasome inhibitor, optimal for caspase-8 and 9 assay) were combined to make 
a ready to use assay reagent. 50 µL of the culture media was aspirated from each well to be 
analysed for caspase activity (originally each well contained 100 µL culture media). The 
ready-to-use reagent was then added to each well of the 96 well plate containing the treated 
or untreated cells in 1:1 ratio (50 µL of culture media : 50 µL of ready-to-use caspase-glo 
reagent). The plates were rocked sideways to mix the contents of the wells and incubated 
(covered by an aluminium foil) at room temperature for 45 minutes. Assay was performed 
for each type of sample in triplicate wells. At the end of the incubation, 75 µL of the 
content of the wells were transferred to a detection tube (Sarstedt) and the luminescence 
was recorded using a tube luminometer (Lumat LB9507, Berthold Technologies, 
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Hertfordshire, UK) set to read for 10 seconds. Data was analysed after correcting for the 
cell numbers measured by crystal violet staining. 
2.8.6. Cell correction using crystal violet staining 
In order to normalize the readings obtained from caspase assay to the number of 
cells, cell correction was carried out. Crystal violet (CV) was used to stain the cells. CV is 
an intense stain that binds to the cell nuclei and gives an OD reading at 595 nM  which is 
proportional to cell number. 
Semi-confluent cultures were challenged with bromocriptine in the absence or 
presence of IPTG. Following challenge the cells were fixed by replacing the growth media 
with 100 µL of 4% formaldehyde (Sigma) in PBS (Sigma). To minimize the escape of 
formaldehyde vapours, a piece of parafilm was placed over the plate and covered with the 
lid. The covered plate was incubated at room temperature for 20 minutes. At the end of the 
incubation, formaldehyde solution was removed and the cells were washed 3 times with 
200 µL of 1X PBS buffer. Each wash step was performed for 5 minutes with gentle 
shaking. Washed plate was air-dried for 10 minutes and used for CV staining. 100 µL of 
1% SDS solution (Sigma) was added to each well and incubated at room temperature for 
30 minutes. The wells were washed again and air-dried before adding 100 µL of 1% SDS 
solution (Sigma) to each well. The plate was incubated on a shaker for an hour at room 
temperature. The absorbance was determined on a spectrophotometer (Dynatech MR5000) 
at 595 nm. Occasionally when the signals obtained for certain samples were greater than 
the range of the spectrophotometer, the signal was reduced by removing some (e.g.50 µL) 
of the liquid from each well and replacing with an equivalent volume of ddH2O.  
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Section C: Results and Discussions 
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Chapter 3: Whole genome amplification of bisulphite 
converted DNA 
As described in section 1.3, one of the major constraints  of epigenetic studies 
employing  pituitary tumours and normal gland is their relatively small size. For the whole 
genome analyses described in this thesis a range of techniques and their associated end-
points were proposed. These end-points included: BeadArray analysis, bisulphite 
sequencing, pyrosequencing across multiple genes, quantitative reverse-transcript PCR 
(qRT-PCR), and chromatin immunoprecipitation (ChIP analyses). Of these, the first three 
requires DNA; qRT-PCR requires mRNA; and ChIP requires chromatins. Therefore, to 
reduce the impact imposed by sample limitations, I first optimised and validated the  
technique Whole Genome Amplification of  Bisulphite Converted of DNA (BSC-WGA-
DNA). This technique is expected to provide more material for three end-point analysis 
that works on DNA mentioned above. 
3.1. Whole genome amplification of bisulphite converted DNA 
The literature describes two whole genome amplifications (WGA) methods. The 
first, primer extension pre-amplification (PEP) which  is a PCR-based technique using Taq 
DNA polymerase and random primers to amplify genomic DNA (Zhang et al., 1992). The 
second method, multiple displacement amplification (MDA), is a non-PCR technique 
which employs an isothermal genome amplification of ϕ29 DNA polymerase to amplify 
genomic DNA (Dean et al., 2002). Of these two methods, since the PEP technique has 
been used previously by other investigators (Mill et al., 2006)  to  amplify bisulphite 
converted DNA (BSC)  this method was chosen for preliminary investigation and in the 
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subsequent studies described in this thesis. However, in this case the  WGA amplification 
technique  is a modification of a technique first described by Zhang et al (Zhang et al., 
1992). For convenience, throughout the rest of this thesis, bisulphite converted DNA either 
prior to or following WGA are termed WGA- and WGA+, respectively.  
WGA was performed as described in M&M section and the result is presented in 
figure 3.1. 
 
 
Figure 3.1. Whole genome amplification results in amplification of bisulphite converted DNA 
20 ng of BSC DNA derived from a primary pituitary tumour was used as template for WGA 
reaction. The equal amount of BSC DNA (WGA-) is not visible. The non-template control (NTC) 
is not visible indicating that there is no contamination during the experiment. The whole genome 
amplification (WGA+) results in a clearly visible band and slight smear located closely to the 
loading well. This indicates that BSC DNA was efficiently amplified by WGA technique. 
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In figure 3.1, the DNA from the non-template control WGA reaction (lanes 3) is 
not visible, demonstrating that there is no contamination of the PCR reaction. In lane 2, 20 
ng of converted, but not amplified DNA (WGA-),  is not visible on the gel, however this 
amount was efficiently amplified through WGA (WGA+) that is evident as an intense, 
unresolved band,  located mainly within the electrophoresis well (lanes 4).  
Subsequently, both WGA- and WGA+ were subjected to sequence- and BSC-
specific nested PCR amplification and the results are presented in figure 3.2. In these 
examples different primer pairs, showing different, relative, amplification efficiencies are 
shown in panel A and B respectively. 
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                       (A) 
 
                        (B) 
Figure 3.2. Representative examples of sequence-specific nested PCRs using dilution series of 
WGA- and WGA+ as templates. 
(A) A dilution series from 0 to 12 of 20 ng of BSC DNA derived from a single primary pituitary 
tumour was used as templates for PCR amplification using GLRX gene specific primers (left 
panel). A specific amplicon is visible in dilutions that ranged from 0 to 8. However, this is invisible 
at fold dilution of 10 and above. In WGA+ series (right panel), PCR using dilution series of WGA 
derived from the BSC DNA in the left panel were succeeded at dilution folds from 25 to 100 
relative to the amount used for WGA reaction which is equal to the one used in WGA- lane 0 (20 
ng).  
(B) In the case of MBD primers, the fold dilutions of WGA- and WGA+ which showed clearly 
visible products are 0 and 200, respectively.   
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The success of nested PCRs using not only WGA+ but also WGA- as templates 
shows some differences in amplification efficiencies. However, a range of successful 
amplification is apparent in dilutions that ranged from  25 fold to 500 fold of WGA+ 
relative to WGA-. As example, for the  GLRX gene specific  primers (Fig 3.2A) an 
amplicon is apparent at 25 and 50 fold dilutions in the lanes denoted as  WGA+, whereas 
in the lanes denoted as WGA- dilutions in excess of 8 fold were not visible on the gel. For 
amplifications shown in panel B, using in this case primers to the  MBD3 gene were 
successful at dilutions up to  200 fold  in the WGA+ amplified DNA. Conversely, in the 
WGA- DNA amplification in excess of 0 fold were not detected (figure 3.2 B). In most 
cases,  a 25 dilution fold WGA+ DNA relative to DNA that had been converted, but not 
amplified, DNA  (WGA-) reproducibly provided high quality PCR products for the 
majority of  primers used in this study. On this basis this dilution factor was used for the 
experiments presented in this thesis. In these cases, therefore, the WGA efficiently  
increased the limitation  on DNA availability by  25 fold . 
3.2. Integrity of methylation profile of BSC DNA prior to and following WGA 
The integrity of DNA methylation sequence profiles of WGA- relative to WGA+ 
DNA  were assessed by two independent techniques that included Sanger sequencing and 
Pyrosequencing.  
3.2.1. Sanger sequencing 
PCR products of a methylated gene (MBD3) and non-methylated gene (GLRX) 
derived from WGA- and WGA+ templates were cloned into pGEM-T vector for Sanger 
sequencing. Result is presented in Figure 3.3. For the MBD3 gene, all of the CpG sites of 
three PCR clones derived from WGA- and of four PCR products derived from WGA+ 
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were methylated. For the  GLRX gene, three  CpG sites among a total of 16 CpG sites from 
WGA- were methylated and a single CpG site in the WGA+ were methylated. Although 
the number of sequenced clones is somewhat  limited, the data shows a consistent 
methylation pattern between PCR products derived from WGA- and WGA+. 
 
Figure 3.3. Sanger sequencing of MBD3 and GLRX. 
PCR products from figure 3.2 were cloned and sequenced to determine their methylation status. 
Beads on a string depiction of single DNA molecules post T:A cloning are shown in each case  
strand. Filled circles (beads) are methylated CpGs, un-filled circles are non-methylated CpGs. In 
the case of MBD3 gene, all of the CpG sites of three PCR clones derived from WGA- and of four 
PCR products derived from WGA+ were methylated. In the case of GLRX gene, three  CpG sites 
among a total of 16 CpG sites from WGA- were methylated and a single CpG site in the WGA+ 
were methylated. 
3.2.2. Pyrosequencing 
Pyrosequencing assays of three genes (GLRX, H19, and HAAO) were designed to 
interrogate  the methylation status of a single  CpG per assay for GLRX and HAAO, and 
two CpGs per assay for H19. Nested PCRs were performed on  WGA- and WGA+ of 14 
pituitary samples, and PCR products were subsequently subjected to pyrosequencing 
reactions. Figure 3.4 showed the correlation of 56 pairs of methylation values between 
WGA- and WGA+ samples. Strong positive correlation was observed (R
2 
= 0.9677, 
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p<0.0001). This data confirms that the WGA protocol described in this study is 
reproducible and reliable. 
 
Figure 3.4. Correlation of methylation status produced by pyrosequencing derived from 
WGA- and WGA+. 
Methylation status of a single CpG site of three genes (GLRX, H19, and HAAO) and two CpG 
sites of H19 were interrogate by pyrosequencing. WGA- and WGA+ of 14 pituitary samples were 
used for nested PCR. Subsequently, these PCR products were subjected to pyrosequencing 
reactions that enabled the examination of the correlation of 56 pairs of methylation values between 
WGA- and WGA+ samples. Strong positive correlation was observed (R2 = 0.9677, p<0.0001). 
 
3.3. Discussion 
At the inception of my doctoral studies the technical limitations imposed by tumour 
size were realised. Furthermore, initial discussions and a review of the literature suggested 
the importance of performing analyses across and within individual tumours. It was, 
therefore, considered important to determine epigenetic modifications and expression not 
only within each of the individual adenoma but also across multiple adenoma subtypes. 
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Since, in some cases, pituitary adenomas are less that 5mm in diameter, it was  necessary 
to perform whole genome amplification (WGA) to generate sufficient DNA for analysis. 
However, a caveat associated with this approach is that although it leads to amplification 
of DNA, either pre- or post- sodium bisulphite conversion, it is not suitable for increasing 
the relative amount of material available for analyses of histone modification (ChIP) or 
indeed transcript expression. Therefore, the initial focus of my studies was to employ and 
optimise the whole genome amplification of sodium bisulphite converted DNA (BSC-
WGA) technique to increase the amount of sample DNA. However, it was important to 
determine, not only the approximate amplification but the integrity of the sequence  pre- 
and post- amplification.  
The BSC-WGA protocol described by Mill et al (Mill et al., 2006) was employed 
to amplify genomic DNA extracted from pituitary tumours. In their study, Mills and 
colleagues achieved an amplification of  some 113 fold following amplification (WGA+)   
and relative to converted DNA that had not been subject to amplification (WGA). 
However, in this case the fold amplification was determined on the basis of that obtained 
with four primer pairs. My own studies employed, in total, more than 50 primer pairs, and 
across these different primers a range of amplification efficiencies were apparent (data not 
shown). However, a principle concern was to develop and optimise a technique that was 
reliable and reproducible. Furthermore, it was important to use conditions where the 
sequencing of post amplified DNA reflected that observed pre amplification. In this case, 
and as detailed in the results section, condition were used that provided a reliable and 
consistent 25 fold amplification and in this way provided confidence in the technique and 
in the derived sequencing data.  
The integrity of the DNA sequencing profiles  following the WGA of BSC 
converted DNA was determined by two techniques-Sanger sequencing of individual clones 
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(T:A cloning) and by Pyrosequencing. The first technique, bisulphite sequencing of 
individual clones showed that methylation profiles were maintained, that is faithfully 
replicated between WGA+ and WGA- DNA samples. Although I realised that only four 
Sanger sequencing reactions is a limited number to give a conclusion of unbiased 
methylation profile prior to and after WGA, I did not perform more Sanger sequencing 
because of i) similar findings, with respect to reproducibility, were also reported by Mills 
and colleagues (Mill et al., 2006) and ii) limited source of pituitary DNA. However, I was 
aware that Sanger sequencing of bisulphite converted DNA has some limitations since the 
findings are representative of a limited number of clones. In this case the clones analysed 
are those selected following T:A cloning. Although it is possible to sequence multiple 
clones this is not only time consuming but also have significant cost implications. To 
circumvent this limitation Mill et al employed methylation-sensitive single nucleotide 
primer extension (MS-SNuPE). In this case this technique has been reported to  provide an 
accurate assessment of  methylation to within approximately, 5% (Kaminsky et al., 2005). 
In this thesis, and consequent to technical advances I was able to determine methylation 
using the pyrosequencing technique. In this case the technique and its associated 
technology is capable of interrogating millions molecules in a single  reaction  (Colella et 
al., 2003) and in this way  provides a  more representative analysis of a poly or multi 
clonal population of molecules. Again, and in agreement with Mill’s results, my data 
showed significant correlation of the DNA methylation profiles between WGA+ and 
WGA-. Moreover, the unbiased methylation profile of DNA prior to and after WGA of 
BSC DNA has been widely reported (Mill and Petronis, 2009; Vaissiere et al., 2009; Mill 
et al., 2006).  
A further anticipated limitation associated with my study was that DNA 
methylation profiling strategies based on bisulphite treatment have reported the issue  of 
 109 
 
incomplete conversion of unmethylated C (Grunau et al., 2001; Genereux et al., 2008). To 
circumvent this issue the conditions for the conversion reaction needs to be harsh, 
however, this leads to the further concern of large-scale degradation of converted DNA 
(Grunau et al., 2001). Although  techniques are described that are designed to limit  
degradation of the DNA  these protocols requires multiple further manipulations and thus 
increase the likelihood of introducing errors (Olek et al., 1996). Furthermore, following  
bisulphite conversion the DNA strands loses their complementarity, since unmethylated C 
are converted to T and this contributes further to degradation issues. For these reasons 
commercially available BSC conversion protocols recommend that converted DNA to be 
used within one week of conversion.  However, a key advantage of WGA that we and 
others have noted (Mill et al., 2006) is that  post conversion the DNA again become double 
stranded and as such not only quantitatively increases the amount of BSC DNA, but also 
largely improves the stability and storage  time of valuable samples.  
In conclusion, WGA technique has been successfully adapted toward analysis of 
sodium bisulphite converted DNA from small samples of tumour material. This technique 
significantly increased and improved the sodium bisulphite conversion of DNA in both 
quantitative (typically ~ 25 fold) and qualitative (extended storage) terms. Sequence 
specific PCR were typically  successful using a 25 fold amplification of WGA+ relative to 
WGA- and the DNA methylation profiles derived from WGA- and WGA+ do not appear 
to show any bias. This simple and inexpensive technique is recommended for DNA 
methylation profiling studies where only limited sample are available.  
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Chapter 4: Genome-wide DNA methylation profiling of 
sporadic pituitary tumours 
The optimisation  of the WGA technique provides a reliable and reproducible tool 
to partially overcome the limitation of sample shortage. Therefore, this facilitated genome-
wide DNA methylation analysis of  promoter-associated CpG islands and characterisation 
of theirs consequent effects on gene expression. To determine the genome- wide subtype-
specific methylation profiles of sporadic pituitary adenomas several factors were taken in 
to account and that included, sample throughput, epigenome coverage, sample 
requirements, and costs. A decision between absolute adenoma number on the array and 
the individual adenoma subtypes investigated. A decision was made to use the recently 
commercialised Illumina Infinium 27K Assay. This assay is able to determine the 
methylation status of 27,578 CpG sites that span 14,496 genes. However, each single array 
is capable of interrogating 12 samples at most and with considerable cost implications. A 
further decision was that three samples of each adenoma subtype together with, as control, 
three post-mortem normal pituitaries would be investigated.   
4.1. Methylation profiling of sporadic pituitary adenoma 
As described in the preceding paragraph, the discovery cohort comprised adenomas 
that represented each of the major pituitary adenoma subtypes, non-functioning (NF), 
somatotrophinoma (GH), prolactinoma (PR) and corticotrophinoma (CT). Quantitative 
differential methylation was assessed relative to post-mortem normal pituitaries (NP).  
Before determining differential methylation, 1,092 CpGs (4%) in chromosomes X 
and Y were excluded because my pituitary samples were sex-independent. Next, 1,090 
low-quality probes (4%), which showed either detection probability >0.05 (internal quality 
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control) or null (missing) β value, were removed. In addition, 14,729 probes (53%) where 
β values were either ≤0.2 or ≥0.8 across the 15 samples were removed to reduce the 
number of non-variable loci as we and others have previously described (Byun et al., 2009; 
Fryer et al., 2011). Through application of these criteria, a total of 10,667 probes (39%) 
spanning 7,956 genes were included in the analysis. Compared to our lab’s previous 
publication (Fryer et al., 2011), 39% is the better percentage. Within this probe set, 5,287 
CpG were within and 5,280 were outside of CpG islands. A Kolmogorov–Smirnov test 
was used by our collaborator (Dr Richard Emes) to compare the distribution of β values 
between samples using the NIMBL Software (Wessely and Emes, 2012).  A single NP 
sample was identified as having a significantly different (P<0.05) distribution to the other 
samples and was excluded from further analysis (Appendix 7). To characterise the 
differential methylation profiles of the adenoma subtypes, we first performed a class 
comparison between each of the adenoma subtypes and relative to that apparent in the NP. 
For the comparison, we initially filtered for a minimum increase of Δβ of 0.4 relative to NP 
at single gene-specific CpG sites in at least two of three subtype-specific adenomas. This 
analysis identified 326 genes in the NF adenomas, 49 in PRL, 97 in GH and 4 in CT that 
were hypermethylated relative to NP supplemental data (Appendix 5). In the majority of 
cases and irrespective of subtype, the CpGs were within CpG islands. These findings were 
encouraging, in that they show genes that were methylated in common and also that were 
discrete across and with individual adenoma subtypes respectively. However, it was 
important that I was able to validate the BeadArray findings using an independent 
methodology, and this is described below.  
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4.2. Technical validation of Bead array by pyrosequencing 
To validate the BeadArray-generated data, I performed pyrosequencing analysis of 
six CpGs in six gene-associated CpG islands from the 12 samples (discovery cohort) that 
had been interrogated on the array. Of these seven CpGs, for technical validation purpose, 
the pyrosequencing assays of four sites (cg08047457, cg20289949, cg06197492, and 
cg24739326) were designed directly to target these CpGs which had been interrogated on 
the BeadArray. However, the other two assays were not designed for technical validation 
purpose. The reason is that in the later part of my study where the aim is to search for 
abnormal methylated genes in sporadic pituitary tumours, pyrosequencing assays were 
preferably designed to target 5 to 11 CpG sites (Appendix 3.2) located immediately before 
and partly overlap with the first exon of the corresponding genes because this region is 
usually associated with transcription regulation mechanisms. Because of this strategy of 
pyrosequencing assay designing, the majority of the CpGs interrogated by BeadArray were 
not included in pyrosequencing assays. Only two pyrosequencing assays of COL1A2 and 
KCNE3 includes CpGs on the array (cg18511007 and cg02595219, respectively) and 
therefore these data points were collected and included in this analysis. The analysis 
(Figure 4.1) for the quantitative measurement of CpG methylation showed the two 
techniques to be significantly correlated (Spearman’s r, 089; P≤0.0001). Importantly, the 
correlation involves samples across the range of β values and hence is unlikely to be an 
artefact due to dominance of extreme values (Roessler et al., 2012). In addition, inspection 
of the 20 imprinted genes interrogated on the array showed a mean β value of 0.51 ± 0.1 
across a total of 40 CpG sites. These β values are consistent with monoallelic methylation 
apparent in most normal tissues including pituitaries and providing further confidence in 
the methodological approach. 
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Figure 4 1. Correlation between BeadArray-derived β values (expressed as a percentage) and 
pyrosequencing across a range on β values from 12 adenomas for four CpGs 
The beta values (derived from BeadArray) and the methylation values (derived from 
pyrosequencing) of 6 CpGs (cg08047457, cg20289949, cg06197492, cg24739326, cg18511007, 
and cg02595219) of 12 pituitary tumours were compared. Correlation of 72 data points of data 
shows good correlation (Spearman’s r, 0.89; P≤0.0001) between the two techniques that are 
BeadArray and Pyrosequencing. The aim of this experiment is to technically validate the reliability 
of BeadArray assay, therefore, data points above 0.8 and below 0.2 were not excluded as described 
in section 4.1. 
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4.3. CpG island methylation profiles in primary adenoma subtypes 
To determine the relationship between methylation at array-interrogated CpG sites 
and methylation across the gene-associated CpG islands, pyrosequencing analysis was 
used that encompassed, in each case, between 5 and 11 CpGs (Appendix 3.2). As described 
in section 4.2, the CpGs interrogated by BeadArray were rarely included in 
pyrosequencing assay, except for the two cases of KCNE3 and COL1A2. Initially, 22 genes 
were selected on the basis that they each showed a Δβ of ≥0.4 (in at least two of the three 
NF adenomas) relative to NP and where the array-interrogated CpG are within promoter-
associated CpG islands (Table 4.1). The analysis was initially performed in the discovery 
cohort of adenomas and relative to four NP. Mean methylation across these CpGs, as 
determined by pyrosequencing, was able to confirm the BeadArray methylation status for 
only 12 of the 22 genes (55%). However, it is interesting to note that where concordance 
between the techniques is observed (12 of 22 genes), it was for genes that were represented 
by more than one island-associated CpG on the array, and where the Δβ for the second 
CpG also showed increase.  
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Gene  
BeadArray Pyrosequencing  
Criteria 
Number of NF tumours showing 
increase in mean methylation of 
CpG islands relative to NPs 
EML2 
1st CpG ≥ 0.4 
2
nd
 CpG ≥ 0.25 
2 
RHOD 2 
HOXB1 1 
FLJ46380 2 
MT1G 2 
HAAO 2 
KIAA1822 3 
KCNE3* 3 
TFAP2E 2 
BCL9L 1 
PGLYRP1 2 
COL1A2* 2 
ST6GALNAC6 0 
UBTD1 0 
KIAA0676  0 
PDLIM4 0 
CXCL14 
2nd CpG < 0.25 
0 
FEM1C 0 
MAL 0 
RAMP1 0 
D4ST1 0 
SAMD11 0 
Table 4.1. Identity of 22 randomly selected genes from the BeadArray dataset. 
22 of the genes were selected on the basis that they had at least one CpG within the gene (in at least 
two of three specimens of an adenoma subtype) with a β value of ≥0.4  relative to the values seen 
in NP. Of these 22 genes 16 also harboured a further (second) CpG where the β value was ≥ 0.25 . 
For the 6 genes selected on the basis that they had a single CpG within the gene (in at least two of 
three specimens of an adenoma subtype) with a β value of ≥0.4 the second CpG was ≤0.25and 
relative to the values seen in NP. Genes where pyrosequencing validated their methylation status of 
the promoter-associated CpG islands are shown in bold. Genes indicated by a (*) possess a 
BeadArray CpG which is also interrogated by Pyrosequencing.  
Pyrosequencing was performed on the remained DNA of the 3 NF and 2 NPs of the discovery 
cohort returned from Illumina.  
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For the 22 genes selected for pyrosequence analysis, on the basis of a single CpG 
site, 16 genes also showed increase in a second CpG site (β≥0.25), in at least two of the 
three NF adenomas that had also been interrogated on the array (Table 4.1). Of these 16 
array-identified genes, pyrosequence analysis confirmed increase in mean methylation 
(across 5 to 11 CpG sites) for 12 of 16 (75%) genes in the discovery cohort of NF 
adenomas. It is worth to note that in cases of two genes (KCNE3 and COL1A2) where a 
CpG interrogated by BeadArray were also included in pyrosequencing, the β-value of this 
CpG determined by BeadArray is not only strongly correlated with its methylation level 
determined by pyrosequencing (Figure 4.1),  but also reflects the methylation status of the 
surrounding CpG regions. However, because of the limited number of these cases, it is 
risky to give a conclusion. The aim of my phd study (Section 1.4) was not designed for 
technical validation of BeadArray assay. It was finding novel genes related to 
tumourigenesis of sporadic pituitary tumours. Therefore, there should be another study to 
deal with the question of whether methylation of a single CpG correctly reflect methylation 
of it’s surrounding CpGs region. 
On the basis of the finding described earlier, we modified our filter criteria to 
include genes where one of the two CpGs showed a Δβ of ≥0.4 and a second CpG a Δβ of 
≥0.25 and where these criteria were fulfilled in at least two of the three adenomas (within a 
subtype) interrogated on the array. The revised, more stringent, filtering criteria identified 
40 genes in NF adenomas, 21 in GH, 6 in PRL and 2 in CT that showed increase in 
methylation-relative to NP (Table 4.2). Table 4.2 also shows genes that are methylated in 
common across adenoma subtypes and those that segregate with one or more pituitary 
adenoma subtypes. In addition, and for two of the adenoma subtypes, NF and GH, where 
these criteria were met in multiple genes, we generated a heatmap displaying β values 
across individual adenomas within these subtypes (Figure 4.2).  
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Gene GH NF PRL CUSH 
SEPT9         
ACTA1   
  
  
ADRA1A 
  
   
ALX4  
  
  
BCL9L 
 
 
 
  
BIK 
 
  
 
  
BMP8A 
 
  
 
  
C1QTNF5 
 
  
 
  
C6orf150  
 
   
CHST8   
  
  
CNFN 
 
 
 
  
COL1A2    
 
  
CRIP1 
 
  
 
  
DLX5  
  
  
EFEMP1   
  
  
EFS 
 
 
 
  
ELN 
 
  
 
  
EML2 
 
  
 
  
ENTPD2 
 
  
 
  
ERBB2    
 
  
FLJ32569   
  
  
FLJ32569 
   
  
FLJ46380   
 
  
FLJ90166     
 
  
HAAO     
 
  
HAS1 
 
  
 
  
HDAC11 
 
  
 
  
HOXB1 
 
  
 
  
KCNE3 
 
  
 
  
KCNQ1 
  
   
KIAA0676       
KIAA1822         
LDHC 
 
  
 
  
MT1G 
 
  
 
  
NPPB 
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PDLIM4 
 
  
 
  
PGLYRP1    
 
  
PON3 
 
  
 
  
RAB34 
 
  
 
  
RAC2  
  
  
RASSF1   
 
   
RHOD    
 
  
SECTM1   
  
  
SIPA1    
 
  
SLC5A1 
 
  
 
  
SLITL2 
 
  
 
  
SOCS1 
 
  
 
  
SOCS2 
 
  
 
  
ST6GALNAC6 
 
  
 
  
TCF15 
 
  
 
  
TFAP2E 
 
  
 
  
TNFRSF10D 
 
  
 
  
UBTD1 
 
  
 
  
VILL  
  
  
WFIKKN2       
Total 21 40 6 2 
 
Table 4.2. Genes identified on the BeadArray as hypermethylated. 
Genes were identified as hypermethylated on the basis of one of two CpGs (in two of three 
adenomas within a subtype) showing a β value of ≥0.4 and a second CpG showed a β ≥0.25 relative 
to the mean of the NP. The table shows the genes fulfilling these criteria in each of adenoma 
subtypes and where the CpG is within a CpG island. Genes shown in bold and underlined were 
subject to the additional analyses described in Figure. 4.3 and Table 4.3 
 
 
 119 
 
 
Figure 4.2. Heatmap of genes in individual NF and GH adenomas that fulfilled the criteria of 
elevated β in two gene-associated CpGs relative to the NP. 
For each gene that satisfied the criteria, the mean of the two β values is used and displayed as a 
graded colour scale that is shown in the figure. 
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4.4. Gene specific methylation frequencies in non-functioning adenomas 
Through constraints imposed by methodologies (sodium bisulphite conversion, 
pyrosequencing and transcript expression analyses), the availability of some adenoma 
subtypes (number and amount of tumour tissue) with the exception of NF adenomas was 
limited. I, therefore, focused this part of the study primarily, but not exclusively, on the NF 
adenoma cohort. Through analysis of the 12 genes identified by BeadArray and confirmed 
by pyrosequencing in the discovery cohort, I determine the frequency of aberrant 
methylation across, in this case,  an independent cohort of 13 NF adenomas relative to four 
NP. Figure 4.3 shows the analysis where each gene in the NP, with the exception of 
HOXB1, shows low but variable levels of methylation. I set a stringent cut-off criterion for 
increased methylation in individual adenomas of ≥4S.D. higher than the S.D. of the mean 
(for each of the genes) that was apparent in the four NP. The proportion of adenomas 
showing increase, above each of the gene-specific thresholds, is shown in Figure 4.3 and is 
summarised in Table 4.3. Within the NF cohort, the number of adenomas that show gene-
specific increase in methylation is variable, where the CpG island methylation of the 
KIAA1822 (HHIPL1) and TFAP2E is found in 12 of 13 NF adenomas whereas the 
COL1A2 CpG island shows increased methylation in only two of 13 adenomas. 
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#  Gene 
Hypermethylated 
tumours 
Normal methylated 
tumours 
1 BCL9L 4 9 
2 COL1A2 2 11 
3 EML2 7 6 
4 FLJ46380 9 4 
5 HAAO 11 2 
6 HOXB1 7 6 
7 KCNE3 10 3 
8 KIAA1822 12 1 
9 MT1G 11 2 
10 PGLYRP1 7 6 
11 RHOD 8 5 
12 TFAP2E 12 1 
 
Table 4.3. Frequencies of gene-specific methylation in an independent cohort of NF 
adenomas. 
Genes were first identified in the discovery cohort and using the criteria described in the text and in 
Figures 4.2 and 4.3 
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Figure 4.3. Pyrosequence analysis of promoter-associated CpG island methylation of genes first identified as hypermethylated by BeadArray 
analysis. 
The figure shows methylation in an independent cohort of 13 NF adenomas relative to the mean methylation for each gene examined in the four NP. For 
each gene, in the NP, the mean percentage methylation and four times the S.D. of the mean are shown as horizontal bars, either without or with arrows 
respectively. Only adenomas equal to or greater than this upper threshold were deemed hypermethylated and are shown as filled circles. Adenomas in 
which methylation is not increased relative to NP are shown as unfilled circles. The NP are shown as diamonds to the left of the adenomas (circles) in each 
case.
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4.5. Subtype specific gene methylation frequencies 
Of the 12 genes subject to validation in the NF adenomas, six of these genes also 
fulfilled the Δβ criterion in two or more of the other adenoma subtypes (Table 4.2). To 
gain insight into the subtype specificity of hypermethylation, I performed pyrosequence 
analysis for three of these genes where, in addition to the NF adenomas, I included each of 
the other pituitary adenoma subtypes (Figure 4.4). For EML2, and confirming the 
BeadArray finding, methylation is confined to NF adenomas. Cross subtype-specific 
methylation is apparent for the RHOD and KIAA1822 genes where the array (Table 4.2) 
and pyrosequencing shows increased methylation in a proportion of the NF- and GH-
secreting adenomas and in the NF-, GH- and PRL-secreting adenomas respectively (Figure 
4.4). 
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Figure 4.4. Adenoma subtype specificity of hypermethylation for three genes in which pyrosequencing confirmed their methylation status in NF 
adenomas is shown in Figure 4.3. 
For subtype specificity, in addition to the 13 NF adenomas, the methylation status of each gene was also determined in an investigation cohort comprising, 
seven GH, six PRL and six CT (CUSH) adenomas. Symbols and cut-off criteria are as described in Figure 4.3. The NP are shown as diamonds on the right 
side of each of the gene investigated. 
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4.6. Methylation associated gene silencing 
For the 12 genes where pyrosequencing confirmed methylation status, I used 
quantitative RT-PCR (RT-qPCR) to determine associations between CpG island 
methylation and gene silencing. In these cases, loss or significantly reduced transcript 
expression was assigned on the basis of the stringent criterion described for gene-specific 
methylation. However, in these cases, it was ≤4S.D of the NP. In the 13 NF adenomas, an 
inverse relationship between increased methylation and reciprocal significant decrease in 
transcript expression is apparent for three of the 12 genes examined. Figure 4.5 shows that 
relative to NP, all the methylated tumours (filled circles) show significantly reduced 
transcript expression. Conversely, in adenomas that were not hypermethylated (unfilled 
circles), expression levels are similar to or in some cases higher than that apparent in the 
NP. A single exception to these findings is apparent for the HOXB1 gene, where a single 
adenoma that was not methylated also shows reduced transcript expression. In addition, as 
multiple studies using candidate gene approaches have shown frequent methylation-
associated loss of CDKN2A (Woloschak et al., 1997; Simpson et al., 1999; Vandeva et al., 
2010), we included RT-qPCR analysis of this transcript. These studies show significantly 
reduced expression of this transcript in 12 of 13 adenomas relative to NP (Appendix 8) 
further confirming and reinforcing the robustness of the approach. 
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Figure 4.5. Quantitative RT-PCR analysis for three of 12 gene transcripts that show an 
inverse relationship between hypermethylation and decrease in transcript expression. 
For each gene, their methylation status in NF adenomas was first validated in the discovery cohort 
(Table 4.2) and in the independent cohort shown in Figure. 4.3. Expression is shown relative to 
four NP and the same cut-off criteria of four S.D., but in this case lower than the mean level shown 
in NP (horizontal bars with arrow heads). Filled and unfilled circles represent adenomas that are 
hypermethylated and those that were not for individual NF adenoma respectively. The NP are 
shown as diamonds on the left side of each the gene investigated. Relative to the housekeeping 
gene GAPDH, mean expression levels of EML2, HOXB1, and RHOD in 4 NPs, as estimated by 
absolute Ct values in RT-qPCR, are approximately 1%, 0.01%, and 1%, respectively.  
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4.7. Gene ontology analysis of hypermethylated genes 
Gene ontology analysis of the hypermethylated genes was performed to determine 
the biological processes where these genes are known to contribute together with their 
molecular function and finally their associated Kyoto Encyclopedia of Genes and Genomes 
(KEGG) pathways. These analyses are shown in Appendix 6. The aberrantly methylated, 
promoter-associated CpG islands were distributed across various categories of biological 
processes, molecular function and pathways. However, multiple genes associated with 
particular biological processes showed frequent methylation in the analysis. In this context, 
we noted that 11 genes in intracellular signalling cascades (Appendix 5.1) were 
hypermethylated in pituitary adenomas. Interestingly, among these genes, the majority 
(SOCS2, RAC2, ERBB2, RASSF1, SOCS1 and COL1A2) have also been shown to exhibit 
tumour suppressor properties in multiple other tumour types. RASSF1 was shown to be 
frequently inactivated by hypermethylation of its promoter region in a number of tumour 
types including bladder cancer, breast cancer, cervical cancer, and pituitary adenomas 
(Mitra et al., 2012; Jiang et al., 2012; Ha et al., 2012; Gil et al., 2012; Qian et al., 2005).   
Higher expression level of SOCS1 is associated with earlier tumour stage and better 
clinical outcome in human breast cancer (Sasi et al., 2010). COL1A2 frequently silenced 
by promoter hypermethylation in melanoma  (Bonazzi et al., 2011). RAC2 is critical to the 
initiation of acute myeloid leukemia in a retroviral expression model of MLLAF9 
leukemogenesis (Mizukawa et al., 2011). ERBB2 methylation status is strongly associated 
with an epithelial phenotype in NSCLC cell lines, surgically resected tumours, and 
formalin-fixed biopsies from patients with non-small-cell lung cancer who went on to fail 
frontline chemotherapy (Walter et al., 2012). KEGG pathway analysis shows multiple 
genes associated in various types of cancer (bladder cancer, non-small cell lung cancer, 
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pancreatic cancer, colorectal cancer, endometrial cancer, prostate cancer) or tumorigenesis-
related pathways (apoptosis, VEGF signalling).  
4.8. Discussion 
The study of the epigenome in normal and disease states, and in particular as it 
relates to tumourigenesis, is an area of growing interest and research focus. In this thesis, 
the role of changes in DNA methylation at CpG dinucleotides has been analysed in each of 
the major pituitary adenoma subtypes. Through use of an Infinium BeadArray approach, I 
performed a genome-wide analysis, thus providing a quantitative measure of DNA 
methylation at CpG sites across the genome. The analysis revealed aberrant methylation in 
each of the adenoma subtypes. Furthermore, it showed that hypermethylation, at CpG sites 
within gene-associated CpG islands, is more frequent compared with CpG sites outside of 
CpG islands and similar findings in other tumour types have been reported elsewhere (Kim 
et al., 2011a). The epigenetic changes were more frequent in NF adenomas than other 
pituitary adenoma subtypes; however, I recognise that the absolute numbers of sites 
identified as hypermethylated is dependent on the cut-off criteria employed. 
As in our previous studies and those of other groups, the technical validation of the 
BeadArray approach shows it to be a robust approach for the quantitative determination of 
methylation (Fryer et al., 2011; Lima et al., 2011).  Furthermore, and although not reported 
by others, I found, in NP, that the imprinted genes show β values that reflect silencing of 
one of two alleles and provides further confidence in the derived data. 
For the majority of genes interrogated by the 27K BeadArray technology, most are 
represented by one or two CpG sites on the array (Irizarry et al., 2008; Wilop et al., 2011). 
In these cases, although the number of CpG sites interrogated, as representations of a CpG 
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islands, are few in number, the a priori of the technology is that CpG sites in close 
proximity are often co-methylated (Ogoshi et al., 2011; Irizarry et al., 2008). However, my 
validation studies on the basis of an elevated β value at a single CpG site failed to show a 
robust correlation. In these cases and by pyrosequence analysis, I had determined mean 
methylation across 5–11 CpGs within the promoter-associated CpG islands. Using 
modified and more stringent criteria, which considered two promoter-associated CpGs on 
the BeadArray, I found significant concordance between the techniques. In this case, 12 of 
16 (75%) genes were validated by pyrosequencing. Other studies, where they report 
validation of BeadArray data, frequently use techniques such as methylation-sensitive PCR 
(Wilop et al., 2011; Yoon et al., 2010). A limitation of this technique is that they determine 
methylation at a limited number of CpG sites. Equally, this approach is reliant upon an 
amplification step and may not necessarily accurately reflect the methylation status of the 
CpG islands that is representative of the majority of cells within the specimen (Zeller et al., 
2012; Irizarry et al., 2008; Wilop et al., 2011).  
The gene ontogeny analysis, on the basis of the more stringent cut-off criteria, 
shows the genes to be distributed across various categories of biological processes, 
molecular function and pathways. Although no biological processes are specifically 
enriched, I found that multiple genes involved in intracellular signalling pathways are 
hypermethylated relative to NP. Interestingly, many of these genes are silenced in 
association with CpG methylation in other tumour types (Bonazzi et al., 2011; Mizukawa 
et al., 2011; Mottok et al., 2007; Qian et al., 2005; Sasi et al., 2010; Walter et al., 2012) 
and interestingly the RASSF1 gene has been identified in earlier studies using a candidate 
gene approach of sporadic pituitary adenomas (Qian et al., 2005). 
Although the BeadArray allowed me to examine each of the major pituitary 
adenoma subtypes in a single experiment, which is on the same array, I were aware of the 
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constraints and limitations of any conclusions reached through examining a limited number 
of each of the adenoma subtypes. Equally the amount and absolute number of each 
adenoma subtype were also a limitation for all the analyses I wished to undertake. 
However, through focusing my studies, post-BeadArray analysis, principally but not 
exclusively on NF adenomas, I gained further insight into the aspects of epigenetic change. 
In this case, in an independent cohort that comprised 13 NF adenomas, and for 12 genes 
(identified in the discovery cohort), I determined methylation frequencies relative to NP. 
Again using stringent criteria (four times the S.D. apparent in NP), I determined the 
frequencies of differential methylation across the cohorts for each of these genes. The 
genes show variable frequencies of methylation and have not been previously described in 
pituitary adenomas. Indeed, for many of the genes identified in our discovery cohort, as 
example, SOCS1, SEPT9, PDLIM4, TFAP2E, MT1G, HAAO, TFAP2E, CRIP1 and 
COL1A2 methylation-mediated gene silencing, together with known or putative tumour 
suppressor characteristics has been reported in other tumour types (Bonazzi et al., 2011; 
Mizukawa et al., 2011; Mottok et al., 2007; Qian et al., 2005; Sasi et al., 2010; Walter et 
al., 2012). 
Although the absolute number and amount of tumour tissue, for the other adenoma 
subtypes, was limiting, I considered it important to validate the subtype specificity of 
aberrant methylation. To that end, I examined hypermethylation of CpG islands that were 
methylated in common and those where this change is apparent in two or more subtypes as 
determined by BeadArray analysis. The analysis shows, by an independent technique, 
namely pyrosequencing, that the identified changes and differences in hypermethylation 
were indeed subtype specific. 
In this first report of unbiased genome-wide changes in methylation, I focused my 
studies on increase in methylation of CpG islands associated with gene promoters. In these 
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cases, these regions are considered the most relevant for expression of the corresponding 
gene (Irizarry et al., 2008; Moran et al., 2012). In the 13 NF adenomas and across the 12 
genes studied, only three showed an association between hypermethylation and reduced 
transcript expression. Similar findings have been reported by others and specifically where 
associations between increased BeadArray-identified CpG methylation and loss or reduced 
transcript expression has been investigated (Irizarry et al., 2008; Kim et al., 2011a; Wilop 
et al., 2011; Zeller et al., 2012). Multiple factors might account for this lack of association, 
including density of methylation across the CpG islands, histone modification or the milieu 
of transcription factors within a cell or cell type (Irizarry et al., 2008; Wilop et al., 2011). 
These findings have led some authors to conclude that mRNA expression is more likely to 
be down regulated when the promoter region is hyper-methylated even through it is not 
statistically significant (Kim et al., 2011a). Therefor, and by extension, this likely reflects 
the view put forward by other investigators that many epigenetic and genetic alterations in 
cancer are ‘passenger’ as opposed to ‘driver’ events in the evolution and progression of a 
tumour (Kim et al., 2011a; Zeller et al., 2012).  
In conclusion, this chapter provides a first, unbiased survey of the pituitary tumour 
epigenome across different adenoma subtype. Further studies will be needed to corroborate 
identification of these CpG islands, characterised on the basis of their hypermethylation 
and relative to that seen in normal pituitaries. Because of the limitation of the number of 
pituitary samples interrogated by the Infinium 27K array, this study does not provide a 
biomarker that is good enough for clinical diagnostic applications. However, the evolution 
of techniques, such as 27K to 450K array, couples with larger number of samples will 
make these types of studies useful for identification of biomarker that perhaps predict or 
characterise tumours likely to show aggressive or recurrent growth characteristics. In 
addition, the functional characterisation of down-regulated genes will provide new 
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understanding of tumour aetiology and biology and perhaps identify novel genes or 
pathways that provide us with new therapeutic targets or options. 
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Chapter 5: The EFEMP1 gene: a frequent target for 
epigenetic silencing in multiple human pituitary adenoma 
subtypes  
As an extension to my genome-wide investigation I sought to clarify the functional 
relationship between epigenetic changes and gene expression. For these studies I focused 
attention on the EGF containing fibulin-like extracellular matrix protein 1 gene (EFEMP1). 
My choice of EFEMP1, also known as fibulin-3, was on the basis that the BeadArray 
analysis had revealed subtype-specific differential methylation that was confined to the GH 
secreting adenomas. I, therefore, considered it may represent an important subtype-specific 
aberration. In other tumour types EFEMP1 expression patterns are associated with either 
growth-promotion or growth-inhibition in a cell- or tissue- type context (de Vega et al., 
2009; Gallagher et al., 2005; Obaya et al., 2012). In those cases where cell- and or tumour- 
type are associated with loss or reduced EFEMP1 transcript expression it is frequently, but 
not invariably, associated with CpG island methylation (Hu et al., 2012; Kim et al., 
2011b). Moreover, multiple studies show that EFEMP1 impacts on multiple distinct 
cellular pathways and these properties provided several functional endpoints for 
investigation in a pituitary context (de Vega et al., 2009; Sadr-Nabavi et al., 2009; Seeliger 
et al., 2009). Furthermore, and on the basis of my preliminary studies of pituitary tumour 
cell lines these revealed that they do not express EFEMP1 thus providing useful models  to 
gain functional insight into potential mechanisms associated with gene silencing. In these 
cases I was able to determine the effects of epidrug as mediators of re-expression, and also 
to determine the functional sequelae of heterologous EFEMP1 expression within these 
cells. 
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5.1. Expression of EFEMP1 in pituitary adenomas 
I first determined expression of EFEMP1 in an investigation cohort of adenomas 
comprising each of the major adenoma subtypes. Figure 5.1 shows that by RT-qPCR 
analysis significantly reduced expression of EFEMP1 (by the criteria described in the 
material and methods), in 25 of 33 adenoma (~75%) and relative to expression in post-
mortem normal pituitaries. Although the number of subtype-specific adenomas available 
for each of the analyses is relatively small, reduced EFEMP1 expression appears to be a 
frequent and is also a subtype-independent. However, an interesting observation is that 
where increased expression is apparent, it appears to be confined to the corticotrophinoma. 
The number of subtype-specific adenomas, showing reduced expression of EFEMP1, are 
summarised in Table 5.1.  
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Figure 5.1. Quantitative RT-PCR analysis of EFEMP1 expression in each of the major 
pituitary adenoma subtypes. 
Expression is shown relative to four post-mortem normal pituitaries (NP). Adenoma were assigned 
as showing significantly reduced expression where expression was ≥ 3 SD, lower than the mean of 
expression in the NP (dotted line). The horizontal bars show the mean expression in each adenoma 
subtype and in NP. Small unfilled circles are individual adenoma. Non-functioning adenoma (NF), 
prolactinoma (PRL), growth-hormone secreting adenoma (GH) and corticotrophinoma (CUSH). 
Relative to the housekeeping gene GAPDH, mean expression level of EFEMP1 in 4 NPs, as 
estimated by absolute Ct values in RT-qPCR, is approximately 2%. 
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Subtype Number of sample Reduced expression Normal expression 
NP 4 0 4 
NF 13 9 4 
PRL 7 6 1 
GH 6 6 0 
CUSH 7 4 3 
Table 5.1. EFEMP1 expression status in pituitary adenoma. 
The number of adenomas that express or show reduced expression of EFEMP1. Expression status 
as determined and relative to post-mortem normal pituitaries using the criteria described in the 
materials and methods.  
 
5.2. Methylation status of the EFEMP1 genes CpG island in pituitary adenomas 
I next determined the methylation status of the EFEMP1 gene’s CpG island in the 
investigation cohort of adenoma and relative to post-mortem pituitaries. Pyrosequencing 
analysis showed that methylation (on the basis of the criteria described in the materials and 
methods section), was not confined to GH secreting adenomas but is also apparent in each 
of the other adenoma subtypes. In this case, the segregation with the GH adenoma was on 
the basis of the original array findings of the investigation cohort and shown in Figure 4.2 
(heat map). An example of methylation as determined by pyrosequencing is shown in 
Figure 2.1 and the findings are summarised in Table 5.2. In these cases, mean methylation 
across four normal pituitaries was 15.5% and adenomas were classed as methylated in 
those cases where the mean was  ≥ 3 or more times the S.D. of that mean, that is, ≥ 41.7%. 
The apparent exception are prolactinoma, however, in this and several other instances, not 
all of the adenomas available for expression analysis yielded useable products for 
pyrosequence analysis following sodium bisulphite conversion. Table 5.2 shows, in 
summary, that  none of the adenoma that expressed EFEMP1 are methylated. However, in 
 137 
 
tumours that do not express EFEMP1, approximately equal proportion show this 
epigenetic change as those that do not. I concluded that, although methylation is not seen 
in EFEMP1 expressing adenoma or normal pituitaries neither the absence or the presence 
of this change “predicts” adenomas that failed to express this transcript. These findings 
suggested that mechanisms in addition to CpG island methylation are responsible for 
silencing of EFEMP1. 
 
Subtypes 
Number of 
samples 
EFEMP1 Expressing  
Adenomas 
EFEMP1 Non-Expressing  
Adenomas 
Methylated Unmethylated Methylated Unmethylated 
NP 4 0 4 0 0 
NF 13 0 4 5 4 
GH 5 0 0 2 3 
CUSH 3 0 2 1 0 
PRL 3 0 1 0 2 
Table 5.2. EFEMP1 expression status in pituitary adenoma relative to CpG island 
methylation status. 
The number of adenomas that either express or do not express EFEMP1 are shown relative to their 
methylation status. The criteria for methylation and expression are described in the materials and 
methods section.    
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5.3. Histone modifications associated with EFEMP1 expression in primary 
adenoma 
The influence of histone modification on EFEMP1 expression was assessed by 
ChIP analysis. Primer design was described in section 2.7.5. In these cases it was necessary 
to confine these studies to the non-functioning adenomas due to absolute tumour size and 
the reliability of chromatin extractions. However, clear trends in enrichment and depletion 
are evident. Figure 5.2 shows that in adenomas showing reduced EFEMP1 expression the 
histone modification, H3K9Ac is depleted and the H3K27me3 is enriched relative to post-
mortem normal pituitaries. In adenomas that express EFEMP1 the converse was apparent, 
where adenomas were enriched for the H3K9Ac modification and depleted for H3K27me3. 
Furthermore, for two of adenomas (NF7 and NF10), reduced expression of EFEMP1 is 
associated with histone modifications, however, these adenomas did not show change in 
CpG island methylation. These findings show that histone modification associate with 
active and repressed genes are associated with the expression status of EFEMP1 in primary 
pituitary adenoma. Moreover, the histone modifications associated with reduced EFEMP1 
expression is not invariably accompanied by promoter-associated CpG island methylation.    
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Figure 5.2. ChIP Analysis of the EFEMP1 gene. 
The upper panel shows ChIP enrichment for the H3K9Ac modification and lower panel for the 
H3K27me3 modification. Enrichments are shown for non-functional adenoma (NF) and post-
mortem normal pituitaries (NP). All experiments, in available adenomas, were performed at least 
three times and representative examples shown for each.  Due to limitation of available tumour 
specimen it was not possible to examine all of the adenomas shown in Figure 5.1. Due to small size 
of tumours it was not possible to perform three replicates, therefore only one ChIP was performed 
per tumour. An underline, of an individual adenoma, signifies an adenoma that did not show 
methylation of EFEMP1 within its CpG island. Primers targeted onto the position of -33 to +87 
relative to TSS.  
  
 140 
 
5.4. Epidrug induced re-expression of the Efemp1 gene in AtT20 and GH3 cells 
The murine and rodent pituitary cell lines, AtT20 and GH3 respectively express 
Efemp1 at marginal levels as determined by RT-qPCR. In contrast to these findings their 
cognate normal pituitary counterparts show robust expression of the Efemp1 transcript 
(Figure 5.4). In these cell lines, combined drug challenges, with zebularine and TSA, 
induced re-expression of Efemp1. In cases of pituitary cell lines GH3 and AtT20, 
zebularine instead of 5-Aza-2-Dc was chosen as an epi-drug because of our lab’s previous 
experience regarding 5-Aza-2-Dc cytoxicity to these cell lines. Zebularine was reported by 
others to be a less toxic demethylating agent (Cheng et al., 2003; Cheng et al., 2004b).  
Single drug challenge showed marginal or no effect on transcript expression, however, 
increasing doses of zebularine, and where TSA concentrations were constant, show a dose 
dependent increase in Efemp1 as determined by RT-qPCR. 
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Figure 5.3. Expression status of Efemp1 in pituitary cell lines. 
Upper panel, GH3 cells and lower panel, AtT20 cells following challenge with zebularine (ZEB) or 
TSA alone or in combined incubations. In each case, the panels show RT-qPCR analysis of Efemp1 
in response to the challenges and drug doses shown in the figures. All experiments were done three 
times with triplicate determinations in each experiment. Error bars show SEM. **, P < 0.01; ***, P 
< 0.001; ****, P < 0.0001 vs. vehicle alone. Data were analysed for significance by one-way 
ANOVA with Dunnett’s multiple comparison posttest. Relative to the housekeeping gene Pbgd, 
expression levels of Efemp1 in NRP and NMP, as estimated by absolute Ct values in RT-qPCR, are 
approximately equal and slightly higher, respectively. NRP, Normal rat pituitary; NMP, normal 
mouse pituitary; WT, wild type.  
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5.5. Epigenomic changes associated with expression of Efemp1 in pituitary cell 
lines 
In both the AtT20 and GH3 cell lines, silencing of the Efemp1 gene is associated 
with a significant increase in CpG methylation as determined by pyrosequencing and 
within their respective CpG islands. In these cases increase was determined relative to their 
cognate normal pituitaries (Figure 5.4). On the basis of these findings I reasoned that gene 
silencing and epidrug induced re-expression was consequent to CpG island methylation. 
However, analysis of cell lines following the drug treatment described in Figure 5.3 did not 
show change in DNA methylation in either AtT20 or GH3 cells. 
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Figure 5.4. Inverse correlation between transcriptional expression and promoter methylation 
of Efemp1 in rat and mouse pituitary models. 
Expression at transcriptional level of Efemp1 (upper panel) in both GH3 and AtT20 cell lines is 
significantly reduced relative to normal rat and normal mouse pituitary, respectively. Low 
expression levels in cell lines are correlated with high methylation levels of promoter-associated 
CGI (lower panel) while the reverse phenomenon is apparent in normal rat and mouse pituitary. 
Relative to the housekeeping gene Pbgd, expression levels of Efemp1 in NRP and NMP, as 
estimated by absolute Ct values in RT-qPCR, are approximately equal and slightly higher, 
respectively. NRP, Normal rat pituitary; NMP, normal mouse pituitary. 142. 
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5.6. Histone modifications in epidrug challenged pituitary cell lines 
Previous reports from our laboratory have shown that epidrugs induce histone 
modifications and that these change are associated with re-expression of silenced genes 
(Al-Azzawi et al., 2011; Yacqub-Usman et al., 2012a). We therefore investigated histone 
modifications associated with the promoter region of the Efemp1 gene in AtT20 and GH3 
cells. Figure 5.5 shows that combined epidrug challenges leads to increase, which is clearly 
in GH3 and slightly in AtT20, in the enriched fraction of the H3K9Ac modification. 
Conversely, in both cell lines drug challenges led to a decrease in the modification 
commonly associated gene silencing, H3K27me3. These findings suggest that histone 
modification and specifically enrichment of the H3K27me3 mark and depletion of the 
H3K9Ac modification are responsible for silencing of the Efemp1 gene in AtT20 and GH3 
cells.  
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Figure 5.5. ChIP analysis of Efemp1 promoter region in pituitary cell lines. 
Analyses are shown relative to the modification seen in input DNA for the H3K9Ac and 
H3K27Me3 Enrichment in the pituitary cell line GH3 and AtT20, left and right side of the figure 
respectively. Enrichment is shown following drug challenge (treated) or vehicle control (WT) 
shown in figure 3 and relative to the enrichment observed in either, normal rat (NRP) or normal 
mouse (NMP) pituitary. All experiments were done three times with triplicate determinations in 
each experiment. Primers for rat and mouse targeted onto the position of +77 to +175 and +159 to 
+221 relative to TSS, respectively. Error bars show SEM. *, P < 0.05; **, P < 0.01; ***, P < 0.001; 
****, P < 0.0001 vs. vehicle alone. Data were analyzed for significance by one-way ANOVA with 
Dunnett’s multiple comparison posttest. NRP, Normal rat pituitary; NMP, normal mouse pituitary; 
WT, wild type. 
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5.7. Function end-points contingent on heterologous EFEMP1 expression in GH3 
cells 
To investigate putative functional end points, stable transfected GH3 cells 
harbouring and inducible human EFEMP1 construct was first generated. Figure 5.6 shows 
EFEMP1 expression as determine by RT-qPCR in the presence and absence of the 
inducing agent, IPTG. In these studies, a dose dependent increase in EFEMP1 expression 
between 5-100 µM was observed.  
5.7.1. Proliferation and apoptotic end-points 
The effects of enforced EFEMP1 expression (100 µM IPTG) on cell proliferation 
and apoptosis were assessed in GH3. Relative to GH3 harbouring an empty vector control 
or the EFEMP1 construct challenged with vehicle alone, no change in proliferation was 
apparent in a 12 day growth curve. In studies designed to assess inhibition or augmentation 
of apoptotic response we used bromocriptine challenge and caspase 3/7 activation and as 
we have described previously (Rowther et al., 2010).  In these experiments and similar to 
those described for proliferative responses I did not detect an effect on this end point (data 
not shown).   
5.7.2. EFEMP1 target gene end-points 
The effects of enforced EFEMP1 expression in GH3 cells and as described above 
were determined for genes shown by others to be subject to the effects of enforced 
EFEMP1 expression. In these cases, EFEMP1 expression had no discernible effects on the 
expression of the endogenous genes coding for VEGF-A, HIF1A, MMP7 or MMP9 (data 
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not shown). However, a dose dependent inverse relationship between enforced EFEMP1 
expression and that of MMP2 was observed (Figure 5.6).  
 
Figure 5.6. MMP2 expression in stable transfected GH3 cells. 
Upper panel shows EFEMP1 expression induced by varying doses of IPTG and as determined by 
RT-qPCR. Lower panel shows MMP2 expression in corresponding cells indicated in the upper 
panel. In each case the fold induced is shown relative to cells challenged with vehicle alone. All 
experiments were done three times with triplicate determinations in each experiment. Error bars 
show SEM. ***, P < 0.001; ****, P < 0.0001 vs. vehicle alone. Data were analyzed for 
significance by one-way ANOVA with Dunnett’s multiple comparison posttest. Open bars are 
control experiments performed on cells transfected by empty vector. 
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Finally, in the pituitary adenoma cohort used in this study I determined the 
relationship, if any, between EFEMP1 expression and the target genes described above. 
Using the cut-off criteria described above we found a positive relationship between 
EFEMP1 expression and that of MMP7 (Figure 5.7), however, for the others genes I 
investigated in GH3 cell I did not see this relationship.    
 
 
Figure 5.7. Expression of MMP7 in pituitary adenoma in the absence and presence of 
EFEMP1. 
The dotted line is three SD less than the mean expression of MMP7 in post mortem pituitaries 
(diamonds). For each of the adenoma subtypes, MMP7 expression is plotted relative to the average 
MMP7 expression in four NP. In these cases, filled circles are adenoma that express EFEMP1 and 
unfilled circles are adenoma that show loss or significantly reduced EFEMP1 expression. 
Abbreviations are as shown in the legend to Figure 5.1.  
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5.8. Discussion 
Recent years have witnessed considerable and rapid advances in the technologies 
applicable to the analyses of the genome and of the epigenome in normal and disease states 
(Emes and Farrell, 2012). Furthermore, our understanding of changes to the epigenome 
and that impact on gene expression has burgeoned (Emes and Farrell, 2012; Yacqub-
Usman et al., 2012b). We now know that DNA methylation, histone modifications and 
miRNA expression patterns, either alone or more usually in concert impact on gene 
expression and translation (Dudley et al., 2009; Yacqub-Usman et al., 2012b). In addition 
to the repertoire of modification, their consequences at the transcript or protein level are 
frequently apparent in a cell- or tissue- specific context (Hayward et al., 2001; Farrell and 
Clayton, 2000; Simpson et al., 2000; Fedele et al., 2006).    
In this thesis, I focused attention on the EFEMP1 gene where Illumina BeadArray 
analysis had demonstrated differential CpG island methylation confined to GH secreting 
adenomas relative to the other major adenoma subtypes and to that apparent in post-
mortem normal pituitaries (Table 4.2). However, in an independent cohort of pituitary 
adenomas I now show by pyrosequencing analysis that methylation of the EFEMP1 gene’s 
CpG island is  not confined to GH secreting adenomas but is also detected in the other 
adenoma subtypes. Our failure to detect this change in a previous investigation cohort is 
most likely a consequence of only three, of each adenoma subtype, being interrogated on 
the BeadArray. Moreover, I now show that this epigenetic modification, if considered in 
isolation, is not invariantly associated with loss or reduced EFEMP1 expression. Indeed, 
although the majority of adenomas showed barely detectable EFEMP1 transcript 
expression approximately equal numbers of adenoma showed CpG methylation as did not 
show this change. Our research group and others have made this observation in previous 
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studies where CpG island methylation is variantly associated with gene silencing (Duong 
et al., 2012; Kim et al., 2011a; Zeller et al., 2012). 
These observations, of gene silencing in the presence and absence of CpG island 
methylation suggested alternate mechanisms of gene silencing. I, therefore, determine the 
influence of histone modifications, as a potential independent or co-dependent contributor 
toward gene silencing. For those tumours where sufficient sample was available ChIP 
analysis showed enrichment for the histone modification, H3K27me3 and depletion of the 
H3K9Ac modification associated with reduced expression of EFEMP1. Enrichment for 
these histone tail modifications, as shown by several groups, including our own, are 
associated with active (H3K9Ac) and repressed (H3K27Me3) gene expression (Al-Azzawi 
et al., 2011; Yacqub-Usman et al., 2012a; Cao et al., 2002b; Jenuwein and Allis, 2001).   
These conclusions were reinforced by the contrary findings, where enrichment (H3K9Ac) 
and depletion (H3K27me3), in tumours and post-mortem pituitaries that expressed the 
EFEMP1 gene, is observed. Indeed, in a previous studies our research group observed that 
significantly reduced expression of BMP-4, in pituitary adenoma, is also associated with 
the histone modifications that I now described for the EFEMP1 gene (Yacqub-Usman et 
al., 2012a).  
Since multiple studies show that epimutations, apparent as CpG methylation and/or 
as histone modifications are potentially reversible (Yacqub-Usman et al., 2012b; Sharma et 
al., 2010) I adopted these types of approach in the pituitary tumour cell lines, GH3 and 
AtT20. Both cell lines expressed Efemp1 at marginal levels but in contrast to human 
pituitary tumours, their gene associated CpG islands were heavily methylated. However, in 
common with human pituitary tumours they also showed histone modification indicative of 
gene silencing. Combined incubations with the epidrugs, zebularine and TSA led to a dose 
dependent increase in Efemp1 as determined by RT-qPCR. In these cases, epidrug-
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mediated expression did not induce or lead to change in the methylation status of the CpG 
islands associated with the Efemp1 gene. However, the epidrug induced histone 
modifications that are indicative of and associated with active gene and these modifications 
were more marked in GH3 cells than apparent in AtT20 cells. In previous studies of 
epidrug challenged cells, in these cases for the D2R and BMP-4 gene we saw similar, 
marked changes in histone modifications (Al-Azzawi et al., 2011; Yacqub-Usman et al., 
2012a). Moreover, in these cases these changes were also accompanied by a decrease, 
albeit marginal, in CpG island methylation. While the differences in drug-induced changes 
to the epigenome are not entirely clear we did note that, although the increase in Efemp1 
was significant the absolute levels, as determined by RT-qPCR, were significantly lower 
than that see in their normal pituitary counterparts (data not shown). 
The EFEMP1 gene encodes fibulin-3 and is one of seven members of the fibulin 
family of extracellular matrix proteins (ECM) (Lecka-Czernik et al., 1995). These multi-
functional proteins are located in basement membranes, stroma, and ECM fibres and their 
functions include cell-to-cell and cell-to-matrix communication, organogenesis and 
vasculogenesis and the organization and stabilization of ECM structures (de Vega et al., 
2009).  In the context of tumourigenesis fibulins impact on multiple pathways that include 
tumour suppressor, apoptotic, angiogenic, metastatic, and invasion (Gallagher et al., 2005; 
Obaya et al., 2012; Seeliger et al., 2009). Moreover, the contribution of some family 
members, as either promoters or inhibitors of these pathways is frequently apparent in a 
cell- or tumour- type context (Obaya et al., 2012). As example, several studies show that 
EFEMP1 has bona fide activity as either a tumour promoter or tumour suppressor (Seeliger 
et al., 2009; Albig et al., 2006; Hu et al., 2011; Song et al., 2011b). Indeed, increased 
expression of EFEMP1 is apparent in pancreatic and cervical cancers and malignant 
glioma, (Song et al., 2011b; Hu et al., 2009; Seeliger et al., 2009), whereas, reduced 
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expression is apparent in breast, prostate, hepatocellular, and non-small-cell lung cancer 
(NSCLC) (Kim et al., 2011b; Sadr-Nabavi et al., 2009; Nomoto et al., 2010; Kim et al., 
2012). The mechanisms responsible for inappropriate expression of EFEMP1, and in 
particular for increase are poorly understood. However in multiple tumour types, including 
NSCLC, breast, prostate, and hepatocellular cancer loss or reduced expression is associated 
with CpG island methylation (Sadr-Nabavi et al., 2009; Kim et al., 2011b; Nomoto et al., 
2010; Kim et al., 2012). Indeed, and similar to our findings in GH secreting adenoma Kim 
and colleagues employed a BeadArray approach and identified increase methylation of the 
EFEMP1 gene in prostate cancer (Kim et al., 2011b).    
The functional consequences of enforced EFEMP1 expression were determined in 
GH3 cells harbouring an inducible construct. The end-points measured included effects of 
EFEMP1 expression on cell proliferation, apoptosis and expression of EFEMP1 
responsive genes. In these cases and for these end-points several studies have shown 
EFEMP1 mediated effects in different cell and tumour types (Kim et al., 2012; Song et al., 
2011b; Seeliger et al., 2009; Hu et al., 2011; Albig et al., 2006). Enforced expression of 
EFEMP1 in GH3 cells did not inhibit their proliferation or drug-induced apoptotic 
response, whereas, in NSCLC, pancreatic, and glioma tumours EFEMP1 inhibits one or 
more of these functional endpoints (Kim et al., 2012; Seeliger et al., 2009; Hu et al., 
2012). Our findings in pituitary cells might, therefore, reflect the fact that these functional 
end points represent cell- or tumour- type specific phenomenon, as observed by other 
investigators (Song et al., 2011b; Seeliger et al., 2009; Hu et al., 2011). Indeed and in this 
context, enforced expression of EFEMP1 in Hela cell, promotes, and in NSCLC cells 
inhibits proliferation (Kim et al., 2012; Song et al., 2011b) and similar finding of an 
association between growth promotion or growth inhibition in xenograft models of 
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pancreatic tumours and glioma respectively are also reported (Seeliger et al., 2009; Hu et 
al., 2011).    
The functional consequences of EFEMP1 expression on tumour invasion and 
angiogenesis also show tumour type specificities, where expression may either promotes or 
inhibits these endpoints (Albig et al., 2006; Hu et al., 2009; Hu et al., 2011; Song et al., 
2011b). The impact of EFEMP1 on these end-points is frequently mediated through effects 
on expression of multiple gene targets, including VEGF-A, HIF1A and MMPs. As 
example, overexpression of EFEMP1 leads to increase in VEGF-A expression in pancreatic 
and cervical cancer cells (Seeliger et al., 2009; Song et al., 2011b) and to decrease of this 
growth factor in malignant glioma cells (Hu et al., 2011). For the MMPs, a positive 
correlation is apparent between EFEMP1 and MMP2 and MMP9 expression in glioma, and 
enforced expression of EFEMP1 in a cell line model also up-regulates these genes (Hu et 
al., 2009). Conversely, in NSCLC cells line, enforced expression and siRNA knock-down 
of EFEMP1 leads to decreases or increase of MMP2/7 respectively (Kim et al., 2012). 
However, although our studies of enforced EFEMP1 expression in GH3 did not show 
change in the expression of either, VEGF-A or that of HIF1A I did observe a dose 
dependent, EFEMP1 mediated, decrease in MMP2 expression in these cells. Finally, I 
looked for correlation between EFEMP1 expression and that of VEGF-A, HIF1A and 
MMPs in the cohort of primary human tumours. A positive correlation between EFEMP1 
and MMP7 was apparent, however, no other correlation or associations were apparent 
across the tumour cohort. The lack of an association between EFEMP1 and MMP2, 
apparent in GH3 cells but not in human tumours, might reflect species or tumour type 
difference in our studies. 
In conclusion, my thesis shows that the majority of pituitary adenomas show 
significantly reduced expression of the multi-functional protein fibulin-3 encoded by the 
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EFEMP1 gene. I show for the first time that loss is subtype independent and is frequently 
but not invariably associated with CpG island methylation and or histone modification. For 
histone modifications this change may lead to silencing that is independent of CpG island 
methylation. Epidrug challenges lead to re-expression of EFEMP1 in a cell line model and 
show a functional relationship between histone modification and gene silencing. Of several 
endpoints investigated, through enforced expression of EFEMP1, an inverse relationship 
was apparent between EFEMP1 and MMP2; however, this relationship was not apparent in 
primary human tumours and might represent species or cell type differences. The positive 
relationship between EFEMP1 and MMP7 expression in human tumours is intriguing and 
warrants further investigation.    
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Chapter 6: Conclusions and future works 
6.1. Conclusions 
The introduction to this thesis has provided an overview of pituitary tumourigenesis 
and described the genetic and epigenetic changes/aberrations associate with this tumour 
type. Furthermore, with respect to the balance between genetic and epigenetic changes the 
literature suggests that the latter are more frequent than the former (Yacqub-Usman et al., 
2012b). Moreover, most of these changes, that are epigenetic, have been identified by 
candidate gene approaches. In those infrequent cases where novel genes have been 
identified the identification has been constrained, by technical limitations to identification 
on a gene-by-gene approach. These inherent limitations have also been compounded by the 
small size of these adenomas and, therefore, limited material, be it DNA, RNA or protein 
for down-stream analysis. In this final chapter I will review the progress made toward 
surmounting these limitations and also described potential future studies that address some 
of the questions raised by these new findings.  
The initial aim of this thesis was to profile DNA methylation at genome-wide level 
within each of the four major pituitary adenoma subtypes. For this purpose, I first need to 
overcome the technical limitation imposed by limited primary tumour material. Therefore, 
in Chapter 3, I described the optimisation and validation of WGA as applied to sodium 
bisulphite converted DNA. I was able to show that WGA is reliable and reproducible in the 
context of quantitative amplification and also with respect to qualitative aspects. 
Quantitatively, it provides a reliable and consistent 25 fold amplifications of sodium 
bisulphite converted DNA. Qualitatively, there is no discernible bias in the DNA 
methylation profile between DNA prior to WGA and that after derived after this 
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amplification process. Interestingly, although not part of published data I found that whole 
genome amplified DNA could be stored for longer periods that converted DNA and that 
primers directed to converted DNA provided more consistent amplification than those used 
on DNA prior to amplification. 
The materials derived from WGA were interrogated using the Illumina Infinium 
27K assay that interrogates 27,578 CpG sites across 14,495 genes. In Chapter 4, I first 
described how this genome-wide study was designed. In this case, the 27K assay was 
performed on 15 pituitary tumours (discovery cohort) that included 3 samples of each 
pituitary adenoma subtype (NF, GH, PRL, and CUSH) and relative to three post-mortem 
pituitary glands. The data set generated by 27K BeadArray assay was processed in silico 
using various exclusion criteria,  initially for quality control and subsequently by exclusion 
of all CpGs that were regarded to be lower than or at the limits of detection (≤ 0.2 [β 
value]) or showed values ≥ 0.8 across the data set. The resulting data set (after exclusion of 
data from the X-chromosome resulted in 10,667 CpGs spanning 7,956 genes. Second, the 
reliability of the BeadArray-derived data was assessed through validation experiments 
using sodium bisulphite pyrosequencing. The results section describes the validation and 
shows that the majority of array derived β values were confirmed using an independent 
technique, in this case pyrosequencing. Having established the validity and feasibility of 
the genome-wide approach it was possible to identify genes that are hypermethylated in 
pituitary tumours relative to post mortem normal pituitaries. In this case preliminary 
studies showed that it was necessary to use a stringent cut off criteria where one of  two 
CpGs showed a Δβ of ≥0.4 and a second CpG a Δβ of ≥0.25. This identified 40 genes in 
NF adenomas, 21 in GH, 6 in PRL and 2 in CUSH. Of these, I randomly selected 22 genes 
for promoter methylation analysis by pyrosequencing using, in this case a larger 
investigation cohort of pituitary tumours. Of the 22 genes investigated I was able to 
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confirm methylation in 16 cases, that is 75% and relative to normal pituitaries. Of the 16 
genes studies in the investigation cohort different frequencies of methylation were 
observed. Moreover, and interestingly, 3 genes showed subtype-specific DNA methylation 
patterns. To determine potential associations between methylation and gene expression I 
used RT-qPCR. In these cases a causal relationship between methylation and expression 
was only observed for three of these genes. In these cases a likely explanation is the 
“driver-passenger” theory (Zeller et al., 2012; Kim et al., 2011a)  and/or multiple 
epigenetic mechanisms where mechanisms other than or in addition to promoter 
hypermethylation are responsible for gene inactivation. In the final results chapter of my 
thesis I addressed this phenomenon by looking at histone modification for one of the 
identified genes (see below). Finally, I performed gene ontology analysis and found that a 
number of hypermethylated genes identified in my BeadArray analysis had also reported as 
tumour suppressor genes in other types of tumours. The output of my genome-wide study 
provides the first, subtype-specific, identification of candidate genes probably involved in 
pituitary tumourigenesis for further studies. Moreover, while candidate gene studies 
frequently show an association between CpG island methylation and loss or significantly 
reduced gene expression the BeadArray analysis did not. We presume this reflects the 
following: assuming reduced transcript levels are first shown then the likelihood of finding 
this to be associated with methylation is significant. However, where the initial part of the 
investigation is methylation status then the presence of this change is not invariably 
associated with loss of transcript. Our conclusion would be that the presence of increased 
methylation “suggests” that a gene might be transcriptionally incompetent but does not 
establish a significant association.   
To extend my studies  toward a functional analysis of identified hypermethylated 
genes, I focused  attention on the  EFEMP1 gene. In part the rationale for investigating this 
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gene was that it appeared to show subtype-specific hypermethylation that was confined to 
the GH secreting adenomas. Furthermore it has been reported as multi-functional protein in 
different  tumour types and show context specific actions. Somewhat surprisingly I found  
that expression of EFEMP1 at transcriptional level is significantly reduced in 25 of 33 
pituitary tumours (~75%) and loss or reduced expression was irrespective of pituitary 
adenoma subtype. To investigate mechanisms responsible for reduced expression, I first 
examine DNA methylation of the promoter-associated CpG island  of the EFEMP1 gene 
by pyrosequencing. Due to sample limitations, only 28 of 33 samples were available for 
this analysis. While these studies showed that adenomas that expressed EFEMP1 were no 
methylated (relative to normal pituitary) a more complex picture was apparent for tumour 
showing reduced expression. In these cases, of the 17 adenomas that showed reduced 
expression of EFEMP1 only 8 were methylated. Therefore, in some tumours methylation 
could not account for reduced expression.  
To gain further insight into mechanisms associated with expression of the  
EFEMP1 gene, I extended studies to rat and mouse pituitary cell line models. In both 
species, significantly reduced expression of Efemp1  was associated with CpG island 
methylation and histone modifications. In human pituitary adenomas I also showed a 
significant association between histone modification and gene silencing. Taken together, 
ChIP data clearly showed a correlation between histone modifications and EFEMP1 gene 
expression. However, additional experiments were needed to examine the causal effects of 
DNA methylation and/or histone modifications on EFEMP1 gene expression. Toward this 
goal, I treated rat and mouse pituitary cells lines with epidrugs either alone or in 
combination. In these cases, co-incubation with the epidrugs restored expression of this 
transcript. Restored expression was associated with increased and decreased enrichments 
of histone modifications indicative of active- and inactive-gene expression, respectively. 
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Taken together, my data determined a causal effect of histone modifications on EFEMP1 
gene expression.  
Finally, for functional analysis I used  enforced-expression of EFEMP1  in rat 
pituitary cells  by using an inducible expression vector. The results showed that this gene 
had no effects  on cell proliferation or apoptotic end points. However,  a dose-dependent 
inverse effect  EFEMP1 and MMP2 was apparent. Interestingly, in human pituitary 
samples this observation was not seen, but there  was a direct correlation between 
EFEMP1 and MMP7. These initial observations require further studies. However, the data 
gained within this thesis added to the literature in which fibulin-3 showed different 
behaviours dependent on cell types.  
6.2. Suggestions for future work 
6.2.1. Up-to-date genome-wide DNA methylation profiling of pituitary tumours 
Genome-wide DNA profiling technologies have made significant advances. At the 
start of  my PhD studies the Illumina 27K BeadArray was the most technically advanced 
means of investigating the genome on an genome-wide basis. Subsequent to these studies 
arrays that interrogated more than 450,000 CpG sites have been described and are 
commercially available. In addition there are a number of commercially available Next 
Generation Sequencing technologies and other array-based genome-wide DNA 
methylation strategies available. Some of these techniques and technologies are  reviewed 
in section 1.3.2.II of this thesis and may form avenues for further studies in this tumour 
type. A limitation of my studies was also apparent and due to the limited number of 
samples interrogated for each adenoma subtype. Therefore, I would like to perform another 
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genome-wide study in which a larger number of pituitary samples is interrogated at higher 
coverage ratio of epigenome. 
In this thesis, I focused on CpGs located within CpG islands where I saw increased 
methylation relative to normal pituitaries. In this way an aim was to identify putative 
tumour suppressor genes. However, there are some studies  of oncogenes reported to be 
over-expressed in tumours relative to normal tissues through promoter hypomethylation 
(De Smet et al., 1996; Singh et al., 2003). In these cases it is necessary to identify 
hypomethylated CpGs. Using the similar stringent cut-off criteria applied to identify 
hypermethylated CpGs, screening of hypomethylated CpGs did not return any result. This 
was likely because of the limitation of the number of samples interrogated. Therefore, in 
the next 450K genome-wide investigation I suggest it will be important to give equal 
attention to the finding of hypomethylation genes. Moreover, recent reports showed that 
methylation of CpG sites located outside of CpG islands is also important (Doi et al., 2009; 
Irizarry et al., 2009; Portela and Esteller, 2010). Thus, I am keen to investigate aberrantly 
methylated CpG sites located within CpG island shores. 
6.2.2. Further investigation of the candidate genes identified in this thesis 
One of the major outputs of my thesis is the list of genes which have their 
promoter-associated CpG islands hypermethylated in tumours relative to normal 
pituitaries. One of them, EFEMP1, had been investigated in the later part of this thesis. 
The results indicated that the rest of this list can potentially be a valuable resource of 
candidate genes for further studies in pituitary tumourigenesis research. Attention probably 
should focus on 16 genes whose aberrant methylation status between tumours and normal 
pituitaries had been confirmed by pyrosequencing. Of these, I would suggest high attention 
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on to 3 candidates (EML2, HOXB1, RHOD) which showed inverse correlation between 
DNA methylation and gene expression.  
7.2.3. Further functional studies of EFEMP1 
In other tumour types, multiple functions of fibulin-3 in tumourigenesis have been 
reported including tumour suppressor, apoptotic, angiogenic, metastatic, and invasion 
(Gallagher et al., 2005; Obaya et al., 2012; Seeliger et al., 2009). My study showed for the 
first time fibulin-3 was significantly down-regulated in a large number of pituitary tumours 
in all 3 species investigated which are human, rat, and mouse. This phenomenon suggests 
that fibulin-3 may plays roles in pituitary tumourigenesis. In my thesis, initial attempts had 
been done which shed some light toward the functions of this protein. For the subsequent 
studies I would suggest the following directions. 
Enforced-expression of EFEMP1 in other cells line model systems 
Due to time limitation I had only been able to enforce the expression of EFEMP1 
in rat GH3 cells line which is corresponding to the GH subtype. In agreement with the 
literature reported for other tumour types, in case of pituitary tumours my data also suggest 
a bi-functional property of fibulin-3 where positive- and negative-correlations between this 
protein and MMP2/MMP7 were observed in rat and human samples, respectively. 
Moreover, previous studies of pituitary tumourigenesis showed species- and/or subtype 
specificity of the target genes, for example the BMP-4 behaved differently in lactotroph- 
and corticotroph-derived adenomas (Yacqub-Usman et al., 2012a). Therefore, it is 
necessary to enforce expression of EFEMP1 in other pituitary cell lines corresponding to 
other species and tumour subtypes.  
Investigate the effect of fibulin-3 on pituitary cell migration and invasion  
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My data suggest that fibulin-3 does not have effects neither on cell proliferation nor 
apoptosis pathway. However, the correlation between this protein and MMP2/MMP7 
suggest a function in cell migration and invasion which were observed in cervical and 
malignant cancers (Song et al., 2011b; En-lin et al., 2010; Hu et al., 2012; Hu et al., 2009). 
Therefore, it is apparent that cell invasion and migration assays should be performed on 
pituitary cell lines.  
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Appendix 1: Primary pituitary adenomas used within the 
study  
Discovery cohort 
Study Number Tumour Number Classification Grade 
GH1 99 Somatotrophinoma 2 
GH2 217 Somatotrophinoma 2 
GH3 676 Somatotrophinoma 2 
ACTH1 4 Corticotrophinoma 1 
ACTH2 10 Corticotrophinoma 2 
ACTH3 59 Corticotrophinoma 3 
PRL1 25 Prolactinoma 2 
PRL2 56 Prolactinoma 2 
PRL3 57 Prolactinoma 1 
NF1 551 Non-functioning  2 
NF2 593 Non-functioning 2 
NF3 598 Non-functioning 2 
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Investigation cohort 
Study Number Tumour Number Classification Grade 
GH1 16 Somatotrophinoma 2 
GH2 23 Somatotrophinoma 2 
GH3 27 Somatotrophinoma 2 
GH4 529 Somatotrophinoma 2 
GH5 596 Somatotrophinoma 2 
GH6 676 Somatotrophinoma 2 
GH7 686 Somatotrophinoma 2 
ACTH1 4 Corticotrophinoma 1 
ACTH2 10 Corticotrophinoma 2 
ACTH3 22 Corticotrophinoma 1 
ACTH4 32 Corticotrophinoma 1 
ACTH5 59 Corticotrophinoma 2 
ACTH6 195 Corticotrophinoma 2 
ACTH7 207 Corticotrophinoma 1 
PRL1 25 Prolactinoma 2 
PRL2 29 Prolactinoma 2 
PRL3 46 Prolactinoma 1 
PRL4 56 Prolactinoma 1 
PRL5 57 Prolactinoma 1 
PRL6 396 Prolactinoma 1 
PRL7 535 Prolactinoma 1 
NF1 512 Non-functioning  3 
NF2 577 Non-functioning 2 
NF3 579 Non-functioning 2 
NF4 581 Non-functioning 2 
NF5 594 Non-functioning 3 
NF6 607 Non-functioning 3 
NF7 608 Non-functioning 2 
NF8 613 Non-functioning 3 
NF9 618 Non-functioning 3 
NF10 624 Non-functioning 2 
NF11 684 Non-functioning 2 
NF12 688 Non-functioning 2 
NF13 689 Non-functioning 3 
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Appendix 2: Commonly used solutions 
All reagents were purchased from Sigma-Aldrich unless stated otherwise. 
2.1. DNA extraction 
The regents used for DNA extraction in addition to those in the materials and methods are as 
follows:  
Lysis buffer: TE buffer (pH8.0), 0.5% SDS pH 7.2 and 200µg/mL of Proteinase K 
TE buffer (pH 8.0) 
10mM Tris HCl (pH 8.0) 
1mM EDTA (pH 8.0) 
Mix well and autoclave. The amount of TE buffer added to the reaction will vary between samples 
and between experiments. Cells require 1.5mL of TE buffer whereas tissue requires 3mL of TE 
buffer. 
20% SDS 
10g of SDS added to 50mL of H2O and rotate on the rotary shaker at room temperature for 2 hours. 
Proteinase K 
Obtained from Sigma in a powdered form. Add H20 to give a concentration of 10mg/mL. Add 
desired amount to give 200µg/mL final concentration in lysis buffer.  
2.2. RNA extraction 
The reagents stated below are used in the extraction of RNA in addition to those stated in the 
materials and methods: 
Lysis buffer: 5M Guanidinium thiocyanate: 
5M Guanidinium isothiocyanate 
0.5% (w/v) Sarkosyl (N-lauroylsarcosine) 
25mM sodium citrate 
8% (v/v) β-mercaptoethanol 
Mix well and autoclave 
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Chloroform Isoamyl-alcohol (24:1) 
Add 239.6mL of chloroform to 10.4mL of isoamyl-alcohol (250ml total volume), mix well and 
store at 4°C 
2M Sodium acetate pH4.0: 
Add 82.03g of sodium acetate to 200mL of H2O. Adjust the pH to 4.0 using glacial acetic acid, 
adjust the volume to 500mL by adding H2O and autoclave. 
70% Ethanol 
Take 70mL of 100% ethanol and add 30mL of H2O. 
2.3. cDNA synthesis 
All reagents arrived ready prepared (Promega, Southampton, UK). However the dNTP’s require 
diluting. 
Dilution of dNTP (Bioline, London, UK) 
The dNTP’s are purchased as a 100mM stock and, therefore, comprise 25mM of each of the four 
bases. For the majority of experiments the working concentration for each base was 5mM. 
Therefore 200µL of the supplied dNTP was added to 800µL of ddH2O. Aliquots were stored at -
20°C and thawed on no more than three occasions. 
2.4. Gel electrophoresis 
Products from RNA extraction, DNA extraction and PCR were in some cases resolved by gel 
electrophoresis. In these cases the following reagents were used: 
TAE buffer (50X) 
To 800ml ddH2O add 242g Tris base, 57.1ml glacial acetic acid, 100ml 0.5M EDTA. Make up to 
1X final volume using dH2O. 
10X Tris-Borate-EDTA (TBE) electrophoresis buffer (10X): 
108g Tris base 
55g Boric acid 
40mL 0.5M EDTA (pH8.0) 
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Mix well and store at room temperature. 
Loading buffer: 
1mg/ml Bromophenol blue in 50% glycerol. Store aliquots at -20°C 
Loading dye: 
0.25% Bromophenol blue 
0.25% Xylene cyanol FF 
40% Sucrose. 
 Make up to required volume in dH2O. Loading buffer is X6 therefore when loading 5µL of PCR 
product add 1µL of loading buffer. Mix well and load onto gel. If adding more or even less sample 
scale up or down the loading buffer quantities. 
2.5. Bacterial transformation 
DNA sequencing analysis: 
DNA sequencing was performed commercially. In this case sequencing of native DNA or of DNA 
subject to sodium bisulphite conversion was performed. Converted DNA and amplified PCR 
product was first eluted from Gene Elute PCR column prior sub-cloning into the T:A vector prior 
to bacterial cloning and transformation (and as described in the M&M).  
LB Medium: 
Luria Broth is used for maintenance and propagation of E.coli. LB broth comprises Bacto-tryptone, 
Yeast and NaCl.  
To 500mL of ddH2O add 12.5g of LB broth mix well and autoclave immediately 
LB agar plates containing ampicillin, IPTG and X-Gal: 
Dissolve 12.5g of LB and 7.5g agar in 500mL of ddH2O. Mix well and autoclave immediately. 
Cool to 50 °C before adding 60µL/mL ampicillin, 0.5mM IPTG, 0.08mg/ml X-gal. Mix solution 
avoiding frothing and pour into 90mm petri dishes at a depth of 3-5mm. Allow to set on the bench 
and further incubating at 37°C for complete setting. Once plates have set store at 4°C until ready to 
use. 
Preparation of competent cells 
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Chemically Competent JM109 cells (Promega) were routinely prepared for transformation 
purposes. A colony from an LB plate was inoculated into 5mL of LB media and incubated for 16 
hours at 37°C with shaking in the orbital shaker (150-200rpm). The entire 5mL culture was used to 
inoculate 250mL of LB medium containing 20mM MgSO4 in a sterile glass flask and incubated at 
37°C again with shaking. The culture was allowed to grow to an absorbance (OD600) of 0.4-0.6 
(typically 3-5 hours). The cells were collected by centrifugation at 914 x g for 10 minutes at 4°C 
using IEC Centra-8R Centrifuge (International equipment company, USA) a temperature controlled 
centrifuge. The supernatant was discarded and the cells were re-suspended in 10mL of ice cold 
chemical buffer 1: TFB1 (see below) and incubated on ice for 30 minutes. Cells were then 
centrifuged at 914 x g for 10 minutes at 4°C. The supernatant was removed again and cells were re-
suspended in chemical buffer 2: TFB2 (see below) and incubated for a further 30 minutes on ice. 
This was then aliquoted into 0.5mL cold microcentrifuge tubes. These aliquoted chemically 
competent cells were then flash frozen by liquid nitrogen and were placed at -80°C until ready to 
use, and were used once without refreezing. 
TFB1: 
30mM Potassium acetate 
10mM CaCl2 
50mM MnCl2 
100mM RbCl 
15% glycerol 
Adjust pH to 5.8 with 1M acetic acid, Filter sterilise and store at room temperature. 
TFB2: 
10mM MOPS (4-Morpholinepropanesulfonic acid) pH6.5 
75mM CaCl2 
10mM RbCl 
15% glycerol 
Adjust to pH 6.5 with 1M KOH, filter sterilise and store at room temperature. 
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Appendix 3: Primer sequences  
3.1. Bisulphite sequencing primers 
Primers were directed toward sodium bisulphite modified DNA.  
Human GLRX  
Forward primer 1 TTATTTTGTTATTTTAATTTTAGTAA 
Reverse primer 1 TCAAAAAAAAACTATATCCTTTAAA 
Forward primer 2 AGTAAAAAGTTGTTTTTGGGAGTG 
Reverse primer 2 ATCATCCTTTCCCCAAAAAATTTTATA 
Amplified bisulphite converted 
sequence and CpGs interrogated 
AGTAAAAAGTTGTTTTTGGGAGTGGATTTTTTTTTTTTTTTTTGATCGTA
GTATGTTTGGGATTTTTTTTACGTGGTAGTCGTGGTGTTTAGTTTTGGTT
TTGGTTTCGTTTTTTTGAAGATATTTTGGTTTTATTATAAAATTTTTTGG
GGAAAGGATGAT 
Human MBD3  
Forward primer TGGAGAAATTGTTTTGGTTTTA 
Reverse primer AAAACTCTATCTCCATCAATCA 
Amplified bisulphite converted 
sequence and CpGs interrogated 
TGGAGAAATTGTTTTGGTTTTAAGGATTTTTTTGTTGATATTGGGTTTAT
TCGATTTGGGATGTTTTTTTATTTGAAGATTTCGTTTTATTTTTAAAGTT
TTTTTAGTTGTAGGTTTTAGGGAGTAGGATAGGTATATTTATTTATTGAT
TGATTGATTGATTGATGGAGATAGAGTTTT 
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3.2. Pyrosequencing primers 
Primers were directed toward sodium bisulphite modified DNA. The table also shows the number 
of CpG interrogated by the primer combinations 
Biotinylated primers are underlined   
Gene/CpG 
  
Human  Forward primer 1 ATTTGGGTGTAGGGATTGT 
cg08047457 Reverse primer 1 AACCAAAACCCAATATAAAAACCCTCTTC 
 
Forward primer 2 GGGAAGGAGTTGAGGAGAGT 
 
Reverse primer 2 CCACCCAATAAATAAACCAAATATATTACT 
 
Sequencing  primer TGTAGGGATTGTGGG 
 
Number of CpGs 3 
 
Sequence to analyse GTTYGAAGGYGGGGTTGGGYG 
Human  Forward primer 1 GGTTTGGGTGAAGGAGAAT 
cg20289949 Reverse primer 1 AAACCCAAACAACCTATCTCCATCT 
 
Forward primer 2 GTGAGTTTGGGATTTTGGTTAA 
 
Reverse primer 2 CACCCTATCATATCATCTCCT 
 
Sequencing  primer ACTAAACTCACATAAACTTATTAC 
 
Number of CpGs 1 
 
Sequence to analyse AAACCRAAAA CTAAAAAAAA CCCC 
Human  Forward primer 1 AGATGGGGAGTAATGGAATGTTT 
cg06197492 Reverse primer 1 ATATAAACCACCTTAACAAATACCTATAC 
 
Forward primer 2 AGTTTAGGGTTTTTGTTGAAGT 
 
Reverse primer 2 TCCCTTCTAAATTTAATTTACACTAAATCA 
 
Sequencing  primer GGTTTAGATGGAGGG 
 
Number of CpGs 2 
 
Sequence to analyse YGGTYGGGTTTTGTATAGGTATTTGT 
Human  Forward primer 1 TTGGGGATTTTAGGATTTAGGT 
cg24739326 Reverse primer 1 CCTCCTTCTATTTTATCAAACTAATTCTTC 
 
Forward primer 2 GTAGGGGTTTGGGTGTGTTAA 
 
Reverse primer 2 CTAATCTCTAAACCCTAACTTCC 
 
Sequencing  primer AGTAGGGTAGGAGGTA 
 
Number of CpGs 2 
 
Sequence to analyse GTTTGAGAGTYGGTAGTTTYGTTTTGGAGT TTGAGTA 
Human  Forward primer 1 GGTTTTGTGAGTGTTTTTTTGTGATTAT 
BCL9L Reverse primer 1 CCCCAACTCTAACTCACACACACT 
 
Forward primer 2 AGGTTTTTGTGTTTGTGTAAGTTTG 
 
Reverse primer 2 AAACTCAAAAACCCACAAACACC 
 
Sequencing  primer GGTTTTAGTTTTTTTATTTGTTTAA 
 
Number of CpGs 6 
 
Sequence to analyse 
TGGGTTYGGY GTTTTTATTT AGTTTTYGGG TAGTTTYGGT 
GTTTGYGYGT GTTTTAGGTT  
Human  Forward primer 1 GGTGAGGAGGGATTGGATAGT 
COL1A2 Reverse primer 1 CCTCCCCCCCCCTTTCCAAA 
 
Forward primer 2 AGTGTATTATTGTTGAAATAGTGGG 
 
Reverse primer 2 CCTAACCCTAAAATACCTCCAAA 
 
Sequencing  primer GATTGGATAGTTTTTGTTTTG 
 
Number of CpGs 5 
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Sequence to analyse 
ATYGTYGGAG ATTTGTAAAT TTTGTTTATG TYGGGGTTGT 
AGAGTATTTY GAYGTGTTTT ATAGTGTTTT  
Human  Forward primer 1 GGTTTGTAGGGTTAGAGAGAGAAT 
CXCL14 Reverse primer 1 AAAAAAAACCTTCCCAACCC 
 
Forward primer 2 TTTTTAGGTTTTTGAGGATTTGA 
 
Reverse primer 2 ATAACTCACTAAAATTTCTCAAT 
 
Sequencing  primer GGGTTTTTTAAAGGTAGAG 
 
Number of CpGs 7 
 
Sequence to analyse 
YGGGAYGTTG GAAATGTGTG YGYGTTGTGG TATGGGTGTG 
TAAGTGTGYG AAGGYGGYGT GTTGTGTGAG 
Human  Forward primer 1 GTTAAGGGTGGTAAGGGGGAGTAT 
D4ST1 Reverse primer 1 AACCACCCCTATCCTCTAAACTT 
 
Forward primer 2 TGGAGTGGTTAAGATTTGTAGGA 
 
Reverse primer 2 ACCCCTACCCCAAAAAAAACG 
 
Sequencing  primer TTTTAGTTGGAAAGATTAGTTT 
 
Number of CpGs 5 
 
Sequence to analyse 
TYGGTAYGTT TGGATTYGGA GAGAGYGTTG TTYGTTTTTT 
TGTTTTTAGA TT 
Human Forward primer 1 TTGTTGTTAAGAAAGGGGATTTTATTT 
EFEMP1 Reverse primer 1 CCTTCTCACATATCTCAAAACTTCT 
 
Forward primer 2 GGGGATTTAGATTGATAAGATAAAAGAGA 
 
Reverse primer 2 CCCCCAACACAAACTCTCAAAATA 
 
Sequencing  primer ATTTGGGATTTTTAAATAAAGTT 
 
Number of CpGs 2 
 
Sequence to analyse GTGYGTAGAG AAAGGYGTGG AAATGTTATT TTGAGAGTTT GT 
Human  Forward primer 1 GGTTTTAGGGGTGGTTGT 
EML2 Reverse primer 1 TCACCCAACTCCAAAACTACTCAT 
 
Forward primer 2 ATTAGTAGAATTGGGGTTTTAATTTA 
 
Reverse primer 2 TAAAACCTAAAATCTAAACCCC 
 
Sequencing  primer GGTTAGGGAGTTTTTTAGGGT 
 
Number of CpGs 6 
 
Sequence to analyse 
YGGAAGYGGT AGAGTYGGTT TYGGTTTTAT TTTYGGTTTY 
GAAGTTT 
Human  Forward primer 1 GGGATAGAAAGATTTTTTAAGGGAGTATT 
FEM1C Reverse primer 1 CAAACCTAAACCTCACATCACTAACTATAC 
 
Forward primer 2 ATTTTTTTTTTGGGGTTTTTGAGAT 
 
Reverse primer 2 taaaccaaactataacctccaaccc 
 
Sequencing  primer GTAAGTAGGTAAGTTTTTTTAGTAG 
 
Number of CpGs 10 
 
Sequence to analyse 
TTTAGGTTTY GTTTTTTTTT YGTYGTTTTA TTTYGGTYGY 
GAYGTTTYGT TTYGYGTTTA GGTTGTTGTT GGT 
Human  Forward primer 1 GTTGAGGTTTTGAGAGGTTAGTAATATG 
FLJ46380 Reverse primer 1 CCCCACTCTTCCATCCCATTTA 
 
Forward primer 2 ATTATTAGGATATTAGTTTTATTTTAA 
 
Reverse primer 2 ACTACAAAACCAAACTATCTTA 
 
Sequencing  primer GGAAAGTAGGTGGAGG 
 
Number of CpGs 7 
 
Sequence to analyse 
GGYGTTYGTT GTTTTTTGGY GTTTTTAATT GGTYGTYGAG 
GAAATGAGGY GGYGATGATT  
Human  Forward primer 1 AATGAAAAAAGAGAGGAGGTTTAG 
GLRX Reverse primer 1 CAAAATACCCATTCTCCTTATCCC 
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Forward primer 2 AGTAAAAAGTTGTTTTTGGGAGTG 
 
Reverse primer 2 ATCATCCTTTCCCCAAAAAATTTTATA 
 
Sequencing  primer AAAAATCCCAAACATACTAC 
 
Number of CpGs 1 
 
Sequence to analyse RATCAAAAAA AAAAAAAAAA ATCCAC 
Human  Forward primer 1 AGTTTAGGGTTTTTGTTGAAGT 
H19 Reverse primer 1 TCCCTTCTAAATTTAATTTACACTAAATCA 
 
Forward primer 2 AGATGGGGAGTAATGGAATGTTT 
 
Reverse primer 2 ATATAAACCACCTTAACAAATACCTATAC 
 
Sequencing  primer GGTTTAGATGGAGGG 
 
Number of CpGs 2 
 
Sequence to analyse YGGTYGGGTT TTGTATAGGT ATTTGT 
Human  Forward primer 1 GTGAGTTTGGGATTTTGGTTAA 
HAAO Reverse primer 1 CACCCTATCATATCATCTCCT 
Assay1 Forward primer 2 GGTTTGGGTGAAGGAGAAT 
 
Reverse primer 2 AAACCCAAACAACCTATCTCCATCT 
 
Sequencing  primer ACTAAACTCACATAAACTTATTAC 
 
Number of CpGs 1 
 
Sequence to analyse AAACCRAAAA CTAAAAAAAA CCCC 
Human  Forward primer 1 GGGTTTAGATTAAAGTTTATTAGGGGGTAA 
HAAO Reverse primer 1 TTCACCCAAACCCTCACT 
Assay2 Forward primer 2 TTAGTTAGGGTTTGGAGT 
 
Reverse primer 2 ACTCACATAAACTTATTACAA 
 
Sequencing  primer GTTTATTAGGGGGTAAAG 
 
Number of CpGs 7 
 
Sequence to analyse 
TTYGYGGGTT TTAAGTTTTT ATTAYGGGGT YGYGGGGGTT 
TGTTTYGTTT YG 
Human  Forward primer 1 TTGGTTTGGGAGAGATTATATGTGTT 
HOXB1 Reverse primer 1 ACACCCTCTTACCCTACA 
 
Forward primer 2 AGGAGTTTATTGAAGGTTTTGG 
 
Reverse primer 2 AAATTCATCCTATTATAATCCATAC 
 
Sequencing  primer CTTACCCTACAACCTT 
 
Number of CpGs 6 
 
Sequence to analyse 
TCRACAATAT ATCACAACRC TAAAACTCRA ATCCATAACC 
TAACCCRCTC RCCTAAACAA ACRCTTCCCT  
Human  Forward primer 1 TGAAGAATGTATGGAGGAATTGTAT 
KCNE3 Reverse primer 1 AAATACCTCCCCCCAACTCCTTAAC 
 
Forward primer 2 ATATTTTGGATTTAAAGGTTTTATTTG 
 
Reverse primer 2 CTCTAACTCTAAACTCCCAC 
 
Sequencing  primer GTTTTATGTTGGGTTTGT 
 
Number of CpGs 6 
 
Sequence to analyse 
TGAGGTTTAG YGGAGYGAGA GGTTTTYGGT TTTTGGTTTA 
GGAAGTAGGY GTTGTAGGGG AYGGAAGGGT YGG 
Human  Forward primer 1 GTTGTATAGTTTTAGGAGGTTAGGTT 
KIAA0676  Reverse primer 1 ACAACCCATTAACCACCAACACCT 
 
Forward primer 2 GTTTTGGATTTAGGTCGGAGG 
 
Reverse primer 2 CGACGTCGCTACAACACGAA 
 
Sequencing  primer TTTAGGAGGTTAGGTTG 
 
Number of CpGs 8 
 
Sequence to analyse GYGYGYGTTY GAGGTYGGGG TTGAGGGGGY GGYGYGGAAT T 
Human  Forward primer 1 GAGAGTTTTGTGGGGAGGAAGTA 
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KIAA1822 Reverse primer 1 ACAACCCCCATCCCCTCC 
 
Forward primer 2 GGAGGTGGAATAGAAGTTTA 
 
Reverse primer 2 ACACCCAAAACGCCAACAA 
 
Sequencing  primer ATTTGGAAAGAGGTTAAAAGAG 
 
Number of CpGs 8 
 
Sequence to analyse 
GTYGTGTYGT ATTTTGYGTY GYGTTTTTTT TTTTTTAGTT 
TYGTYGAGTG TTTTYGAT 
Human  Forward primer 1 GGTTGGAAAGTAGGAGTTAGATTTATAGT 
MAL Reverse primer 1 ACCCAAAAACCACTAAACAAAATACTACC 
 
Forward primer 2 GATTAAAGTGGTTTTGTTTTGTT 
 
Reverse primer 2 ACAAACTCAAAAATAAAAAACAAATC 
 
Sequencing  primer GGGGTTTAGAAGAGGTTTA 
 
Number of CpGs 10 
 
Sequence to analyse 
GGGYGGTGTT YGYGGYGTTY GGGTYGGGTT TTTYGGGGYG 
TGGGGYGGGG GGYGG 
Human  Forward primer 1 AGGGAAGTTGGGAAGGTT 
MT1G Reverse primer 1 ACCCAACAACCAACCACTATTTTTATAATC 
 
Forward primer 2 TTTAGTTATTGATTAGAGATTTGGG 
 
Reverse primer 2 AATTTAACATCCCAAAACACAAAAC 
 
Sequencing  primer ATTTAGAGGGTTGGGTGTA 
 
Number of CpGs 6 
 
Sequence to analyse 
AGGGYGGGGY GGGGYGTTTG YGTTYGGTTT YGTTTTTTGA 
TTATAAAAAT AGT 
Human  Forward primer 1 GGTTGGGTAGAGTGGGGATAG 
PDLIM4 Reverse primer 1 CCACCAAACCAAAACCCCAAAAC 
 
Forward primer 2 AATTTAGGCGTATAGGGA 
 
Reverse primer 2 CAAACTCACCCGTAAAATA 
 
Sequencing  primer GAGTGGGGATAGGGG 
 
Number of CpGs 11 
 
Sequence to analyse 
YGGGYGGGTY GGGGGYGGGY GYGGYGTTTA GGYGGYGGYG 
GYGGTTG 
Human  Forward primer 1 GGGGAGAAGATGTGTTAATGT 
PGLYRP1 Reverse primer 1 CCCCAAACTCAACTTCCTTCTCTAA 
 
Forward primer 2 ATGGTATTAGGTTTGGATTTGGG 
 
Reverse primer 2 TTCACACCCTACTAAAACTTCCT 
 
Sequencing  primer GAGAGGAGAGATAAGTAG 
 
Number of CpGs 7 
 
Sequence to analyse 
GATYGGGATT TYGGTTTYGG GTTTTTTAGA AAYGGYGGGG 
YGAAGYGTTT AGGGGTTTGT G 
Human  Forward primer 1 GGAGGTTTTTTTGGGATTTTAAGT 
RAMP1 Reverse primer 1 ACACAAAACCCCAACCATAATACACA 
 
Forward primer 2 AGGGGAAGATTTTTAGGTGGAGAT 
 
Reverse primer 2 CTACTCACCCAAAAACAACCAAAAAC 
 
Sequencing  primer TGGGAGTTTTAGGTTTTGGTATTTA 
 
Number of CpGs 10 
 
Sequence to analyse 
YGYGGGGAGT YGTAGTGGGT YGGGTYGYGY GGTYGTYGTT 
TTTTATYGTT TT 
Human  Forward primer 1 GGAGAGGAAGGGTTTTAGTTT 
RHOD Reverse primer 1 CCCACCAAAACCACCTTAAC 
 
Forward primer 2 TTTAGGGATTTAGACGGTTTGGA 
 
Reverse primer 2 CATCGACGAAAACCATCAACAA 
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Sequencing  primer GAGGAAGGGTTTTAGTTTA 
 
Number of CpGs 9 
 
Sequence to analyse 
GTYGTTYGGG TTTTTTATTT GGTTTTYGGG GYGTTYGGTT 
YGTATTTTTT TTYGTYGTTT YGTTTTTTTT ATATTTTTG 
Human  Forward primer 1 GTTTAGTATTTTTATTTGTTTAGGGATT 
SAMD11 Reverse primer 1 CCCTTACTACCCTAACAAAATTT 
 
Forward primer 2 GAGGATTTGGTTTTGGTTTTGGTTA 
 
Reverse primer 2 AATACTACCCTTCCAATCCTTAACC 
 
Sequencing  primer GGATTTTTAGTAGTTGTTGGATAA 
 
Number of CpGs 9 
 
Sequence to analyse 
YGGYGAGTYG TGTATYGAGG TGGAGTGYGG YGTTAATYGY 
GYGTTGTTTT A 
Human  Forward primer 1 GGTTGTTTAGTGGGGTGAT 
ST6GALNAC6 Reverse primer 1 CCCCCAACCCCCTCACAT 
 
Forward primer 2 AGGTTGTTGTATTTTGGTGGTTATT 
 
Reverse primer 2 CGAAACCCTAACCCCAACTAA 
 
Sequencing  primer CCCCACCCAAACCTAAAAAATA 
 
Number of CpGs 9 
 
Sequence to analyse 
A ACRAAACCT CRAAACCRCR AATAACTCCR CCCACRAACR 
ACRCRAAC 
Human  Forward primer 1 TTATTATAATTGGAGTGTATGGAGTAGG 
TFAP2E Reverse primer 1 AACCCCAAACTACTCACCATAAC 
 
Forward primer 2 AGAATTGTTATAGTTTGTTTTTTTAATG 
 
Reverse primer 2 AAAATTAAAAAATCCAACACTCAAAC 
 
Sequencing  primer GTTTAGAGGAGGAAGG 
 
Number of CpGs 7 
 
Sequence to analyse 
GYGGGYGTTG GGTATTYGTT GATYGATTTT TTTAAGTGYG 
ATTAGTGTTY GTTYGTTTTG TTTTTATGGA TT 
Human  Forward primer 1 GGGAAGTTAATGAGAAAATTAGGTTTAGT 
UBTD1 Reverse primer 1 CCCCTAAAACCTATCACTCACCTAC 
 
Forward primer 2 GGTATTTGGTTGGGTGGGG 
 
Reverse primer 2 GTGTTGGGGAGTTTGTTATTTTTTTT 
 
Sequencing  primer ACTCACCTACCTAAC 
 
Number of CpGs 11 
 
Sequence to analyse 
CCCRCCCCAA ACCRACCCCT CTCCCTTCCR CCRACTCRCR 
ATACCCRCRC CRCCRCCACC ACCCRCCCCA AATAC 
Rat Forward primer GTGGTTGTTGTTGTTGTTAGAT 
Efemp1 Reverse primer ATACAATCCCTACCCATACAATACACTTCT 
 
Sequencing  primer GTTAGTTTAGATTTATTAGATTG 
 
Number of CpGs 6 
 
Sequence to analyse 
T T TTTTTTTG YGTATTTTTT YGTTGTYGGG GTTGGATTGT 
YGYGYGGTTT TTYGTAGGTA GGAGTTTTTA GTTAAGGT 
Mouse Forward primer 1 TTTTTGTGGTTGTTGTTGTAGT 
Efemp1 Reverse primer 1 CAACAAATCCACCTCCATCTT 
 
Forward primer 2 TGGTTGGAAGTTTGGGTAGG 
 
Reverse primer 2 CACAAACTAACAAATTATAATCCCAAA 
 
Sequencing  primer GGTTTTTTAGTAGGTAGGAGTTTAA 
 
Number of CpGs 4 
 
Sequence to analyse AGTYGAGGTY GTAAGATTTG YGTTATATTA GYGAGAGTTA TAT 
 
 176 
 
3.3. qRT-PCR primers 
 
Gene Forward primer Reverse primer 
Amplicon 
size (bp) 
Human GAPHD CGACCACTTTGTCAAGCTCA GGGTCTTACTCCTTGGAGGC 102 
 
BCL9L AGCAGGCTCAAGTCTCCTTC GGGTACCCTGTTCCATGTTG 154 
 
COL1A2 TGTGGGTAGTCCTGGAGTCA ACCAACAGGACCAGAAGGAC 232 
 
EML2 CTCATGATGGGAAGTTGCTG ATGCTGTCATCCCACAAGAA 151 
 
FLJ46380 GCAGAGATGCAGAGCCTAAA TCCCAAATCTCCTGGAAGAC 185 
 
HAAO CCCATCATCCAGGAGTTCTT CGATCACCTGGGTCTCATAG 211 
 
HOXB1 AAGACAGCGAAGGTGTCAGA CGGCTCAGGTACTTGTTGAA 119 
 
KCNE3 GCCAGCAGTCTGAGCTTCTA CGCCTCTCTTCAGTCTGGTT 192 
 
KIAA1822 gccaacacctctctcaatgactt gtacgggtagtagttgttgatgagg 261 
 
MT1G ATGGACCCCAACTGCTCCTG TCAGGCGCAGCAGCTGCAC 189 
 
PGLYRP1 GACGTGGGCTACAACTTCCT CATGTAGTTGCCCATGAAGC 135 
 
RHOD GCAGGGCAAGATGACTATGA GGTAGGTCACAGGCTCCAAT 244 
 
TFAP2E AATGTGACGCTGCTGACTTC GGTCCTGAGCCATCAAGTCT 214 
 
EFEMP1 GTCACAGGACACCGAAGAAAC TTGCATTGCTGTCTCACAGGA 81 
 
MMP2 TTGACGGTAAGGACGGACTC  ACTTGCAGTACTCCCCATCG  153 
 
MMP7 GCTGACATCATGATTGGCTT CCCATCAAATGGGTAGGAGT 60 
 
MMP9 CCGGACCAAGGATACAGTTT CGGCACTGAGGAATGATCTA 81 
 
VEGFA AGGGCAGAATCATCACGAAGT AGGGTCTCGATTGGATGGCA 75 
 
HIF1A GAACGTCGAAAAGAAAAGTCTCG CCTTATCAAGATGCGAACTCACA 124 
Rat Pbgd CAGCATCGCTACCACAGTGTC ATGTCCGGTAACGGCGGC 126 
 
Efemp1 GGCCGAAATAACTTCGTCAT CATCAATGTCTTGGCACACA 130 
 
Mmp2 GAAGGACAAGTGGTCCGAGT TGCTGTATTCCCGACCATTA 88 
 
Mmp7 CCAAACAGTCCTAAGTGGCA AAGAACCGAGGCAAGTCTGT 77 
 
Mmp9 GCTGGCAGAGGATTACCTGT TGCTTCTCTCCCATCATCTG 66 
 
Vegfa CAATGATGAAGCCCTGGAGT TTTTTCGCGCTTTCGTTTTT 205 
 
Hif1a GCAGCGATGACACGGAAA  CATATCGCTGTCCACATCAAA 342 
Mouse Pbgd CGGGAAAACCCTTGTGATGC TTCTTCTGGGTGCAAAATCTGG 285 
 
Efemp1 TGGCCGAAATAACTTTGTCA TGCACTCATCAATATCTTGGC 137 
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3.4. ChIP primers 
Gene Forward primer Reverse primer 
Amplicon 
size (bp) 
Human EFEMP1 TGGTCTCTGAGGGAGATGCT CCAGAGAGGACACGTTGACA 121 
Rat Efemp1 TCGCAGAAGTGCATTGTACC TCCATCTTCTCTGCCCAGTT 98 
Mouse Efemp1 ACTGTCCCCGACTGTGAAAC GTGATCCCAGACCAGCAAGT 62 
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Appendix 4: Vector maps 
 
pGEM
®
-T Easy Vector Map and Sequence Reference Points 
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Schematic of the pTUNE Inducible Vector and its Multiple Cloning Sites 
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Appendix 5: List of hypermethylated genes fulfil criteria of 
0.4 in a single CpG site - 
5.1. - within the CpG island  
Gene GH NF PRL CUSH 
SEPT9         
ACTA1         
ACTG1         
ACTN2         
ADAM11         
ADRA1A         
ADRA2C         
AGMAT         
ALX4         
APCDD1         
APOB         
AXIN1         
B3GNT5         
BAI1         
BCAR1         
BCL7B         
BCL9L         
BFSP1         
BIK         
BMP8A         
BTBD14A         
BZRP         
C10orf116         
C14orf58         
C16orf28         
C18orf22         
C19orf35         
C1orf59         
C1QTNF5         
C6orf150         
C7orf20         
C9orf112         
C9orf66         
CASP2         
CCDC69         
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CD109         
CD9         
CDC42EP1         
CDCP1         
CDK5R1         
CHAT         
CHD5         
CHRNB1         
CHST8         
CLSTN1         
CNFN         
CNTN2         
COL1A2         
COL6A1         
CORO6         
CPXM2         
CRIP1         
CSMD2         
CTSZ         
CXCL14         
CYB561         
CYGB         
D4ST1         
DDAH2         
DHRS3         
DLX5         
DUSP2         
DYDC1         
EFEMP1         
EFNA2         
EFS         
ELN         
EMILIN3         
EML2         
ENG         
ENO3         
ENTPD2         
ERBB2         
ERBB3         
F3         
FAM69B         
FEM1C         
FLJ20032         
FLJ32569         
FLJ46380         
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FLJ90166         
FMOD         
FOSL1         
FOXJ1         
FXYD7         
GABBR2         
GAPDHS         
GAS2L1         
GAS6         
GEFT         
GFRA3         
GNG12         
GPR133         
GSH2         
GSTM5         
HAAO         
HAS1         
HCLS1         
HCP5         
HDAC11         
HES6         
HEYL         
HOXB1         
HOXB2         
HSPA12B         
HTR6         
ICAM4         
IER3         
IFITM3         
IGF2BP1         
IGFBP1         
IL17R         
IQSEC1         
IRX2         
KAZALD1         
KBTBD5         
KCNE3         
KCNH4         
KCNK4         
KCNQ1         
KCNQ1DN         
KIAA0676         
KIAA1446         
KIAA1822         
KIF17         
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KLHL21         
KRT7         
LAMA5         
LDHC         
LHX3         
LOC153684         
LOC57228         
LYPD5         
MAL         
MCAM         
MEGF11         
MEIS3         
METRN         
MGC13168         
MGC14289         
MGC3207         
MGMT         
MMP14         
MPST         
MT1G         
MYL9         
NDRG2         
NEF3         
NEUROG1         
NODAL         
NPPB         
NPTX2         
NTF3         
NUDT4         
NUDT8         
OTOP3         
P4HA2         
PDLIM2         
PDLIM4         
PEX10         
PGAM2         
PGLYRP1         
PHLDA2         
PON3         
POU2F2         
POU3F1         
PPIE         
PPP1R3B         
PRKCDBP         
PSCD3         
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PTPN5         
PYGM         
RAB11FIP4         
RAB34         
RAC2         
RAMP1         
RAP1GA1         
RAPGEFL1         
RASSF1         
RCN3         
RGL3         
RHOD         
RIPK3         
RTKN         
SAMD11         
SAMD4A         
SCARA3         
SEC14L4         
SECTM1         
SEMA3F         
SH2D3A         
SIPA1         
SLC15A3         
SLC25A10         
SLC2A4RG         
SLC5A1         
SLITL2         
SLMAP         
SNX8         
SOCS1         
SOCS2         
SPATS1         
ST6GALNAC6         
STK32C         
STUB1         
TBX4         
TBX6         
TCF15         
TCF21         
TCL1A         
TDRD5         
TFAP2E         
TINAGL1         
TLE1         
TMBIM1         
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TMEM106A         
TMEM109         
TMEM41A         
TMEM44         
TMPRSS2         
TNFRSF10D         
TNFRSF13C         
TRIB2         
TRMU         
UAP1L1         
UBTD1         
UNQ9438         
VILL         
VWA1         
WFDC1         
WFIKKN2         
WNT4         
ZAR1         
ZNF135         
ZNF710         
Total 65 181 39 3 
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5.2. - outside of a CpG island  
Gene GH NF PRL CUSH 
ACADVL         
ACTN3         
ANXA9         
APOBEC2         
AXL         
Bles03         
BPI         
BST2         
C10orf26         
C1orf161         
C1orf38         
C1orf52         
C1QTNF3         
C20orf38         
CA9         
CARD15         
CD14         
CD248         
CD302         
CDC42EP5         
CDKN1A         
CFB         
CHI3L1         
CHRNA2         
CHRNB4         
CHRNE         
CHST13         
CKMT2         
CLCA1         
CLEC1A         
CLEC3A         
CLEC3B         
COL16A1         
COL5A2         
COL6A3         
COX6A2         
CX3CL1         
CYP4F12         
DCT         
DDR2         
EDAR         
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EMP1         
EMP2         
FAM101A         
FAM107A         
FAM49A         
FBN3         
FBXL22         
FES         
FGF1         
FGFBP1         
FLJ20152         
FLJ20184         
FLJ20581         
FLJ25422         
FLJ34503         
FLJ36070         
FLJ43582         
FUT1         
FUT3         
GAL3ST4         
GDF5         
GIT1         
GLRX         
GPR92         
GRP         
GUCY2D         
HAPLN1         
HAPLN2         
HFE2         
HMGCS2         
HTR3A         
HYAL2         
IL16         
IL22RA1         
IL32         
INCA1         
INHBE         
ISLR         
KCNJ9         
KLK10         
KLK12         
LAMA4         
LGALS1         
LGI1         
LOC284948         
 188 
 
LOC340061         
LOXL3         
LRFN3         
LRRC8E         
LTC4S         
LYST         
MAP4K1         
MBD3         
MCEMP1         
MFAP4         
MGC18079         
MGC23244         
MGC4677         
MMP9         
MPG         
MRGPRF         
MRGPRX2         
MRVI1         
MT1H         
NFAM1         
NINJ2         
NRIP2         
NTF5         
NTN2L         
OASL         
PAQR4         
PAQR6         
PHKG1         
PLA2G3         
PLAT         
PLXNB1         
PRAP1         
PRKCG         
PRMT8         
PRTN3         
PRX         
PTMS         
RARRES3         
RASSF2         
RBP7         
RGS5         
S100A16         
S100A2         
SCGB3A2         
SDPR         
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SERPINA12         
SERPING1         
SGCD         
SH3TC2         
SLC19A1         
SLC22A8         
SLC24A4         
SLC2A5         
SLC39A2         
SLC39A7         
SLC43A3         
SLC9A3R2         
SN         
SPON2         
STARD13         
STAT5A         
STIM1         
SULT1C1         
SUSD2         
TBX19         
TGM3         
TIMP3         
TIMP4         
TMEM71         
TMPRSS6         
TNFRSF14         
TNFSF15         
TRIP6         
TRPV6         
Total 32 145 10 1 
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Appendix 6: Gene ontology of hypermethylated genes  
6.1. Go biological process 
Term Count Genes 
GO:0001501~skeletal system development 6 HOXB1, DLX5, COL1A2, ALX4, 
TCF15, BMP8A 
GO:0007517~muscle organ development 5 ACTA1, ERBB2, ELN, ALX4, TCF15 
GO:0007242~intracellular signaling cascade 11 SOCS2, RAC2, ERBB2, RASSF1, 
SOCS1, SIPA1, RAB34, COL1A2, EFS, 
ADRA1A, RHOD 
GO:0032535~regulation of cellular component size 5 ACTA1, SIPA1, ELN, NPPB, VILL 
GO:0007264~small GTPase mediated signal 
transduction 
5 RAC2, RASSF1, RAB34, COL1A2, 
RHOD 
GO:0007519~skeletal muscle tissue development 3 ACTA1, ERBB2, ELN 
GO:0060538~skeletal muscle organ development 3 ACTA1, ERBB2, ELN 
GO:0008015~blood circulation 4 ELN, COL1A2, NPPB, KCNQ1 
GO:0003013~circulatory system process 4 ELN, COL1A2, NPPB, KCNQ1 
GO:0048545~response to steroid hormone stimulus 4 SOCS2, ACTA1, ERBB2, SOCS1 
GO:0007265~Ras protein signal transduction 3 RASSF1, COL1A2, RHOD 
GO:0007010~cytoskeleton organization 5 ACTA1, RAC2, SIPA1, ELN, VILL 
GO:0048705~skeletal system morphogenesis 3 HOXB1, ALX4, TCF15 
GO:0014706~striated muscle tissue development 3 ACTA1, ERBB2, ELN 
GO:0048483~autonomic nervous system 
development 
2 HOXB1, ERBB2 
GO:0060537~muscle tissue development 3 ACTA1, ERBB2, ELN 
GO:0032570~response to progesterone stimulus 2 ERBB2, SOCS1 
GO:0048562~embryonic organ morphogenesis 3 HOXB1, DLX5, ALX4 
GO:0009952~anterior/posterior pattern formation 3 HOXB1, ALX4, TCF15 
GO:0006936~muscle contraction 3 ACTA1, ADRA1A, KCNQ1 
GO:0048741~skeletal muscle fiber development 2 ACTA1, ERBB2 
GO:0043588~skin development 2 COL1A2, TCF15 
GO:0040008~regulation of growth 4 SOCS2, SOCS1, SIPA1, NPPB 
GO:0007167~enzyme linked receptor protein 
signaling pathway 
4 WFIKKN2, SOCS2, ERBB2, COL1A2 
GO:0043062~extracellular structure organization 3 ERBB2, ELN, COL1A2 
GO:0003012~muscle system process 3 ACTA1, ADRA1A, KCNQ1 
GO:0048568~embryonic organ development 3 HOXB1, DLX5, ALX4 
GO:0048747~muscle fiber development 2 ACTA1, ERBB2 
GO:0007585~respiratory gaseous exchange 2 ELN, TCF15 
GO:0009725~response to hormone stimulus 4 SOCS2, ACTA1, ERBB2, SOCS1 
GO:0007243~protein kinase cascade 4 SOCS2, ERBB2, SOCS1, ADRA1A 
GO:0007266~Rho protein signal transduction 2 COL1A2, RHOD 
GO:0008544~epidermis development 3 CNFN, COL1A2, TCF15 
GO:0007259~JAK-STAT cascade 2 SOCS2, SOCS1 
GO:0050679~positive regulation of epithelial cell 
proliferation 
2 ERBB2, DLX5 
GO:0001558~regulation of cell growth 3 SOCS2, SIPA1, NPPB 
GO:0003002~regionalization 3 HOXB1, ALX4, TCF15 
GO:0007398~ectoderm development 3 CNFN, COL1A2, TCF15 
GO:0009719~response to endogenous stimulus 4 SOCS2, ACTA1, ERBB2, SOCS1 
GO:0008361~regulation of cell size 3 ACTA1, SIPA1, NPPB 
GO:0007601~visual perception 3 EML2, C1QTNF5, EFEMP1 
GO:0050953~sensory perception of light stimulus 3 EML2, C1QTNF5, EFEMP1 
GO:0055002~striated muscle cell development 2 ACTA1, ERBB2 
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GO:0032355~response to estradiol stimulus 2 SOCS2, SOCS1 
GO:0030833~regulation of actin filament 
polymerization 
2 ELN, VILL 
GO:0008283~cell proliferation 4 CRIP1, ERBB2, SIPA1, ELN 
GO:0030203~glycosaminoglycan metabolic process 2 HAS1, PGLYRP1 
GO:0030036~actin cytoskeleton organization 3 ACTA1, RAC2, ELN 
GO:0055001~muscle cell development 2 ACTA1, ERBB2 
GO:0048771~tissue remodeling 2 RAC2, ERBB2 
GO:0007423~sensory organ development 3 ERBB2, DLX5, TCF15 
GO:0048704~embryonic skeletal system 
morphogenesis 
2 HOXB1, ALX4 
GO:0007179~transforming growth factor beta 
receptor signaling pathway 
2 WFIKKN2, COL1A2 
GO:0008064~regulation of actin polymerization or 
depolymerization 
2 ELN, VILL 
GO:0030029~actin filament-based process 3 ACTA1, RAC2, ELN 
GO:0045765~regulation of angiogenesis 2 ERBB2, NPPB 
GO:0030832~regulation of actin filament length 2 ELN, VILL 
GO:0010627~regulation of protein kinase cascade 3 SECTM1, ERBB2, SOCS1 
GO:0006022~aminoglycan metabolic process 2 HAS1, PGLYRP1 
GO:0032271~regulation of protein polymerization 2 ELN, VILL 
GO:0050678~regulation of epithelial cell 
proliferation 
2 ERBB2, DLX5 
GO:0007015~actin filament organization 2 ACTA1, ELN 
GO:0007389~pattern specification process 3 HOXB1, ALX4, TCF15 
GO:0007498~mesoderm development 2 SECTM1, TCF15 
GO:0042592~homeostatic process 5 RAC2, ERBB2, HAAO, NPPB, KCNQ1 
GO:0048706~embryonic skeletal system 
development 
2 HOXB1, ALX4 
GO:0035113~embryonic appendage morphogenesis 2 DLX5, ALX4 
GO:0030326~embryonic limb morphogenesis 2 DLX5, ALX4 
GO:0051146~striated muscle cell differentiation 2 ACTA1, ERBB2 
GO:0032956~regulation of actin cytoskeleton 
organization 
2 ELN, VILL 
GO:0043254~regulation of protein complex assembly 2 ELN, VILL 
GO:0042981~regulation of apoptosis 5 SOCS2, TNFRSF10D, ERBB2, BIK, 
ALX4 
GO:0032970~regulation of actin filament-based 
process 
2 ELN, VILL 
GO:0030308~negative regulation of cell growth 2 SIPA1, NPPB 
GO:0048598~embryonic morphogenesis 3 HOXB1, DLX5, ALX4 
GO:0043067~regulation of programmed cell death 5 SOCS2, TNFRSF10D, ERBB2, BIK, 
ALX4 
GO:0010941~regulation of cell death 5 SOCS2, TNFRSF10D, ERBB2, BIK, 
ALX4 
GO:0043583~ear development 2 DLX5, TCF15 
GO:0007605~sensory perception of sound 2 EML2, KCNQ1 
GO:0015672~monovalent inorganic cation transport 3 SLC5A1, KCNQ1, KCNE3 
GO:0045792~negative regulation of cell size 2 SIPA1, NPPB 
GO:0035108~limb morphogenesis 2 DLX5, ALX4 
GO:0035107~appendage morphogenesis 2 DLX5, ALX4 
GO:0008217~regulation of blood pressure 2 COL1A2, NPPB 
GO:0007178~transmembrane receptor protein 
serine/threonine kinase signaling pathway 
2 WFIKKN2, COL1A2 
GO:0048736~appendage development 2 DLX5, ALX4 
GO:0050954~sensory perception of mechanical 
stimulus 
2 EML2, KCNQ1 
GO:0060173~limb development 2 DLX5, ALX4 
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GO:0030198~extracellular matrix organization 2 ELN, COL1A2 
GO:0043009~chordate embryonic development 3 HOXB1, ALX4, TCF15 
GO:0043627~response to estrogen stimulus 2 SOCS2, SOCS1 
GO:0009792~embryonic development ending in birth 
or egg hatching 
3 HOXB1, ALX4, TCF15 
GO:0060249~anatomical structure homeostasis 2 RAC2, HAAO 
GO:0016051~carbohydrate biosynthetic process 2 HAS1, CHST8 
GO:0016052~carbohydrate catabolic process 2 LDHC, PGLYRP1 
GO:0045926~negative regulation of growth 2 SIPA1, NPPB 
GO:0005976~polysaccharide metabolic process 2 HAS1, PGLYRP1 
GO:0043066~negative regulation of apoptosis 3 SOCS2, TNFRSF10D, ERBB2 
GO:0043069~negative regulation of programmed cell 
death 
3 SOCS2, TNFRSF10D, ERBB2 
GO:0060548~negative regulation of cell death 3 SOCS2, TNFRSF10D, ERBB2 
GO:0042692~muscle cell differentiation 2 ACTA1, ERBB2 
GO:0030030~cell projection organization 3 RAC2, ERBB2, DLX5 
GO:0045944~positive regulation of transcription 
from RNA polymerase II promoter 
3 HOXB1, ALX4, TFAP2E 
GO:0048511~rhythmic process 2 ERBB2, PGLYRP1 
GO:0050877~neurological system process 6 EML2, C1QTNF5, ERBB2, EFEMP1, 
KCNQ1, TCF15 
GO:0042391~regulation of membrane potential 2 ERBB2, KCNQ1 
GO:0051493~regulation of cytoskeleton organization 2 ELN, VILL 
GO:0030155~regulation of cell adhesion 2 ERBB2, SIPA1 
GO:0030855~epithelial cell differentiation 2 DLX5, CNFN 
GO:0032989~cellular component morphogenesis 3 ACTA1, ERBB2, DLX5 
GO:0050878~regulation of body fluid levels 2 NPPB, ENTPD2 
GO:0044087~regulation of cellular component 
biogenesis 
2 ELN, VILL 
GO:0050801~ion homeostasis 3 ERBB2, NPPB, KCNQ1 
GO:0008284~positive regulation of cell proliferation 3 RAC2, ERBB2, DLX5 
GO:0043434~response to peptide hormone stimulus 2 SOCS2, SOCS1 
GO:0009101~glycoprotein biosynthetic process 2 ST6GALNAC6, CHST8 
GO:0006813~potassium ion transport 2 KCNQ1, KCNE3 
GO:0010033~response to organic substance 4 SOCS2, ACTA1, ERBB2, SOCS1 
GO:0016265~death 4 TNFRSF10D, ADRA1A, BIK, TCF15 
GO:0006357~regulation of transcription from RNA 
polymerase II promoter 
4 HOXB1, ALX4, TFAP2E, TCF15 
GO:0010740~positive regulation of protein kinase 
cascade 
2 SECTM1, ERBB2 
GO:0030001~metal ion transport 3 SLC5A1, KCNQ1, KCNE3 
GO:0019725~cellular homeostasis 3 ERBB2, HAAO, KCNQ1 
GO:0007610~behavior 3 RAC2, PGLYRP1, TCF15 
GO:0040007~growth 2 ACTA1, BMP8A 
GO:0045893~positive regulation of transcription, 
DNA-dependent 
3 HOXB1, ALX4, TFAP2E 
GO:0051254~positive regulation of RNA metabolic 
process 
3 HOXB1, ALX4, TFAP2E 
GO:0042060~wound healing 2 ERBB2, ENTPD2 
GO:0042127~regulation of cell proliferation 4 RAC2, ERBB2, DLX5, ADRA1A 
GO:0009617~response to bacterium 2 SOCS1, PGLYRP1 
GO:0007409~axonogenesis 2 ERBB2, DLX5 
GO:0009100~glycoprotein metabolic process 2 ST6GALNAC6, CHST8 
GO:0007600~sensory perception 4 EML2, C1QTNF5, EFEMP1, KCNQ1 
GO:0006916~anti-apoptosis 2 SOCS2, TNFRSF10D 
GO:0048878~chemical homeostasis 3 ERBB2, NPPB, KCNQ1 
GO:0048667~cell morphogenesis involved in neuron 
differentiation 
2 ERBB2, DLX5 
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GO:0048812~neuron projection morphogenesis 2 ERBB2, DLX5 
GO:0042493~response to drug 2 ERBB2, SOCS1 
GO:0033043~regulation of organelle organization 2 ELN, VILL 
GO:0009968~negative regulation of signal 
transduction 
2 SOCS2, SOCS1 
GO:0007169~transmembrane receptor protein 
tyrosine kinase signaling pathway 
2 SOCS2, ERBB2 
GO:0060429~epithelium development 2 DLX5, CNFN 
GO:0006812~cation transport 3 SLC5A1, KCNQ1, KCNE3 
GO:0045941~positive regulation of transcription 3 HOXB1, ALX4, TFAP2E 
GO:0000904~cell morphogenesis involved in 
differentiation 
2 ERBB2, DLX5 
GO:0048858~cell projection morphogenesis 2 ERBB2, DLX5 
GO:0007166~cell surface receptor linked signal 
transduction 
7 WFIKKN2, SOCS2, ERBB2, COL1A2, 
NPPB, ADRA1A, ENTPD2 
GO:0010648~negative regulation of cell 
communication 
2 SOCS2, SOCS1 
GO:0051056~regulation of small GTPase mediated 
signal transduction 
2 ERBB2, SIPA1 
GO:0010628~positive regulation of gene expression 3 HOXB1, ALX4, TFAP2E 
GO:0050890~cognition 4 EML2, C1QTNF5, EFEMP1, KCNQ1 
GO:0031175~neuron projection development 2 ERBB2, DLX5 
GO:0032990~cell part morphogenesis 2 ERBB2, DLX5 
GO:0006915~apoptosis 3 TNFRSF10D, ADRA1A, BIK 
GO:0012501~programmed cell death 3 TNFRSF10D, ADRA1A, BIK 
GO:0045935~positive regulation of nucleobase, 
nucleoside, nucleotide and nucleic acid metabolic 
process 
3 HOXB1, ALX4, TFAP2E 
GO:0009967~positive regulation of signal 
transduction 
2 SECTM1, ERBB2 
GO:0051173~positive regulation of nitrogen 
compound metabolic process 
3 HOXB1, ALX4, TFAP2E 
GO:0010557~positive regulation of macromolecule 
biosynthetic process 
3 HOXB1, ALX4, TFAP2E 
GO:0044057~regulation of system process 2 NPPB, KCNQ1 
GO:0031328~positive regulation of cellular 
biosynthetic process 
3 HOXB1, ALX4, TFAP2E 
GO:0010647~positive regulation of cell 
communication 
2 SECTM1, ERBB2 
GO:0009891~positive regulation of biosynthetic 
process 
3 HOXB1, ALX4, TFAP2E 
GO:0048666~neuron development 2 ERBB2, DLX5 
GO:0008219~cell death 3 TNFRSF10D, ADRA1A, BIK 
GO:0000902~cell morphogenesis 2 ERBB2, DLX5 
GO:0008285~negative regulation of cell proliferation 2 ERBB2, ADRA1A 
GO:0006873~cellular ion homeostasis 2 ERBB2, KCNQ1 
GO:0055082~cellular chemical homeostasis 2 ERBB2, KCNQ1 
GO:0006811~ion transport 3 SLC5A1, KCNQ1, KCNE3 
GO:0009057~macromolecule catabolic process 3 SOCS2, SOCS1, PGLYRP1 
GO:0030182~neuron differentiation 2 ERBB2, DLX5 
GO:0010604~positive regulation of macromolecule 
metabolic process 
3 HOXB1, ALX4, TFAP2E 
GO:0042325~regulation of phosphorylation 2 ERBB2, SOCS1 
GO:0051174~regulation of phosphorus metabolic 
process 
2 ERBB2, SOCS1 
GO:0019220~regulation of phosphate metabolic 
process 
2 ERBB2, SOCS1 
GO:0032504~multicellular organism reproduction 2 ERBB2, BIK 
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GO:0048609~reproductive process in a multicellular 
organism 
2 ERBB2, BIK 
GO:0006350~transcription 6 HOXB1, BCL9L, HDAC11, ALX4, 
TFAP2E, TCF15 
GO:0009611~response to wounding 2 ERBB2, ENTPD2 
GO:0006355~regulation of transcription, DNA-
dependent 
5 HOXB1, DLX5, ALX4, TFAP2E, TCF15 
GO:0055085~transmembrane transport 2 SLC5A1, KCNQ1 
GO:0043632~modification-dependent macromolecule 
catabolic process 
2 SOCS2, SOCS1 
GO:0019941~modification-dependent protein 
catabolic process 
2 SOCS2, SOCS1 
GO:0051252~regulation of RNA metabolic process 5 HOXB1, DLX5, ALX4, TFAP2E, TCF15 
GO:0051603~proteolysis involved in cellular protein 
catabolic process 
2 SOCS2, SOCS1 
GO:0006508~proteolysis 3 EML2, SOCS2, SOCS1 
GO:0044257~cellular protein catabolic process 2 SOCS2, SOCS1 
GO:0045449~regulation of transcription 7 HOXB1, DLX5, BCL9L, HDAC11, 
ALX4, TFAP2E, TCF15 
GO:0030163~protein catabolic process 2 SOCS2, SOCS1 
GO:0055114~oxidation reduction 2 LDHC, HAAO 
GO:0006955~immune response 2 SECTM1, PGLYRP1 
GO:0007155~cell adhesion 2 HAS1, EFS 
GO:0022610~biological adhesion 2 HAS1, EFS 
GO:0044265~cellular macromolecule catabolic 
process 
2 SOCS2, SOCS1 
GO:0010605~negative regulation of macromolecule 
metabolic process 
2 SOCS1, KCNQ1 
GO:0007049~cell cycle 2 RASSF1, SEPT9 
GO:0007186~G-protein coupled receptor protein 
signaling pathway 
2 ADRA1A, ENTPD2 
GO:0050865~regulation of cell activation 1 ERBB2 
GO:0014866~skeletal myofibril assembly 1 ACTA1 
GO:0034655~nucleobase, nucleoside, nucleotide and 
nucleic acid catabolic process 
1 ENTPD2 
GO:0050808~synapse organization 1 ERBB2 
GO:0045453~bone resorption 1 RAC2 
GO:0008406~gonad development 1 BIK 
GO:0050892~intestinal absorption 1 SLC5A1 
GO:0043266~regulation of potassium ion transport 1 KCNE3 
GO:0014888~striated muscle adaptation 1 ACTA1 
GO:0003014~renal system process 1 NPPB 
GO:0001656~metanephros development 1 SLC5A1 
GO:0006793~phosphorus metabolic process 1 ERBB2 
GO:0019805~quinolinate biosynthetic process 1 HAAO 
GO:0042312~regulation of vasodilation 1 NPPB 
GO:0030240~muscle thin filament assembly 1 ACTA1 
GO:0051046~regulation of secretion 1 KCNQ1 
GO:0019228~regulation of action potential in neuron 1 ERBB2 
GO:0050672~negative regulation of lymphocyte 
proliferation 
1 ERBB2 
GO:0006461~protein complex assembly 1 SEPTIN 09 (SEPT9) 
GO:0035282~segmentation 1 TCF15 
GO:0046425~regulation of JAK-STAT cascade 1 SOCS1 
GO:0032944~regulation of mononuclear cell 
proliferation 
1 ERBB2 
GO:0009991~response to extracellular stimulus 1 ACTA1 
GO:0022612~gland morphogenesis 1 ERBB2 
 195 
 
GO:0046394~carboxylic acid biosynthetic process 1 HAAO 
GO:0046579~positive regulation of Ras protein 
signal transduction 
1 ERBB2 
GO:0010741~negative regulation of protein kinase 
cascade 
1 SOCS1 
GO:0007162~negative regulation of cell adhesion 1 SIPA1 
GO:0010043~response to zinc ion 1 HAAO 
GO:0002792~negative regulation of peptide secretion 1 KCNQ1 
GO:0051249~regulation of lymphocyte activation 1 ERBB2 
GO:0042749~regulation of circadian sleep/wake 
cycle 
1 PGLYRP1 
GO:0051347~positive regulation of transferase 
activity 
1 ERBB2 
GO:0046903~secretion 1 NPPB 
GO:0051186~cofactor metabolic process 1 HAAO 
GO:0032268~regulation of cellular protein metabolic 
process 
1 SOCS1 
GO:0019320~hexose catabolic process 1 LDHC 
GO:0019932~second-messenger-mediated signaling 1 ERBB2 
GO:0006766~vitamin metabolic process 1 HAAO 
GO:0046365~monosaccharide catabolic process 1 LDHC 
GO:0006769~nicotinamide metabolic process 1 HAAO 
GO:0016049~cell growth 1 ACTA1 
GO:0030148~sphingolipid biosynthetic process 1 ST6GALNAC6 
GO:0009181~purine ribonucleoside diphosphate 
catabolic process 
1 ENTPD2 
GO:0015749~monosaccharide transport 1 SLC5A1 
GO:0044275~cellular carbohydrate catabolic process 1 LDHC 
GO:0007631~feeding behavior 1 TCF15 
GO:0021561~facial nerve development 1 HOXB1 
GO:0044270~nitrogen compound catabolic process 1 ENTPD2 
GO:0007586~digestion 1 SLC5A1 
GO:0045580~regulation of T cell differentiation 1 ERBB2 
GO:0003006~reproductive developmental process 1 BIK 
GO:0046626~regulation of insulin receptor signaling 
pathway 
1 SOCS1 
GO:0043648~dicarboxylic acid metabolic process 1 HAAO 
GO:0019674~NAD metabolic process 1 HAAO 
GO:0046164~alcohol catabolic process 1 LDHC 
GO:0042446~hormone biosynthetic process 1 CHST8 
GO:0007589~body fluid secretion 1 NPPB 
GO:0031100~organ regeneration 1 SOCS1 
GO:0016569~covalent chromatin modification 1 HDAC11 
GO:0007411~axon guidance 1 ERBB2 
GO:0006767~water-soluble vitamin metabolic 
process 
1 HAAO 
GO:0035150~regulation of tube size 1 NPPB 
GO:0006790~sulfur metabolic process 1 CHST8 
GO:0046849~bone remodeling 1 RAC2 
GO:0003016~respiratory system process 1 TCF15 
GO:0006814~sodium ion transport 1 SLC5A1 
GO:0009150~purine ribonucleotide metabolic 
process 
1 ENTPD2 
GO:0033088~negative regulation of immature T cell 
proliferation in the thymus 
1 ERBB2 
GO:0051494~negative regulation of cytoskeleton 
organization 
1 VILL 
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GO:0009166~nucleotide catabolic process 1 ENTPD2 
GO:0021546~rhombomere development 1 HOXB1 
GO:0006917~induction of apoptosis 1 BIK 
GO:0034097~response to cytokine stimulus 1 SOCS1 
GO:0045860~positive regulation of protein kinase 
activity 
1 ERBB2 
GO:0043589~skin morphogenesis 1 COL1A2 
GO:0006486~protein amino acid glycosylation 1 ST6GALNAC6 
GO:0042476~odontogenesis 1 COL1A2 
GO:0070663~regulation of leukocyte proliferation 1 ERBB2 
GO:0019362~pyridine nucleotide metabolic process 1 HAAO 
GO:0007528~neuromuscular junction development 1 ERBB2 
GO:0019363~pyridine nucleotide biosynthetic 
process 
1 HAAO 
GO:0010629~negative regulation of gene expression 1 KCNQ1 
GO:0042552~myelination 1 ERBB2 
GO:0050884~neuromuscular process controlling 
posture 
1 TCF15 
GO:0009185~ribonucleoside diphosphate metabolic 
process 
1 ENTPD2 
GO:0006023~aminoglycan biosynthetic process 1 HAS1 
GO:0021604~cranial nerve structural organization 1 HOXB1 
GO:0016458~gene silencing 1 KCNQ1 
GO:0050732~negative regulation of peptidyl-tyrosine 
phosphorylation 
1 SOCS1 
GO:0009137~purine nucleoside diphosphate 
catabolic process 
1 ENTPD2 
GO:0006468~protein amino acid phosphorylation 1 ERBB2 
GO:0006935~chemotaxis 1 RAC2 
GO:0043406~positive regulation of MAP kinase 
activity 
1 ERBB2 
GO:0051094~positive regulation of developmental 
process 
1 DLX5 
GO:0001822~kidney development 1 SLC5A1 
GO:0045936~negative regulation of phosphate 
metabolic process 
1 SOCS1 
GO:0009191~ribonucleoside diphosphate catabolic 
process 
1 ENTPD2 
GO:0021545~cranial nerve development 1 HOXB1 
GO:0080010~regulation of oxygen and reactive 
oxygen species metabolic process 
1 RAC2 
GO:0043503~skeletal muscle fiber adaptation 1 ACTA1 
GO:0021570~rhombomere 4 development 1 HOXB1 
GO:0006006~glucose metabolic process 1 LDHC 
GO:0007507~heart development 1 ERBB2 
GO:0051259~protein oligomerization 1 SEPTIN 09 (SEPT9) 
GO:0014065~phosphoinositide 3-kinase cascade 1 ERBB2 
GO:0046883~regulation of hormone secretion 1 KCNQ1 
GO:0050795~regulation of behavior 1 PGLYRP1 
GO:0001894~tissue homeostasis 1 RAC2 
GO:0010035~response to inorganic substance 1 HAAO 
GO:0042330~taxis 1 RAC2 
GO:0045187~regulation of circadian sleep/wake 
cycle, sleep 
1 PGLYRP1 
GO:0048532~anatomical structure arrangement 1 HOXB1 
GO:0003091~renal water homeostasis 1 NPPB 
GO:0033081~regulation of T cell differentiation in 
the thymus 
1 ERBB2 
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GO:0043114~regulation of vascular permeability 1 NPPB 
GO:0070271~protein complex biogenesis 1 SEPTIN 09 (SEPT9) 
GO:0050670~regulation of lymphocyte proliferation 1 ERBB2 
GO:0009110~vitamin biosynthetic process 1 HAAO 
GO:0009179~purine ribonucleoside diphosphate 
metabolic process 
1 ENTPD2 
GO:0042698~ovulation cycle 1 ERBB2 
GO:0042532~negative regulation of tyrosine 
phosphorylation of STAT protein 
1 SOCS1 
GO:0048729~tissue morphogenesis 1 COL1A2 
GO:0051726~regulation of cell cycle 1 SIPA1 
GO:0006687~glycosphingolipid metabolic process 1 ST6GALNAC6 
GO:0002237~response to molecule of bacterial origin 1 SOCS1 
GO:0046395~carboxylic acid catabolic process 1 PON3 
GO:0051338~regulation of transferase activity 1 ERBB2 
GO:0007623~circadian rhythm 1 PGLYRP1 
GO:0021548~pons development 1 HOXB1 
GO:0016045~detection of bacterium 1 PGLYRP1 
GO:0050817~coagulation 1 ENTPD2 
GO:0034654~nucleobase, nucleoside, nucleotide and 
nucleic acid biosynthetic process 
1 HAAO 
GO:0006096~glycolysis 1 LDHC 
GO:0007422~peripheral nervous system development 1 ERBB2 
GO:0010927~cellular component assembly involved 
in morphogenesis 
1 ACTA1 
GO:0021783~preganglionic parasympathetic nervous 
system development 
1 HOXB1 
GO:0009628~response to abiotic stimulus 1 ACTA1 
GO:0033674~positive regulation of kinase activity 1 ERBB2 
GO:0048730~epidermis morphogenesis 1 COL1A2 
GO:0006664~glycolipid metabolic process 1 ST6GALNAC6 
GO:0030834~regulation of actin filament 
depolymerization 
1 VILL 
GO:0030146~diuresis 1 NPPB 
GO:0009132~nucleoside diphosphate metabolic 
process 
1 ENTPD2 
GO:0007272~ensheathment of neurons 1 ERBB2 
GO:0040029~regulation of gene expression, 
epigenetic 
1 KCNQ1 
GO:0035116~embryonic hindlimb morphogenesis 1 ALX4 
GO:0001503~ossification 1 BMP8A 
GO:0000270~peptidoglycan metabolic process 1 PGLYRP1 
GO:0048512~circadian behavior 1 PGLYRP1 
GO:0033084~regulation of immature T cell 
proliferation in the thymus 
1 ERBB2 
GO:0043068~positive regulation of programmed cell 
death 
1 BIK 
GO:0006195~purine nucleotide catabolic process 1 ENTPD2 
GO:0042516~regulation of tyrosine phosphorylation 
of Stat3 protein 
1 SOCS1 
GO:0001756~somitogenesis 1 TCF15 
GO:0042063~gliogenesis 1 ERBB2 
GO:0051129~negative regulation of cellular 
component organization 
1 VILL 
GO:0051017~actin filament bundle formation 1 ELN 
GO:0043149~stress fiber formation 1 ELN 
GO:0008643~carbohydrate transport 1 SLC5A1 
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GO:0030879~mammary gland development 1 ERBB2 
GO:0006733~oxidoreduction coenzyme metabolic 
process 
1 HAAO 
GO:0048339~paraxial mesoderm development 1 TCF15 
GO:0048485~sympathetic nervous system 
development 
1 ERBB2 
GO:0042518~negative regulation of tyrosine 
phosphorylation of Stat3 protein 
1 SOCS1 
GO:0031400~negative regulation of protein 
modification process 
1 SOCS1 
GO:0050866~negative regulation of cell activation 1 ERBB2 
GO:0046777~protein amino acid autophosphorylation 1 ERBB2 
GO:0051250~negative regulation of lymphocyte 
activation 
1 ERBB2 
GO:0042364~water-soluble vitamin biosynthetic 
process 
1 HAAO 
GO:0046700~heterocycle catabolic process 1 ENTPD2 
GO:0019318~hexose metabolic process 1 LDHC 
GO:0009253~peptidoglycan catabolic process 1 PGLYRP1 
GO:0032269~negative regulation of cellular protein 
metabolic process 
1 SOCS1 
GO:0042326~negative regulation of phosphorylation 1 SOCS1 
GO:0003018~vascular process in circulatory system 1 NPPB 
GO:0048608~reproductive structure development 1 BIK 
GO:0045184~establishment of protein localization 1 RAB34 
GO:0016568~chromatin modification 1 HDAC11 
GO:0035137~hindlimb morphogenesis 1 ALX4 
GO:0001655~urogenital system development 1 SLC5A1 
GO:0034656~nucleobase, nucleoside and nucleotide 
catabolic process 
1 ENTPD2 
GO:0022602~ovulation cycle process 1 ERBB2 
GO:0046686~response to cadmium ion 1 HAAO 
GO:0015758~glucose transport 1 SLC5A1 
GO:0009595~detection of biotic stimulus 1 PGLYRP1 
GO:0007596~blood coagulation 1 ENTPD2 
GO:0045786~negative regulation of cell cycle 1 SIPA1 
GO:0006688~glycosphingolipid biosynthetic process 1 ST6GALNAC6 
GO:0030104~water homeostasis 1 NPPB 
GO:0060021~palate development 1 ALX4 
GO:0045597~positive regulation of cell 
differentiation 
1 DLX5 
GO:0035121~tail morphogenesis 1 TCF15 
GO:0002694~regulation of leukocyte activation 1 ERBB2 
GO:0042471~ear morphogenesis 1 DLX5 
GO:0010310~regulation of hydrogen peroxide 
metabolic process 
1 RAC2 
GO:0043500~muscle adaptation 1 ACTA1 
GO:0009261~ribonucleotide catabolic process 1 ENTPD2 
GO:0022410~circadian sleep/wake cycle process 1 PGLYRP1 
GO:0031333~negative regulation of protein complex 
assembly 
1 VILL 
GO:0060206~estrous cycle phase 1 ERBB2 
GO:0007626~locomotory behavior 1 RAC2 
GO:0050863~regulation of T cell activation 1 ERBB2 
GO:0043933~macromolecular complex subunit 
organization 
1 SEPTIN 09 (SEPT9) 
GO:0016054~organic acid catabolic process 1 PON3 
GO:0007276~gamete generation 1 BIK 
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GO:0001508~regulation of action potential 1 ERBB2 
GO:0043122~regulation of I-kappaB kinase/NF-
kappaB cascade 
1 SECTM1 
GO:0009820~alkaloid metabolic process 1 HAAO 
GO:0010563~negative regulation of phosphorus 
metabolic process 
1 SOCS1 
GO:0051188~cofactor biosynthetic process 1 HAAO 
GO:0051276~chromosome organization 1 HDAC11 
GO:0007588~excretion 1 NPPB 
GO:0046578~regulation of Ras protein signal 
transduction 
1 ERBB2 
GO:0070664~negative regulation of leukocyte 
proliferation 
1 ERBB2 
GO:0009612~response to mechanical stimulus 1 ACTA1 
GO:0043603~cellular amide metabolic process 1 HAAO 
GO:0065003~macromolecular complex assembly 1 SEPTIN 09 (SEPT9) 
GO:0009259~ribonucleotide metabolic process 1 ENTPD2 
GO:0050905~neuromuscular process 1 TCF15 
GO:0014066~regulation of phosphoinositide 3-kinase 
cascade 
1 ERBB2 
GO:0009108~coenzyme biosynthetic process 1 HAAO 
GO:0030837~negative regulation of actin filament 
polymerization 
1 VILL 
GO:0045087~innate immune response 1 PGLYRP1 
GO:0016044~membrane organization 1 RAB34 
GO:0021675~nerve development 1 HOXB1 
GO:0030031~cell projection assembly 1 RAC2 
GO:0045785~positive regulation of cell adhesion 1 ERBB2 
GO:0008104~protein localization 1 RAB34 
GO:0008584~male gonad development 1 BIK 
GO:0046467~membrane lipid biosynthetic process 1 ST6GALNAC6 
GO:0060263~regulation of respiratory burst 1 RAC2 
GO:0008610~lipid biosynthetic process 1 ST6GALNAC6 
GO:0021610~facial nerve morphogenesis 1 HOXB1 
GO:0048839~inner ear development 1 DLX5 
GO:0019221~cytokine-mediated signaling pathway 1 SOCS1 
GO:0048486~parasympathetic nervous system 
development 
1 HOXB1 
GO:0030278~regulation of ossification 1 DLX5 
GO:0050891~multicellular organismal water 
homeostasis 
1 NPPB 
GO:0048871~multicellular organismal homeostasis 1 RAC2 
GO:0009247~glycolipid biosynthetic process 1 ST6GALNAC6 
GO:0060443~mammary gland morphogenesis 1 ERBB2 
GO:0006163~purine nucleotide metabolic process 1 ENTPD2 
GO:0060056~mammary gland involution 1 ERBB2 
GO:0048585~negative regulation of response to 
stimulus 
1 SOCS1 
GO:0006952~defense response 1 PGLYRP1 
GO:0043410~positive regulation of MAPKKK 
cascade 
1 ERBB2 
GO:0006928~cell motion 1 ERBB2 
GO:0030835~negative regulation of actin filament 
depolymerization 
1 VILL 
GO:0002683~negative regulation of immune system 
process 
1 ERBB2 
GO:0035136~forelimb morphogenesis 1 ALX4 
GO:0051057~positive regulation of small GTPase 1 ERBB2 
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mediated signal transduction 
GO:0043413~biopolymer glycosylation 1 ST6GALNAC6 
GO:0043242~negative regulation of protein complex 
disassembly 
1 VILL 
GO:0046426~negative regulation of JAK-STAT 
cascade 
1 SOCS1 
GO:0030902~hindbrain development 1 HOXB1 
GO:0022037~metencephalon development 1 HOXB1 
GO:0051291~protein heterooligomerization 1 SEPTIN 09 (SEPT9) 
GO:0031424~keratinization 1 CNFN 
GO:0042752~regulation of circadian rhythm 1 PGLYRP1 
GO:0048232~male gamete generation 1 BIK 
GO:0030199~collagen fibril organization 1 COL1A2 
GO:0048644~muscle organ morphogenesis 1 TCF15 
GO:0010324~membrane invagination 1 RAB34 
GO:0007622~rhythmic behavior 1 PGLYRP1 
GO:0006026~aminoglycan catabolic process 1 PGLYRP1 
GO:0046661~male sex differentiation 1 BIK 
GO:0006024~glycosaminoglycan biosynthetic 
process 
1 HAS1 
GO:0009913~epidermal cell differentiation 1 CNFN 
GO:0060416~response to growth hormone stimulus 1 SOCS2 
GO:0009581~detection of external stimulus 1 PGLYRP1 
GO:0006476~protein amino acid deacetylation 1 HDAC11 
GO:0022600~digestive system process 1 SLC5A1 
GO:0046676~negative regulation of insulin secretion 1 KCNQ1 
GO:0006007~glucose catabolic process 1 LDHC 
GO:0043586~tongue development 1 ERBB2 
GO:0012502~induction of programmed cell death 1 BIK 
GO:0007267~cell-cell signaling 1 ADRA1A 
GO:0046546~development of primary male sexual 
characteristics 
1 BIK 
GO:0001775~cell activation 1 ENTPD2 
GO:0006796~phosphate metabolic process 1 ERBB2 
GO:0000271~polysaccharide biosynthetic process 1 HAS1 
GO:0043269~regulation of ion transport 1 KCNE3 
GO:0045619~regulation of lymphocyte 
differentiation 
1 ERBB2 
GO:0043549~regulation of kinase activity 1 ERBB2 
GO:0010038~response to metal ion 1 HAAO 
GO:0030216~keratinocyte differentiation 1 CNFN 
GO:0046874~quinolinate metabolic process 1 HAAO 
GO:0010001~glial cell differentiation 1 ERBB2 
GO:0006325~chromatin organization 1 HDAC11 
GO:0016525~negative regulation of angiogenesis 1 NPPB 
GO:0010817~regulation of hormone levels 1 CHST8 
GO:0042445~hormone metabolic process 1 CHST8 
GO:0042130~negative regulation of T cell 
proliferation 
1 ERBB2 
GO:0018108~peptidyl-tyrosine phosphorylation 1 ERBB2 
GO:0030212~hyaluronan metabolic process 1 HAS1 
GO:0043408~regulation of MAPKKK cascade 1 ERBB2 
GO:0045669~positive regulation of osteoblast 
differentiation 
1 DLX5 
GO:0048732~gland development 1 ERBB2 
GO:0001568~blood vessel development 1 COL1A2 
GO:0030239~myofibril assembly 1 ACTA1 
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GO:0007283~spermatogenesis 1 BIK 
GO:0035115~embryonic forelimb morphogenesis 1 ALX4 
GO:0046888~negative regulation of hormone 
secretion 
1 KCNQ1 
GO:0005996~monosaccharide metabolic process 1 LDHC 
GO:0007548~sex differentiation 1 BIK 
GO:0006091~generation of precursor metabolites and 
energy 
1 LDHC 
GO:0050730~regulation of peptidyl-tyrosine 
phosphorylation 
1 SOCS1 
GO:0033087~negative regulation of immature T cell 
proliferation 
1 ERBB2 
GO:0060209~estrus 1 ERBB2 
GO:0007568~aging 1 SOCS2 
GO:0016570~histone modification 1 HDAC11 
GO:0007599~hemostasis 1 ENTPD2 
GO:0014068~positive regulation of phosphoinositide 
3-kinase cascade 
1 ERBB2 
GO:0032272~negative regulation of protein 
polymerization 
1 VILL 
GO:0045667~regulation of osteoblast differentiation 1 DLX5 
GO:0042755~eating behavior 1 TCF15 
GO:0006732~coenzyme metabolic process 1 HAAO 
GO:0021571~rhombomere 5 development 1 HOXB1 
GO:0031099~regeneration 1 SOCS1 
GO:0006027~glycosaminoglycan catabolic process 1 PGLYRP1 
GO:0006512~ubiquitin cycle 1 SOCS1 
GO:0006665~sphingolipid metabolic process 1 ST6GALNAC6 
GO:0060396~growth hormone receptor signaling 
pathway 
1 SOCS2 
GO:0043244~regulation of protein complex 
disassembly 
1 VILL 
GO:0043085~positive regulation of catalytic activity 1 ERBB2 
GO:0015031~protein transport 1 RAB34 
GO:0042129~regulation of T cell proliferation 1 ERBB2 
GO:0009154~purine ribonucleotide catabolic process 1 ENTPD2 
GO:0050796~regulation of insulin secretion 1 KCNQ1 
GO:0000272~polysaccharide catabolic process 1 PGLYRP1 
GO:0019748~secondary metabolic process 1 HAAO 
GO:0016575~histone deacetylation 1 HDAC11 
GO:0051048~negative regulation of secretion 1 KCNQ1 
GO:0006029~proteoglycan metabolic process 1 CHST8 
GO:0019439~aromatic compound catabolic process 1 PON3 
GO:0060348~bone development 1 BMP8A 
GO:0032870~cellular response to hormone stimulus 1 SOCS2 
GO:0016053~organic acid biosynthetic process 1 HAAO 
GO:0043460~response to long exposure to lithium 
ion 
1 ACTA1 
GO:0048015~phosphoinositide-mediated signaling 1 ERBB2 
GO:0008645~hexose transport 1 SLC5A1 
GO:0021754~facial nucleus development 1 HOXB1 
GO:0043405~regulation of MAP kinase activity 1 ERBB2 
GO:0060341~regulation of cellular localization 1 KCNQ1 
GO:0016192~vesicle-mediated transport 1 RAB34 
GO:0019953~sexual reproduction 1 BIK 
GO:0008016~regulation of heart contraction 1 KCNQ1 
GO:0050880~regulation of blood vessel size 1 NPPB 
GO:0051301~cell division 1 SEPTIN 09 (SEPT9) 
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GO:0006349~genetic imprinting 1 KCNQ1 
GO:0043065~positive regulation of apoptosis 1 BIK 
GO:0019226~transmission of nerve impulse 1 ERBB2 
GO:0045444~fat cell differentiation 1 SOCS1 
GO:0045137~development of primary sexual 
characteristics 
1 BIK 
GO:0051899~membrane depolarization 1 KCNQ1 
GO:0008045~motor axon guidance 1 ERBB2 
GO:0018212~peptidyl-tyrosine modification 1 ERBB2 
GO:0030168~platelet activation 1 ENTPD2 
GO:0007050~cell cycle arrest 1 RASSF1 
GO:0050830~defense response to Gram-positive 
bacterium 
1 PGLYRP1 
GO:0030213~hyaluronan biosynthetic process 1 HAS1 
GO:0043123~positive regulation of I-kappaB 
kinase/NF-kappaB cascade 
1 SECTM1 
GO:0051216~cartilage development 1 BMP8A 
GO:0051606~detection of stimulus 1 PGLYRP1 
GO:0009134~nucleoside diphosphate catabolic 
process 
1 ENTPD2 
GO:0008366~axon ensheathment 1 ERBB2 
GO:0002791~regulation of peptide secretion 1 KCNQ1 
GO:0010639~negative regulation of organelle 
organization 
1 VILL 
GO:0042472~inner ear morphogenesis 1 DLX5 
GO:0001889~liver development 1 ERBB2 
GO:0032945~negative regulation of mononuclear cell 
proliferation 
1 ERBB2 
GO:0042509~regulation of tyrosine phosphorylation 
of STAT protein 
1 SOCS1 
GO:0051693~actin filament capping 1 VILL 
GO:0048857~neural nucleus development 1 HOXB1 
GO:0033083~regulation of immature T cell 
proliferation 
1 ERBB2 
GO:0045859~regulation of protein kinase activity 1 ERBB2 
GO:0046627~negative regulation of insulin receptor 
signaling pathway 
1 SOCS1 
GO:0001932~regulation of protein amino acid 
phosphorylation 
1 SOCS1 
GO:0006939~smooth muscle contraction 1 ADRA1A 
GO:0030147~natriuresis 1 NPPB 
GO:0009165~nucleotide biosynthetic process 1 HAAO 
GO:0006897~endocytosis 1 RAB34 
GO:0010959~regulation of metal ion transport 1 KCNE3 
GO:0034404~nucleobase, nucleoside and nucleotide 
biosynthetic process 
1 HAAO 
GO:0002695~negative regulation of leukocyte 
activation 
1 ERBB2 
GO:0021602~cranial nerve morphogenesis 1 HOXB1 
GO:0016310~phosphorylation 1 ERBB2 
GO:0050868~negative regulation of T cell activation 1 ERBB2 
GO:0046496~nicotinamide nucleotide metabolic 
process 
1 HAAO 
GO:0001933~negative regulation of protein amino 
acid phosphorylation 
1 SOCS1 
GO:0001944~vasculature development 1 COL1A2 
GO:0031399~regulation of protein modification 
process 
1 SOCS1 
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GO:0031032~actomyosin structure organization 1 ACTA1 
GO:0043501~skeletal muscle adaptation 1 ACTA1 
GO:0044271~nitrogen compound biosynthetic 
process 
1 HAAO 
GO:0032496~response to lipopolysaccharide 1 SOCS1 
GO:0051051~negative regulation of transport 1 KCNQ1 
GO:0042742~defense response to bacterium 1 PGLYRP1 
GO:0042745~circadian sleep/wake cycle 1 PGLYRP1 
GO:0021612~facial nerve structural organization 1 HOXB1 
GO:0009135~purine nucleoside diphosphate 
metabolic process 
1 ENTPD2 
GO:0022402~cell cycle process 1 RASSF1 
GO:0070085~glycosylation 1 ST6GALNAC6 
GO:0070050~neuron maintenance 1 HAAO 
GO:0048678~response to axon injury 1 ERBB2 
GO:0051248~negative regulation of protein 
metabolic process 
1 SOCS1 
GO:0006643~membrane lipid metabolic process 1 ST6GALNAC6 
GO:0030166~proteoglycan biosynthetic process 1 CHST8 
GO:0010942~positive regulation of cell death 1 BIK 
GO:0044093~positive regulation of molecular 
function 
1 ERBB2 
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6.2. Go molecular function 
Count Genes 
4 RAC2, RAB34, RHOD, SEPT9 
2 SOCS2, SOCS1 
4 RAC2, RAB34, RHOD, SEPT9 
4 RAC2, RAB34, RHOD, SEPT9 
4 RAC2, RAB34, RHOD, SEPT9 
5 ERBB2, RASSF1, COL1A2, TFAP2E, PON3 
3 ERBB2, ALX4, TFAP2E 
3 SLC5A1, KCNQ1, KCNE3 
2 PGLYRP1, HDAC11 
2 ACTA1, VILL 
4 ERBB2, ALX4, TFAP2E, PON3 
2 ELN, COL1A2 
2 SOCS2, COL1A2 
2 KCNQ1, KCNE3 
2 ERBB2, COL1A2 
4 ACTA1, ELN, COL1A2, VILL 
2 KCNQ1, KCNE3 
2 KCNQ1, KCNE3 
5 HOXB1, DLX5, ALX4, TFAP2E, TCF15 
2 KCNQ1, KCNE3 
2 KCNQ1, KCNE3 
2 SECTM1, BMP8A 
2 KCNQ1, KCNE3 
3 HOXB1, DLX5, ALX4 
2 WFIKKN2, SOCS1 
2 KCNQ1, KCNE3 
2 KCNQ1, KCNE3 
2 KCNQ1, KCNE3 
2 HOXB1, EFS 
2 TFAP2E, PON3 
6 ACTA1, RAC2, ERBB2, RAB34, RHOD, SEPT9 
6 ACTA1, RAC2, ERBB2, RAB34, RHOD, SEPT9 
5 HOXB1, DLX5, ALX4, TFAP2E, TCF15 
2 KCNQ1, KCNE3 
2 KCNQ1, KCNE3 
6 ACTA1, RAC2, ERBB2, RAB34, RHOD, SEPT9 
2 KCNQ1, KCNE3 
2 KCNQ1, KCNE3 
3 EFEMP1, ENTPD2, VILL 
2 ACTA1, VILL 
2 ERBB2, SOCS1 
6 ACTA1, RAC2, ERBB2, RAB34, RHOD, SEPT9 
11 CRIP1, SLC5A1, RASSF1, PDLIM4, EFEMP1, HAAO, KCNQ1, ENTPD2, KCNE3, MT1G, 
VILL 
11 CRIP1, SLC5A1, RASSF1, PDLIM4, EFEMP1, HAAO, KCNQ1, ENTPD2, KCNE3, MT1G, 
VILL 
11 CRIP1, SLC5A1, RASSF1, PDLIM4, EFEMP1, HAAO, KCNQ1, ENTPD2, KCNE3, MT1G, 
VILL 
5 HOXB1, DLX5, ALX4, TFAP2E, TCF15 
4 CRIP1, RASSF1, PDLIM4, MT1G 
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5 CRIP1, RASSF1, PDLIM4, HAAO, MT1G 
2 ACTA1, ERBB2 
2 ACTA1, ERBB2 
2 ACTA1, ERBB2 
2 ACTA1, ERBB2 
2 ACTA1, ERBB2 
1 HDAC11 
1 HAAO 
1 SOCS1 
1 ADRA1A 
1 ERBB2 
1 WFIKKN2 
1 SLC5A1 
1 VILL 
1 SOCS1 
1 SOCS2 
1 WFIKKN2 
1 SIPA1 
1 COL1A2 
1 HAAO 
1 ERBB2 
1 SIPA1 
1 ENTPD2 
1 PON3 
1 CHST8 
1 SLC5A1 
1 SOCS1 
1 SLC5A1 
1 PON3 
1 ERBB2 
1 ADRA1A 
1 PGLYRP1 
1 EML2 
1 SOCS1 
1 SIPA1 
1 ERBB2 
1 ERBB2 
1 SIPA1 
1 SLC5A1 
1 HDAC11 
1 NPPB 
1 ELN 
1 RASSF1 
1 ADRA1A 
1 PGLYRP1 
1 PGLYRP1 
1 SIPA1 
1 SLC5A1 
1 ERBB2 
1 ACTA1 
1 EML2 
1 PGLYRP1 
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1 ST6GALNAC6 
1 PGLYRP1 
1 COL1A2 
1 EML2 
1 SOCS2 
1 WFIKKN2 
1 WFIKKN2 
1 CHST8 
1 SIPA1 
1 SIPA1 
1 PGLYRP1 
1 SOCS2 
1 TCF15 
1 WFIKKN2 
1 HAAO 
1 EML2 
1 HAS1 
1 HDAC11 
1 LDHC 
1 RASSF1 
1 SOCS2 
1 SLC5A1 
1 PON3 
1 MT1G 
1 PON3 
1 SOCS1 
1 KCNE3 
1 PGLYRP1 
1 ENTPD2 
1 BMP8A 
1 NPPB 
1 PGLYRP1 
1 HAAO 
1 SOCS2 
1 ERBB2 
1 ERBB2 
1 EML2 
1 SLC5A1 
1 HAAO 
1 PGLYRP1 
1 SOCS1 
1 ERBB2 
1 KCNQ1 
1 ERBB2 
1 EFS 
1 EML2 
1 SLC5A1 
1 ERBB2 
1 ACTA1 
1 KCNQ1 
1 LDHC 
1 MT1G 
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1 CHST8 
1 SOCS2 
1 HAAO 
1 ELN 
1 WFIKKN2 
1 SLC5A1 
1 ERBB2 
1 HDAC11 
1 ERBB2 
1 ADRA1A 
1 HAAO 
1 KCNE3 
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6.3. Kegg pathway 
Term Count Genes 
hsa04510:Focal adhesion 3 RAC2, ERBB2, COL1A2 
hsa05219:Bladder cancer 2 ERBB2, RASSF1 
hsa04930:Type II diabetes mellitus 2 SOCS2, SOCS1 
hsa05223:Non-small cell lung cancer 2 ERBB2, RASSF1 
hsa05212:Pancreatic cancer 2 RAC2, ERBB2 
hsa04520:Adherens junction 2 RAC2, ERBB2 
hsa05200:Pathways in cancer 3 RAC2, ERBB2, RASSF1 
hsa04670:Leukocyte transendothelial migration 2 RAC2, SIPA1 
hsa04360:Axon guidance 2 RAC2, RHOD 
hsa04650:Natural killer cell mediated cytotoxicity 2 RAC2, TNFRSF10D 
hsa04910:Insulin signaling pathway 2 SOCS2, SOCS1 
hsa04630:Jak-STAT signaling pathway 2 SOCS2, SOCS1 
hsa04020:Calcium signaling pathway 2 ERBB2, ADRA1A 
hsa05110:Vibrio cholerae infection 1 KCNQ1 
hsa00620:Pyruvate metabolism 1 LDHC 
hsa04512:ECM-receptor interaction 1 COL1A2 
hsa00230:Purine metabolism 1 ENTPD2 
hsa05210:Colorectal cancer 1 RAC2 
hsa04350:TGF-beta signaling pathway 1 BMP8A 
hsa04666:Fc gamma R-mediated phagocytosis 1 RAC2 
hsa04270:Vascular smooth muscle contraction 1 ADRA1A 
hsa00604:Glycosphingolipid biosynthesis 1 ST6GALNAC6 
hsa04120:Ubiquitin mediated proteolysis 1 SOCS1 
hsa04062:Chemokine signaling pathway 1 RAC2 
hsa04080:Neuroactive ligand-receptor interaction 1 ADRA1A 
hsa04340:Hedgehog signaling pathway 1 BMP8A 
hsa05213:Endometrial cancer 1 ERBB2 
hsa00270:Cysteine and methionine metabolism 1 LDHC 
hsa05215:Prostate cancer 1 ERBB2 
hsa05416:Viral myocarditis 1 RAC2 
hsa04012:ErbB signaling pathway 1 ERBB2 
hsa04664:Fc epsilon RI signaling pathway 1 RAC2 
hsa04370:VEGF signaling pathway 1 RAC2 
hsa04310:Wnt signaling pathway 1 RAC2 
hsa04662:B cell receptor signaling pathway 1 RAC2 
hsa00640:Propanoate metabolism 1 LDHC 
hsa04810:Regulation of actin cytoskeleton 1 RAC2 
hsa04210:Apoptosis 1 TNFRSF10D 
hsa00010:Glycolysis / Gluconeogenesis 1 LDHC 
hsa04060:Cytokine-cytokine receptor interaction 1 TNFRSF10D 
hsa00380:Tryptophan metabolism 1 HAAO 
hsa04010:MAPK signaling pathway 1 RAC2 
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Appendix 7: Quality control of 15 pituitary samples in 
Illumina Infinium 27 BeadArray   
 
A Kolmogorov–Smirnov test was used by our collaborator (Dr Richard Emes) to compare the 
distribution of β values between samples using the NIMBL Software.  A single NP sample was 
identified as having a significantly different (P<0.05) distribution to the other samples and was 
excluded from further analysis. 
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Appendix 8: Expression of CDKN2A in 13 NFs investigation 
cohort relative to 4 NPs   
 
qRT-PCR determination of expression of CDKN2A at transcriptional level in 13 non-functioning 
pituitary tumours of the investigation cohort relative to mean of 4 normal pituitaries. White bars, 
Non-functioning tumours; Black bars, Normal pituitaries; Gray bars, Mean of 4 normal pituitaries; 
NF, Non-functioning; NP, Normal pituitary. 
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